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Outline and Objectives 
Bacterial Ghosts (BGs) represent bacterial envelopes which are produced by the 
controlled expression of the phage derived lysis gene E. Because the cytoplasmatic content is 
expelled through the generated lysis hole, the intracellular space can be filled with any 
biologically active substances. Like their viable counterpart, BGs provide fully intact surface 
structures including macromolecular assemblies such as flagella, pili or LPS and are therefore 
able to stimulate the innate immune system of the host per se. Thus, the BG technology 
provides an innovative system for vaccine, drug or active substance delivery for various cells 
and tissues of animal, human or plant origin.  
Detailed information on the BGs platform system is given in Chapter 1. “Introduction 
to the bacterial ghost technology platform” which consists of the following reviews: 
Chapter 1.1. “Bacterial ghosts as Vaccine and Drug Delivery Platforms”  
(published in “Patho-Biotechnology”, 2008). 
Chapter 1.2. “The Bacterial Ghost Platform System: Production and Applications”
(accepted for publication in “Bioengineered Bugs”, 2010). 
Chapter 1.3. “Bacterial Ghosts (BGs) – Advanced Antigen and Drug Delivery System”
(accepted for publication in “Vaccine”, 2010). 
The main findings, summarized in Chapter 2. “Application of Bacterial Ghosts, are 
categorized into three topics which address fundamental issues for the prospective 
application of the BG system and contain subchapters which are written in the style of 
discrete manuscripts, containing the following sections: Title, Abstract, Introduction, 
Materials and Methods, Results, Discussion, Figures and References. 
Chapter 2.1. Bacterial ghosts as carrier vehicles for cytostatic drugs  
Bacterial ghosts (BGs) are able to target various types of cancer cells and efficient 
endocytosis of BGs was reported after incubation with colon carcinoma, leukaemia and 
melanoma cells. Previous studies showed that the colon cell line CaCo2 effectively internalized 
BGs which were loaded with the cytostatic drug doxorubicin (DOX). Furthermore it was 
demonstrated that the BG’s content was released to the cytoplasm of the target cells and 
accumulation of the drug was found in the nucleus. Incubation with DOX-loaded BGs 
significantly reduced the viability as well as the proliferative capacity of the cells and the effects 
were 2-3 orders of magnitude higher than in comparison to results obtained with free DOX. 
Similar results were obtained with different leukaemia cell lines.  
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In this part of the thesis, the chemotherapeutic compounds resveratrol (RV) and its 
analogues digalloylresveratrol (DIG) and 3,3’,4,4’,5,5’-hexahydroxystilbene (M8) should be 
entrapped into BGs. Furthermore, the impact on the viability of the colon cell line HT29 should 
be determined after long term incubation with the loaded BGs. Additionally, the endogenous 
drug release of RV-BGs should be confirmed by HPLC measurements.  
Chapter 2.2. Bacterial ghosts as targeting vehicles for ocular surfaces 
The conjunctival epithelium on the ocular surface serves as a protective barrier against 
detrimental effects from the environment and the delivery of drugs against ocular diseases is 
challenging.  
As BGs represent a novel carrier and adjuvant system for the delivery of mucosal 
vaccines, the targeting properties of various BGs, produced from different species, should be 
investigated in human conjunctiva derived cells. Uptake efficiencies should be determined by 
flow cytometry. Furthermore, the influence of BGs on the expression of MHC class I and class 
II molecules as well as of ICAM-1 should be examined. 
In order to demonstrate that the LPS content, presented on the BG’s surface, does not 
represent a risk for using them as vaccine candidates, the potential cytotoxic and genotoxic 
effects of BGs should be investigated in the conjunctival cell line CCL 20.2 by use of the 
neutralred assay (viability) as well with the single cell gel electrophoresis technique (DNA-
damage). A previous study demonstrated that bacteria influence (potentiate or reduce) the 
damaging effects of drugs. Therefore, it should be investigated whether the toxic impact of the 
preservative benzalkonium chloride towards the CCL 20.2 cells could be modulated in presence 
of BGs.
Chapter 2.3. Bacterial ghosts as triggers of the innate immune system 
The innate immune system protects the host from invading microorganisms and triggers a 
series of defense responses. As already mentioned at the beginning, BGs retain all of the surface 
structural, morphological and antigenic components which are required for the activation of the 
innate immune system.  
Because little is known about the BG’s capacity concerning the expression of innate 
immune modulators of the skin, human keratinocytes should be investigated after application of 
BGs for their proinflammatory cytokine expression, especially of interleukin (IL)-6 and IL-8. 
Furthermore, it should be determined whether BGs are still able to induce antimicrobial 
peptides such as psoriasin and human ? defensin-2. 
Another defense mechanism of the innate immune system is given by the release of 
radicals, e.g.. reactive nitrogen species like nitric oxide (NO). This molecule represents a 
mediator for various cellular functions and is produced through the inducible nitric oxide 
2
synthase (iNOS). It is known that LPS induces iNOS dependent NO formation in phagocytes. 
Therefore it should be investigated whether BGs can induce NO-accumulation in RAW 264.7 
macrophages and whether this could be modified when BGs would be loaded with the iNOS 
inhibitor resveratrol. 
Appendix
Supplementary data and figures that were not included in the respective chapters are 
subject of the appendix (A.1.-A.5.). Furthermore, the loading capacity of BGs with the coffee 
compounds kahweol and cafestol was investigated by HPLC measurements and the results are 
shortly discussed in section A.6. In the last part of the appendix, the cytotoxic impact of various 
eye drops towards the conventional conjunctiva cell line CCL 20.2 and human conjunctiva 
derived primary cells is shown (A.7.). This study was included because almost all of the 
investigated solutions contained BAC, which was already investigated in Chapter 2.2.2. in 
presence of BGs. Furthermore, preliminary experiments were conducted with two selected eye 
drops and their cytotoxic impact was determined after coincubation with BGs (A.4.).
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Summary
Bacterial ghosts as carrier vehicles for cytostatic drugs  
Many studies demonstrated the chemopreventive and cytostatic effects of the 
hydroxystilbene resveratrol (RV). Furthermore, the novel analogues digalloylresveratrol (DIG) 
and 3,3’,4,4’,5,5’-hexahydroxystilbene (M8) have been shown to exert even more anti-tumor 
activity than RV and provide therefore new drug candidates for treatment of colorectal cancer.  
The advantage that the bioadhesive BGs contain natural immune stimulating compounds 
on their surface and provide a huge reservoir for substances in the inner lumen, make them 
optimal drug delivery vehicles which can be used for tumor treatment and therapy. Thus, the 
cytotoxic impact of BGs which were loaded with the chemotherapeutic compounds mentioned 
above, on the colon cell line HT29 was investigated. Findings from comparative investigations 
showed that the drug, delivered by BGs, significantly reduced the cell viability according to the 
cytotoxic pattern of the compounds alone (DIG > M8 > RV). In order to prove that the cytotoxic 
effects were caused by intracellular drug delivery, experiments were conducted with the less 
toxic RV-BGs, and RV and its metabolites were determined by HPLC. The results showed that 
the entrapped photosensitive RV was highly protected by the BG’s interior and that the loaded 
substance was effectively released within the targeted HT29 cells. Moreover, sustained 
intracellular levels of RV and its metabolites were found even after coincubation of RV-BGs for 
up to 24 hrs and higher concentrations of the compound were detected after RV-BG-treatment 
when compared to treatment with an equivalent dose of the substance alone.  
Bacterial ghosts as targeting vehicles for ocular surfaces 
In general, conjunctiva cells represent not only a mechanical barrier against pathogens but 
also protects the eye against allergens and toxic substances. Nevertheless, disorders of the 
conjunctiva, are affecting people worldwide and there is an extensive need for delivery systems 
which are capable to effectively transfer medical drugs to the eye’s compartment.  
In order to investigate whether BGs can be used as carrier systems for future therapeutic 
applications, the responsiveness of different human conjunctiva-derived cells after coincubation 
with BGs, generated from different bacterial species, was examined. High uptake BG levels 
were found with FACS-analyses in primary cells, with efficiencies modulated by the type of the 
BG species used. Furthermore, increased expression of the molecule ICAM-1 was demonstrated 
on the surface of the conjunctiva cells that might have an additional stimulatory effect on 
leukocyte populations or as a costimulatory signal required for T-cell activation and cytokine 
production.  
Benzalkonium chloride (BAC), which is commonly used as a preserving agent in  
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ophthalmic solutions, is known for its cytotoxic action in conjunctival cells. The 
performed studies revealed that no toxic effects (neither cytotoxic nor genotoxic) were mediated 
by BGs in the conjunctiva cell line CCL 20.2. Therefore, the impact of BAC in presence of BGs 
was investigated. It was found that BGs were highly protective against the BAC induced 
cytotoxicity in CCl 20.2. cells. Furthermore, results from single cell gel electrophoresis (SCGE) 
assays show that BAC also induces DNA-damage in conjunctiva cells, probably due to the 
generation of H2O2. As peroxidase activities were detected in BGs, additional experiments were 
conducted with selected BGs and beneficial effects of BGs were also seen in genotoxicity 
assays. In addition it was demonstrated that the bactericidal nature of the preservative BAC was 
not lost in presence of the BGs.  
Bacterial ghosts as triggers of the innate immune system 
Infectious agents are immediately recognized, inactivated and killed by the innate 
immune system which is built up by certain cells and humoral factors. The defense mechanisms 
include phagocytosis of bacteria by neutrophils or macrophages and the release of antimicrobial 
peptides, proinflammatory cytokines, hydrolytic enzymes or of reactive oxygen/nitrogen species 
by phagocytes.  
The induction of antimicrobial peptides and proinflammatory cytokines, produced by 
epidermal keratinocytes (KCs), provide a protective barrier to invading microorganisms and are 
a critical part of the innate immune system of the skin. Since the antimicrobial peptides 
S100A7c (psoriasin) and human ? defensin-2 (hBD-2) are most efficient agents against skin 
pathogens, their mRNA expression after incubation of KCs with E. coli BGs was investigated. 
In quantitative real-time PCR analyses it was demonstrated that BGs are able to induce the two 
peptides in a particle dependent manner. It was further shown, that the endocytic activity of BGs 
(flagellin-deficient and wild-type) by KCs as well as the release of proinflammatory cytokines 
like interleukin (IL)-6 and IL-8 were dependent on the flagellin content on the surface of the 
BGs.
The production of nitric oxide (NO) by the inducible NO-synthase (iNOS) plays an 
important role in infectious diseases. As bacterial lipopolysaccaride (LPS) is known to be a 
potent inducer of iNOS, the NO formation in a murine macrophage cell line after coincubation 
with BGs was investigated. It was demonstrated that E. coli BGs are rapidly phagocytized by 
RAW 264.7 cells and induced NO-formation in a particle dependent manner. Furthermore, the 
BG-induced NO-accumulation was determined with BGs which were loaded with the iNOS 
inhibitor resveratrol (RV). Indeed, modulated NO-formation was found. Even though, the 
general uptake mechanism of RV is still unclear it was found that endogenous RV-delivery by 
BGs led to modified NO release. Because of this, the existence of an internal RV-receptor is 
postulated which is termed ERVR (endogenous resveratrol receptor).
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Gliederung und Zielsetzung 
Bakterielle Ghosts (BGs) repräsentieren intakte bakterielle Hüllen, die durch kontrollierte 
Expression des Lysegens E gebildet werden. Während des Lyseprozesses wird der gesamte 
zytoplasmatische Inhalt durch ein generiertes Loch freigesetzt. Dieser intrazelluläre Bereich 
kann nun mit jeglichen biologisch aktiven Substanzen gefüllt werden. Oberflächenstrukturen, so 
auch makromolekulare Verbindungen wie z.B. Flagella, Pili oder LPS, bleiben bei BGs genauso 
intakt wie beim nativen Bakterium, wodurch sie per se die unspezifische Immunabwehr 
stimulieren können. Aus diesem Grund bietet die BG Technologie ein innovatives System für 
den Transport von Vakzinen, therapeutischen Wirkstoffen und andere aktive Substanzen für 
verschiedenste Zellen und Gewebe tierischen, menschlichen oder pflanzlichen Ursprungs.   
Detaillierte Informationen über das BG-System sind in Kapitel 1. “Introduction to the 
bacterial ghost technology platform ”, bestehend aus folgenden Reviews, zu finden:
Chapter 1.1. “Bacterial ghosts as Vaccine and Drug Delivery Platforms”;
dieser Review wurde in “Patho-Biotechnology” (2008) publiziert. 
Chapter 1.2. “The Bacterial Ghost Platform System: Production and Applications”;
dieses Manuskript ist bereits als Publikation in “Bioengineered Bugs” (2010) angenommen. 
Chapter 1.3. “Bacterial Ghosts (BGs) – Advanced Antigen and Drug Delivery System”;
dieses Manuskript ist bereits als Publikation in “Vaccine” (2010) angenommen. 
Die relevanten Ergebnisse sind in Kapitel 2. „Application of bacterial ghosts“ 
zusammengefasst. Dieses ist in drei Themengebiete unterteilt und beinhaltet 
fundamentalen Anhaltspunkte für zukünftige Anwendungen des BG-Systems. Die 
jeweiligen Unterkapitel sind als eigenständige Arbeiten im Stil eines Manuskripts verfasst 
und enthalten alle folgenden Abschnitte: Titel, Kurzbeschreibung, Einleitung, Material 
und Methoden, Diskussion, Figuren und Referenzen 
Kapitel 2.1. Bakterielle Ghosts als Trägervehikel von Zytostatika  
Bakterielle Ghosts (BGs) können zielgerichtet an verschiedene Typen von Krebszellen 
anhaften und es wurde gezeigt, dass BGs effektiv von Kolonkarzinoma-, Leukämie- und 
Melanomazellen endozytiert werden. Vorangehende Studien belegen, dass BGs, welche mit 
dem zytostatischen Wirkstoff Doxorubicin (DOX) beladen wurden, erfolgreich von der 
Kolonzellline CaCo2 internalisiert wurden. Weiters konnte gezeigt werden, dass die beladene 
Substanz im Zytoplasma der Zielzelle freigesetzt wurde und akkumulierte Konzentrationen von 
DOX wurden im Zellkern detektiert. Die Inkubation mit DOX-beladenen BGs führte zu einer 
7
signifikanten Reduktion der Zellviabilität sowie Proliferationskapazität. Die Effekte, welche mit 
DOX-BGs erzielt wurden, waren um -2-3 Ordnungen höher als im Vergleich zu jenen die mit 
freiem DOX in äquivalenter Dosis erhalten wurden. Ähnliche Resultate wurden auch mit 
verschiedenen Leukämiezelllinien erhalten. 
In diesem Teil der Arbeit sollten BGs mit den chemotherapeutischen Substanzen 
Resveratrol (RV) und dessen Analoga Digalloylresveratrol (DIG) und 3,3’,4,4’,5,5’-
Hexahydroxystilben (M8) beladen werden. Weiters sollte der Einfluss auf die Viabilität der 
Kolonzelllinie HT29 nach Inkubation mit diesen beladenen BGs untersucht werden. Zusätzlich 
sollte die endogene Freisetzung von RV mittels HPLC  bestimmt werden. 
Kapitel 2.2. Bakterielle Ghosts als „targeting vehicles“ von Augenzellen 
Das konjunktivale Epithelium der Augenoberfläche dient als Schutzbarriere gegen 
schädliche Einflüsse und stellt eine Herausforderung für die Verabreichung von Wirkstoffen 
gegen Augenerkrankungen dar. 
Aufgrund dessen, dass BGs ein neues Träger- und Adjuvans-System für das „delivery“ 
mukosaler Vakzine repräsentieren, sollten die „targeting“ Eigenschaften unterschiedlicher BGs, 
die aus verschiedenen Spezies generiert wurden, in humanen konjunktivalen Zellen untersucht 
werden. Die Aufnahmeraten sollten dabei mittels Durchflusszytometrie bestimmt werden. 
Weiters sollte der Einfluss der BGs auf die Expression verschiedenster Moleküle (MHC-I und 
MHC-II sowie ICAM-1) untersucht werden. 
Um zu beweisen, dass Lipopolysaccharid (LPS), welches auf der Oberfläche von BGs 
vorhanden ist, keinen Risikofaktor für die Verwendung von BGs als Vakzinkandidat darstellt, 
sollten die potentiellen zytotoxischen und genotoxischen Effekte von BGs in der konjunktivalen 
Zelllinie CCL 20.2 mittels Neutralrot Assay (Viabilität) sowie mittels der 
Einzelzellgelelektrophorese Technik (DNA-Schädigung) untersucht werden.
Eine frühere Studie demonstrierte, dass Bakterien einen Einfluss (verstärkend oder 
reduzierend) auf die schädigende Wirkung von Substanzen haben können. Daher sollte 
untersucht werden, ob der toxische Einfluss des Konservierungsmittels Benzalkoniumchlorid 
auf die konjunktivale Zelllinie CCL 20.2 in Anwesenheit von BGs moduliert werden kann.  
Kapitel 2.3. Bakterielle Ghosts als Auslöser des angeborenen Immunsystems  
Das angeborene Immunsystem schützt den Organismus vor eindringenden 
Mikroorganismen und löst eine Reihe von Verteidigungsmechanismen aus. Wie bereits anfangs 
erwähnt, besitzen BGs alle strukturellen sowie morphologischen und antigenischen 
Komponenten, die für die Aktivierung des angeborenen Immunsystems benötigt werden.  
Da nur wenig über die Kapazität der BGs betreffend der Expression von angeborenen 
Immunmodulatoren der Haut bekannt ist, sollte, nach Applikation von BGs, die Expression von 
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proinflammatorischen Zytokinen (v.a. Interleukin (IL)-6 und IL-8) in humane Keratinozyten 
untersucht werden. Weiters sollte festgestellt werden ob BGs antimikrobielle Peptide wie z.B. 
Psoriasin und humanes ? Defensin-2 induzieren können  
Ein weiterer Verteidigungsmechanismus des angeborenen Immunsystems ist durch die 
Freisetzung von Radikalen z.B. reaktiver Stickstoffspezies wie Stickoxid (NO) gegeben. Dieses 
Molekül dient als Mediator verschiedenster zellulärer Funktionen und wird durch die 
induzierbare NO-Synthase (iNOS) produziert. Es ist bekannt, dass LPS iNOS abhängige NO-
Bildung in Phagozyten auslöst. Daher sollte untersucht werden ob BGs die Akkumulierung von 
NO in RAW 264.7 Makrophagen induzieren können und ob die Bildung von NO durch die 
Beladung von BGs mit dem iNOS Inhibitor Resveratrol moduliert werden kann.  
Appendix
Zusätzliche Daten und Figuren, die nicht in den jeweiligen Kapiteln inkludiert wurden, 
sind im Appendix zu finden (A.1.-A.5.). Weiters wurden BGs mit Komponenten von Kaffee 
(Kahweol und Cafestol) beladen und anschließend mittels HPLC analysiert. Die Ergebnisse 
werden in Sektion A.6. kurz diskutiert. Im letzten Teil des Appendix wird die zytotoxische 
Wirkung verschiedenster Augentropfen auf die konventionelle Augenzellline CCL 20.2 sowie 
auf konjunktivalen Primärzellen untersucht (A.7.). Diese Studie wurde inkludiert, da fast alle 
untersuchten Lösungen BAC beinhalteten, welche schon in Kapitel 2.2.2. in Kombination von 
BGs analysiert wurde. Weiters wurden vorläufige Untersuchungen durchgeführt, in denen die 
zytotoxische Wirkung zweier Augentropfen in Anwesenheit von BGs ermittelt wurde (A.4.).
9
Zusammenfassung
Kapitel 2.1. Bakterielle Ghosts als Trägervehikel von Zytostatika  
In vielen Studien wird die chemopräventive und zytostatische Wirkung des 
Hydroxystilbens Resveratol (RV) demonstriert. Die neuartigen, RV-Analoga 
Digalloylresveratrol (DIG) und 3,3’,4,4’,5,5’-Hexahydroxystilben (M8) zeigen höhere 
antitumor-Aktivität als RV und sind daher neue Wirkstoffkandidaten für die Behandlung von 
Kolorektalkrebs.
Der Vorteil, dass die bioadhäsiven bakteriellen Ghosts (BGs) ihre natürlichen 
immunstimulierenden Komponenten auf ihrer Zelloberfläche behalten, prädestinieren sie als 
optimalen „drug delivery“ Vehikel, die für die Behandlung und Therapien von Tumoren 
eingesetzt werden können. Daher wurden BGs, die mit diesen chemotherapeutischen 
Komponenten beladen wurden, auf ihre zytotoxische Wirkung in der Kolonzelllinie HT29 
untersucht. Befunde aus vergleichenden Untersuchungen zeigten, dass durch das „BG-delivery“ 
der Substanzen die Lebensfähigkeit der Zellen signifikant reduziert werden konnte – gemäß des 
zytotoxischen Schemas der freien Substanzen (DIG> M8 > RV). Um zu bestätigen, dass diese 
Effekte auf  intrazelluläres „drug-delivery“ zurückzuführen sind, wurden Experimente mit RV-
BGs durchgeführt und die Konzentration von RV sowie dessen Metaboliten mittels HPLC 
bestimmt. Die Ergebnisse dieser Studien zeigen, dass das beladene photosensitive RV, sehr gut 
durch die BG Hüllen geschützt wurde und dass die beladene Substanz effektiv in den HT29 
Zielzellen freigesetzt wurde. Weiters wurden intrazelluläre RV-Konzentrationen und 
Metaboliten gefunden, die selbst nach Coinkubation von RV-BGs bis zu 24 Stunden 
detektierbar waren. Zudem wurden nach Behandlung mit RV-BGs höhere Konzentrationen von 
RV in HT29 gemessen, als im Vergleich zur Behandlung mit freiem RV in äquivalenter Dosis.  
Kapitel 2.2. Bakterielle Ghosts als „targeting vehicles“ von Augenzellen 
Bindehautszellen repräsentieren nicht nur eine mechanische Barriere für Pathogene, 
sondern schützen das Auge auch gegen Allergene und toxischen Substanzen. Dennoch sind 
weltweit viele Menschen von Erkrankungen der Bindehaut betroffen und es bedarf eines 
„delivery“ Systems, welches effektiv den Transport von Wirkstoffen in den betreffenden 
Bereich des Auges gewährleistet.  
Um die Anwendung von BGs als Trägersysteme für zukünftige therapeutische 
Applikationen zu prüfen, wurden grundlegende Reaktionen von konjunktivalen Zellen nach 
Coinkubation mit BGs analysiert. Die dafür verwendeten Zellen wurden durch Kultivierung 
primärer humaner Bindehäute erhalten und die zu untersuchenden BGs wurden von 
unterschiedlichen bakteriellen Spezies produziert. In Abhängigkeit des BG-Typus, konnten bei 
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konjunktivalen Primärzellen hohe Aufnahmeraten von BGs mittels FACS Analysen 
nachgewiesen werden. Weiters konnte gezeigt werden, dass BGs zu einer erhöhten Expression 
von ICAM-1 auf der Oberfläche von Bindehautszellen führen. Es ist anzunehmen, dass dies 
einen zusätzlichen stimulatorischen Effekt auf die Leukozytenpopulation haben könnte oder als 
kostimulatorisches Signal dient, das für Aktivierung von T-Zellen und Zytokinproduktion 
benötigt wird.
Die zytotoxische Wirkung von Benzalkoniumchlorid (BAC), welches häufig als 
Konservierungsmittel in ophthalmischen Lösungen verwendet wird, ist weitgehend bekannt. Da 
nachgewiesen werden konnte, dass durch BGs keine toxischen Effekte (weder zytotoxisch noch 
genotoxisch) ausgelöst werden, wurden BAC-bedingte toxische Effekte in der konjunktivalen 
CCL 20.2 Zelllinie in Anwesenheit von BGs untersucht. Es stellte sich heraus, dass BGs äußerst 
protektiv gegenüber BAC induzierter Zytotoxizität in CCL 20.2. Zellen wirkten. Weiters konnte 
gezeigt werden, dass BAC, vermutlich durch die Produktion von H2O2, zu DNA-Schäden in 
Bindehautszellen führt. Da nachgewiesen werden konnte, dass selbst lyophilisierte BGs 
Aktivitäten des Enzyms Peroxidase aufweisen, wurden weitere Experimente mit selektierten 
BGs durchgeführt und BAC-protektive Effekte in Gentoxizitätsmessungen gefunden. Weiters 
wurden Tests durchgeführt, in denen bestätigt wurde, dass die bakteriozide Wirkung des 
Konservierungsmittels in Anwesenheit von BGs erhalten bleibt.
Kapitel 2.3. Bakterielle Ghosts als Auslöser des angeborenen Immunsystems  
Das angeborene Immunsystem besteht aus bestimmten Zellen und humoralen Faktoren, 
welche infektiöse Agentien sofort erkennen, inaktivieren und töten. Dieser 
Verteidigungsmechanismus beinhaltet die Phagozytose von Bakterien durch Neutrophile oder 
Makrophagen sowie die Freisetzung von antimikrobiellen Peptiden, proinflammatorischen 
Zytokinen, hydrolytischen Enzymen oder reaktiver Sauerstoff/Stickstoff Spezies durch 
Phagozyten.  
Antimikrobielle Peptide und proinflammatorische Zytokine, welche von epidermalen 
Keratinozyten (KCs) produziert werden, stellen eine Schutzbarriere für eindringende 
Mikroorganismen dar und bilden einen wichtigen Teil in der unspezifischen Immunantwort der 
Haut. Aufgrund der Tatsache, dass die antimikrobiellen Peptide S100A7c (Psoriasin) und 
humanes Beta defensin-2 (hBD-2) zur Eliminierung von Hautpathogenen führen, wurde die 
mRNA Expression dieser Defensine nach Inkubation von KCs mit E. coli BGs untersucht. 
Ergebnisse von quantitativen real-time PCR Tests zeigten, dass BGs diese beiden Peptide in 
einer Partikelzahl-abhängigen Wirkung induzieren. Zudem konnte gezeigt werden, dass die 
Aufnahme der BGs in KCs wie auch die Freisetzung von proinflammatorischen Zytokinen, wie 
Interleukin (IL)-6 oder IL-8, auch vom Flagellingehalt auf der Oberfläche der BGs abhängig ist.  
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Die Freisetzung von Stickoxid (NO), welches durch die induzierbare NO-Synthase 
(iNOS) produziert wird, spielt eine wichtige Rolle bei infektiösen Krankheiten. Da bekannt ist, 
dass bakterielles Lipopolysaccharid (LPS) ein starker „Inducer“ der iNOS ist, wurde die 
Bildung von NO in einer murinen Makrophagenzelllinie nach Inkubation mit BGs untersucht. 
Es zeigte sich, dass E. coli BGs schnell von RAW 264.7 Zellen phagozytiert werden und in 
Abhängigkeit der Partikelzahl die NO-Akkumulierung induzieren. 
Von Resveratrol (RV) weiß man, dass es inhibierend auf die iNOS wirkt. Daher wurden 
weitere Experimente durchgeführt, in denen die BG-induzierte Akkumulierung von NO im 
Vergleich zu RV-beladene BGs untersucht wurde. Tatsächlich konnte die NO-Entwicklung auf 
diese Weise moduliert werden. Obwohl der generelle Aufnahmemechanismus von RV noch 
unklar ist, konnte gezeigt werden, dass endogenes „RV-delivery“ mittels BGs zu einer 
Modifizierung der NO-Freisetzung führt. Durch diese Untersuchungen konnte die Existenz 
eines zellinternen RV-Rezeptors postuliert werden, der als ERVR (Endogener Resveratrol 
Rezeptor) bezeichnet wird. 
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List of Abbreviations
ADDS advanced drug delivery system 
ADH alcohol dehydrogenase 
AG antigen 
APC antigen-presenting cell 
BAC benzalkonium chloride  
BG bacterial ghost 
BPL ?-propiolactone 
C cafestol 
CFU colony forming units 
CLSM confocal laser scanning microscopy 
CPS cytoplasmic space 
DC dendritic cell 
DIG digalloylresveratrol  
DMBA 7,12-dimethylbenz[a]anthracene 
DOX doxorubicin 
EALT eye associated lymphoid tissue  
ETEC enterotoxigenic E. coli  
FITC fluorescein isothiocyanate 
FL1 fluorescence signal 1 
FSC forward scatter 
GFP green fluorescent protein 
GST glutathione S-transferase 
hBD-2 human ? defensin-2 
HCC human conjunctival cell 
HCDEC human conjunctiva-derived epithelial cell 
HPLC high performance liquid chromatography 
ICAM-1 inter-cellular adhesion molecule 1 
IL ionic liquid 
IL-6 interleukin-6 
IL-8 interleukin-7 
IM inner membrane 
iNOS inducible nitric oxide synthase   
IPTG isopropyl ?-D-thiogalactopyranoside 
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K kahweol 
KC keratinocyte 
LPS lipopolysaccharide 
M8 3,3’,4,4’,5,5’-hexahydroxystilbene 
mc minicircle 
MDR multi-drug resistance 
MFI mean fluorescence intensity  
MOI multiplicity of infection 
MPL monophosphoryl lipid A 
NAT N-acetyltransferase 
NLR NOD-like receptor  
NO nitric oxide 
OD optical density 
OM outer membrane 
PAMP pathogen-associated molecular pattern 
PBS phosphate buffered saline 
PGRP peptidoglycan-like recognition protein 
P-HCl pilocarpine hydrochloride 
PhIP 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine 
PPS periplasmatic space 
PSI pounds per square inch 
pSIP self-immobilizing plasmid 
qRT-PCR quantitative real-time PCR  
RV resveratrol 
SCGE single cell gel electrophoresis  
SD standard deviation 
SNUC staphylococcus aureus nuclease 
TAA tumor-associated antigen 
TFF tangential flow filtration 
TLR toll-like receptor 
14
Chapter 1. 
Introduction to the Bacterial Ghost 
Technology Platform
15
16
Chapter 1.1. 
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The Bacterial Ghost (BG) Vaccine Platform Technology represents a particulate carrier 
system for protein subunit or DNA-encoded antigens endowed with intrinsic adjuvant 
properties. By all its biological background BG vaccines alert the immune system with signals 
for a bacterial infection and induce innate and adaptive immune responses against the antigens. 
Presentation of subunit vaccines within the BG complex is of advantage for the recognition of 
the target antigens by the immune system. Delivered as particle, to facilitate the uptake by 
professional antigen presenting cells (APC), BG satisfy the requirement of naturally furnished 
adjuvant particles for submit vaccine candidates. Such BG particles have a surface make-up 
which is not denatured and their surface adhesins are fully functional for the interaction with 
cellular receptors of APCs to induce the release of natural danger signals and cytokines 
characteristics for infections with real pathogens. The specificity for targeting tissues or cells, its 
easy method of production and its versatility in entrapping and packaging various compounds in 
different compartments of ghosts can be used for the creation of Advanced Drug Delivery 
Systems (ADDS). The original targeting functions of the bacteria ghosts are derived from 
enable them to bind to and/or are taken up by specific cells or tissues of animal, human or plant 
origin. The bacterial ghost system represents a platform technology for creating new qualities in 
non-living carriers which can be used for the specific targeting of drugs, DNA or other active 
compounds such as tumour cytostatics to overcome toxic or non desired obstacles. The new 
system is an alternative to liposomes and may have an advantage to its higher specificity for 
targeting different tissues, its easy way of production and its versatility in entrapping and 
packaging various compounds in different compartments of the carriers.
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Introduction
In analogy to empty erythrocyte ghosts which are devoid of cytoplasmic content and to 
bacteriophage ghosts which are free of nucleic acids the empty envelope of Gram-negative 
bacteria produced by PhiX174 gene E-mediated lysis has been named Bacterial Ghosts (BG). 
BG will be used in the following for a single bacterial ghost as well as for multiple bacterial 
ghosts. BG is already a common abbreviation for any type of Gram-negative cell envelope 
produced by expression of controlled expression of cloned PhiX174 gene E. [1] BG have been 
produced from different bacteria including E. coli C, different E.coli K12 laboratory strains, 
enterotoxigenic E. coli (ETEC) and enterohemorrhagic E. coli (EHEC), Salmonella enterica
serovar typhimurium, S. enterititis, Shigella flexneri, Vibrio cholerae O1 and O139, 
Helicobacter pylori, Neisseria meningititis, Bordetella bronchiseptica, Actinobacillus 
pleuropneumoniae, Pasteurella multocida, Mannheimia haemolytica, and Francisella tularensis
LVS and Pectobacterium cypripedii. Except of E.coli C and K12 derivatives and 
Pectobacterium cypripedii all other bacterial strains used are pathogenic strain causing severe 
diseases in animals or man. This imbalance of the number of BG produced from pathogenic 
versus non-pathogenic Gram-negative bacteria reflects one of the major applications of BG as 
vaccines. Investigations with E.coli C and K12 strains were mostly done for genetic engineering 
work to establish the BG system, and with the plant-specific P. cypripedii for plant pesticide 
targeting. [2] 
The other major application of BG is in Advanced Drug Delivery Systems (ADDS) is in 
part an extension of our basic investigations how to produce and to modify BG and to use the 
empty cell envelops for biomedical applications. BG production is characterized by the 
introduction of a small hole in the envelope of the bacteria and release of the cytoplasmic 
content driven by the osmotic pressure difference between the cytoplasma and the outside 
growth medium of the bacteria. This process of E-mediated lysis of bacteria is driven by gene E 
expression and co-translational integration of the E-polypeptide into the inner membrane 
followed by conformational changes of E and represents an endogenous genetic intracellular 
method to inactivate bacteria. [3] Gram-positive bacteria are simply killed by break down of the 
membrane potential without loss of cytoplasmic material. [4] 
BG have multiple applications in biomedicine as vaccines, as adjuvants, as DNA 
transfection vehicle for DNA vaccines or somatic gene transfer, as drug carrier for tumour 
therapy, miniature bioreactors, artificial bacterial life forms, and last but not least as 
construction modules for molecular machines in micro- and nanotechnology. All these different 
applications are based on our knowledge how to produce and modify BG for specific purposes. 
In the following examples the focus are applications of the BG platform technology in vaccines 
and ADDS where the products are based on common components and production processes. 
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More information on the BG vaccination trials can be found in several recent reviews where 
most of the original literature is cited [1, 5-8]as well as for the application as ADDS with 
schematic illustrations. [9, 10]. 
Characterization of BG 
Studies of the E-lysis process of Gram-negative bacteria has been emerged from basic 
science addressing both the lysis mechanism of bacteriophage PhiX174 after infection of 
Escherichia coli, and, the specific mode of action of the cloned lysis gene E of the phage [11-
15] State to the art BG production requires the transformation of the host bacterium with a 
plasmid which carries the gene E under an inducible promoter. Since the gene E product is 
highly lethal the recipient either carries the corresponding repressor system on its chromosome 
or on a plasmid or to use E-lysis plasmids where the repressor system is also encoded on the 
very same plasmid which is able to raise a critical repressor concentration in the bacterium to 
silence gene E expression. Thus, the proper establishment of the genetic repression/expression 
system in a given Gram-negative bacterium determine the success of BG production.  
A series of plasmids have been developed which carry the gene E under an inducible 
expression control. The most elaborate systems are derived from the phage Lambda left or right 
promoter/operator system with expression control by the thermosensitive cI857 repressor or 
derivatives providing the growth of bacteria up to 28, 36 and 39°C, and E-mediated lysis at any 
temperature 2°C above the maximal repression temperature up to 42-44°C for enterobacteriacae 
and most other bacteria [16]. The loss of nucleic acids due to E-mediated lysis greatly 
minimizes the risk of horizontal gene transfer of pathogenic islands or antibiotic resistance 
genes which have been used for the plasmid system(s) used. As DNA can unspecifically adsorb 
to the inner membrane of BG “superclean” BG can be produced by expression and activation of 
the cloned Staphylococcus aureus nuclease (SNUC) which degrades DNA and RNA [2]. The 
remaining DNA level of such BG preparations is below the real-time-PCR detection level and 
sets a new quality criterion for inactivated vaccines, and diminishes the risk of horizontal gene 
transfer in some of our BG preparations. A short characterization of protein E and SNUC is 
given in Table 1.
Minimal amounts of protein E are required to lyse Gram-negative bacteria [17] therefore 
the challenge in BG production is to assure the complete repression of gene E before induction 
of gene E expression. Induction of gene E, however, is not enough to achieve proper E-
mediated lysis. There are additional requirements such as active growth and functional control 
elements of cell division and of autolytic activity of the host bacteria. Membrane adhesion sites, 
FtsZ protein in the septosome [18], cis-trans proline isomerases for conformational change of 
protein E [19], chaperones, the strength of the membrane potential [20], the activity of the 
autolytic system [21], the ph and osmotic strength of the medium [22], and other factors also 
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influence the E-lysis process. A reasonable BG production rate of a growing culture is 
approximately 99.9 - 99.99% and depends largely on exponential growth of the bacterial 
culture. Only growing bacteria can be lysed, bacteria entering stationary phase are 
phenotypically resistant to lysis [23]. Although it seems to be trivial to E-lyse bacteria a good 
and efficient E-lysis needs experience and stringent process control. 
Investigations of the molecular mechanism of E-mediated lysis showed that protein E 
fuses the inner and outer membranes of Gram-negative bacteria, thereby forming a 
transmembrane lysis tunnel in the bacterial envelope through which the cytoplasmic content is 
released. High resolution transmission electron micrographs clearly show the intact structure of 
the bacterial envelope, and of the continuity of the inner and outer membranes forming the 
border of the E-specific transmembrane [13]. 
On average, the diameter of the E-specific transmembrane tunnel varied between 40 and 
80 nm [13]. The variation in size and irregular tunnel structures indicated that the E-specific 
transmembrane tunnel structure is dynamically formed by the strong force ejecting the 
cytoplasmic content through the E-lysis hole which is most probably formed by E-oligomers. 
[24] Under normal bacterial growth conditions the osmotic pressure difference between the total 
solutes of the cytoplasma and the outside growth medium is more than 1 bar.  
Due to the integration of protein E in the inner membrane the paracrystaline 
peptidoglycan net located in the periplasmic space between the inner and outer membrane of the 
cell envelope structure of Gram-negative bacteria exhibits a higher turn-over rate at potential 
sites of lysis tunnel formation. As a consequence, the borders of the E-lysis tunnel are 
determined by the local mash size of the peptidoglycan which is the shape determining rigid 
structure of the bacteria. Except for the hole BG resemble their natural mother bacteria and in 
the outer surface of BG pili, flagella and lipopolysaccharide are well retained. The inner side of 
the BG envelope complex corresponds to the inside of the cytoplasmic membrane and its 
associated products which are not released by E-mediated lysis. As there is a hole in the 
envelope the membrane potential of BG is no longer existing whereas membrane integrated 
enzymes like the ATPases are still functional. [20, 25] The space between both membranes is 
the periplasmic space (PPS) which by its nature is a gel like environment rich in membrane 
derived oligosaccharides, specific enzymes, proteins and peptidoglycan. It should be mentioned 
that because of the fusion of the inner and outer membranes at the E- specific transmembrane 
lysistunnel the PPS is sealed. [13, 20] Again, enzymes specific for the PPS like alkaline 
phosphatase and beta-lactamase are still active. The outer membrane and all its appendices are 
functional preserved which is of major importance for their targeting and adhesion properties. 
Thus, BG are highly sophisticated designed like their mother bacteria for adhesion and 
eventually uptake by cells or tissues and better equipped than any engineered liposome, which 
can be artificially produced. As the nature of BG as well as their architecture is important for 
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their functions when possible in the following sections both applications as vaccines and ADDS 
are discussed together. 
BG as vaccines 
There is no doubt that functional vaccines are the most effective medical interventions to 
safe lives and reduce costs in healthcare. Some of the traditional vaccines still in use do not 
meet the following requirements for novel vaccines: (i) to be safe and immunogenic in young 
children, the adult and the elderly, (ii) include multiple serotypes/species, (iii) be inexpensive 
(less than a Euro per dose), easy to produce, stable without refrigeration, and amenable for 
needle-free administration, and, last but not least, (iv) should confirm robust immunity with 
three or less doses. As far as tested and calculated, BG vaccines meet most the criteria listed and 
provide improvement and substitution for existing vaccines and follow well the paradigm shift 
from single subunit vaccines to multiple antigen vaccines. BG is also excellent alternatives to 
vaccines which use chemicals, heat or irradiation to inactivate the pathogen. All these methods 
denature essential structural components of the bacteria whereas the E-lysis process for BG 
production is a genetic/biochemical method leading to a superior preservation of their antigenic 
properties.
In the simplest form BG vaccines consist of a freeze dried powder of BG particles 
without any additions of stabilizers or adjuvant. The latter is very important as some of the 
adverse reactions against vaccine preparations originate from the adjuvants or stabilizers used. 
The BG system, however, is a potent vaccine delivery system with intrinsic adjuvant properties. 
Due to the particulate nature of BG and the fact that they contain many well known immune 
stimulating compounds such as LPS, lipid A and peptidoglycan BG enhance immune responses 
without any further additions. The results of different in vivo and in vitro studies confirm the 
potential of bacterial ghosts as carrier and adjuvant in modern vaccine development addressing 
key immune cells, such as dendritic cells, macrophages or monocytes via toll-like receptors or 
opsonized antibody facilitated uptake [26]. Oral, intra-nasal, intra-ocular, intra-vaginal, rectal 
and acrogenic are the preferred routes of needle-free BG vaccine delivery. The oral 
immunization of rabbits with V. cholerae BG induced protective immunity determined with the 
RITARD test and conferred cross protection between classical O1 and the recently emerging 
O139 strain [27]. 100% protection levels against heterologous lethal challenge with EHEC was 
achieved in mice after two oral immunizations with EHEC BG [28]. The same result could be 
obtained with a single rectal immunization of mice with EHEC BG (Mayr and Lubitz, to be 
published elsewhere). Here, it should be emphasized that rectal immunization could have a high 
value for vaccine delivery in children as accurate dosing is given by the supensorium and 
parents normally feel comfortable and are familiar with fever reducing supensorium. Intra-nasal 
immunizations with BG in mice gave good immune protection against Shigella infections. 
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Aerosol immunization of pigs with Actinobacillus pleuropneumoniae BG induced sterile 
immunity against lethal bacterial challenge [29]. BG have an ideal aerosol diameter of 1-3 um 
and can be prepared as dry or wet aerosols. [30] The pathogen A. pleuropneumoniae and the 
experimental animal model (pigs) used for the former mentioned study are a good model for 
human lung immunizations or for the aerosol delivery of drugs deep in the alveolar space. 
BG with extended properties 
The BG system offers a construction kit with a modular concept where different 
molecular parcels/bricks are assembled within a living cell by genetic engineering before BG 
formation is induced. [Fig. 1] For specific needs and purposes genetic engineering of the host 
bacteria which are candidates for BG production can be used to modify their cell envelope to 
carry foreign proteins and/or to use such recombinant proteins to bind other proteins, DNA or 
active substances. Some of the applications of such modified BG are in vaccines whereas other 
find their application in BG as carrier of active substances or in more technical applications. It 
should be mentioned here that one of our future aims is to develop for therapeutic use BG 
combinations for drug targeting and vaccines in a single BG. In Table 1 and in the following 
vaccine and ADDS properties of engineered BG are discussed together.  
The following modules are in our construction kid for BG vaccine and BG carrier design: 
i) Plain BG: 
Vaccines: The BG envelope is either derived from a pathogen or from a non-pathogenic 
organism. [Fig. 1] In the first case the envelope itself is sufficient to induce a relevant immune 
response in the host. In the latter case the BG can serve to stimulate the innate immune system 
ADDS: The BG from pathogens are also excellent targeting vehicles for primary immune cells, 
endothelial cells of blood vessels or intestine, or to recognize tumour tissue by specific ligand 
receptor interaction. 
ii) BG as carrier of additional proteins: 
Vaccines: The BG envelope can be derived from a non-pathogenic bacterium and serves as 
carrier and adjuvants in regard to the target antigens, or can be derived from a pathogenic 
organism carrying out the same functions and represent combination vaccines. The additional 
protein represents always multi-epitope antigens which can be presented in several ways, e.g.
anchoring of the foreign protein to the inside of cytoplasmic membrane by fusing it to a N-, C- 
or N- and C-terminal membrane anchor. [Fig. 1B] Fusion of the target antigens with the maltose 
binding protein or fusing it to an export sequence are methods to export foreign protein or 
polypeptide constructs to the periplasmic space. For the insertion of target antigens on the 
surface of the outer membrane OmpA-fusion can be used. Foreign or homologous pili can be 
inserted in the envelope which can either act as subunit vaccine or to broaden the specific 
22
receptor recognition repertoire of the BG. S-layer protein matrices formed by SbsA or SbsB can 
be modified to carry foreign inserts [31]. As both proteins form sheet like self-assembly 
structures they are not expelled with the cytoplasma and remain in the inner cytoplasmic lumen 
after E-mediated lysis. When SbsA or SbsB fusions are exported as maltose-binding protein 
fusion to the periplasmic space they still retain their self assembly capacity and fill this space 
with sheets carrying target antigens.  
ADDS: If the foreign protein is an enzyme or a functional active polypeptide the same methods 
for internalization of the target protein as described above for antigens can be used. In addition, 
if streptavidin is used as foreign protein other biotinylated ligands can be added to the BG 
protein/polypeptide carrier. [Fig. 1B][32] In one of the application examples biotinylated 
dextran has been filled into the cytoplasmic lumen of BG exposing membrane-anchored 
streptavidin.[Fig. 1C] Such polymers themselves can be substituted with drugs and represent a 
slow release system. In a specific formulation with in vivo biotinylated E or E-Streptavidin 
fusions which are still lysis active the ligand receptor moieties of the fusion constructs are 
exposed on the BG surface surrounding the E-specific lysis tunnel. [Fig. 1D] Any streptavidin 
or biotinylated new compound, respectively, can be directed to bind to this crown like ligand 
ring.[Fig. 1E-1C] For example, small vesicles have been bound to the BG carrier piggy-backing 
inside out vesicles of other bacteria. It is also feasible to construct net-like streptavidin-biotin 
chimneys of variable length on top of the E-lysis tunnel structure to form nano tubular structures 
[Fig. 1F] which can modify the release properties of the BG carrier filled with water soluble 
substances. [Fig. 1G]
BG as carrier of nucleic acids: 
Vaccines: BG are derived from non-pathogenic or pathogenic bacteria and serve as carrier of 
DNA and provide for the DNA vaccine targeting functions for antigen-presenting cells and a 
highly efficient intracellular DNA release from the endosome-lysosome compartment. The high 
transformation and target gene expression rates of dendritic cells (75%) and for macrophages 
(60%) with DNA-BG carriers can compete with commercial transfection systems. The method 
for filling BG with DNA is rather simple and in its standard version freeze dried BG are 
resuspended in a DNA solution, and after washing off the excess of DNA which is not bound to 
the inside of the cytoplasmic membrane, the DNA-BG can either be used immediately for gene 
transfer experiments or can be stored after freeze drying for later applications. The number of 
plasmids per BG depends on the concentration of the DNA solution used and as greater the 
DNA concentration the greater the DNA loaded per BG. Loading of BG with DNA is very 
efficient as more than 3,000 copies of a medium sized plasmid can be bound per BG [33]. A 
more sophisticated version of loading BG with DNA uses the specific interaction of an inner 
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membrane anchored DNA binding protein with the corresponding operator region on target 
plasmid. [Fig. 1H]  This allows a one step DNA loading and BG formation process [28]. 
ADDS: For the application of DNA in somatic gene transfer it is desirable to use DNA 
constructs devoid of antibiotic resistance cassettes and origin of replication of the production 
plasmid and to design minimal minicircles including an eukaryotic promoter the gene of interest 
with poly A tail and transcription stop sequences. The improved version of our self-
immobilisation plasmids encodes the par A resolvase which is a specific DNA recombination 
enzyme recognizing homologous sequences on the plasmid. After expression of the par A 
resolvase and the inner membrane anchored DNA binding protein only minicircle DNA is 
bound to the inner membrane. By E-mediated lysis BG are produced with in vivo loaded 
minicircle DNA [34]. In addition to the functional aspects of DNA encoding genes or siRNA 
for regulation of gene expression, DNA can also be considered as pure structural element for 
construction purposes to architecture for instance the inner lumen of BG and to serve as docking 
molecule for other DNA or RNA tailed molecules. 
BG as carrier vehicles for DNA and/or cytostatic drugs in tumour therapy: 
DNA and/or drugs can be used as active substances for tumour treatment, and 
investigations have shown that human melanoma and colon carcinoma cells can be targeted 
with BG for delivery of DNA or drugs, respectively. In a recent study, eight different human 
melanoma cell lines which have many functions in common with antigen presenting cells [35] 
[36] have been investigated for their capacity to bind and phagocytise BG [38]. Bowes cells 
exhibited roughly 80% expression level of BG delivered marker gene indicating that the BG 
system is suitable as vehicle for the transfer of DNA encoded functional RNA such as siRNA, 
enzymes for pro-drug conversion or inducer of other activities with therapeutic effects for the 
host.
Recent investigations of binding polyphenolic compounds to BG confirm the finding that 
molecules with organic ring structures bind unspecifically to the membrane compartments of 
BG and add a group of new compounds to the list of active therapeutic substances for 
intracellular delivery. Treatment of the human colon cancer cell line CaCo2 with doxorubicin 
(DOX) loaded BG showed an effect on proliferation inhibition by two log difference compared 
to the free drug [39]. In extended investigations it was determined that DOX BG reduced the 
growth inhibitory concentrations of the drug up to more than 300 times compared to the EC50 
of the free drug and enhanced the intracellular DOX concentrations up to 42 times compared to 
the free drug (Mader and Lubitz, to be published elsewhere). These results are promising as 
DOX for instance has accumulating side effects on heart functions and the tumour therapy often 
has to be terminated once a critical maximal dose is reached. It is not envisaged to apply DOX 
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BG intravenously but rather local in combination with surgery and pre- and after surgery by 
short term rinsing or flushing of the colon to deliver the therapeutic cargo. We hope that with 
this procedure the time window for DOX therapy can be considerably extended and can also 
contribute to an increased quality of life for the patients as side reactions to the drug are also 
less severe. The concept to specifically target tumour tissue in combination with surgery could 
probably also be applied to other tumours such as head and neck cancer and brain tumours as 
certain BG have a surface make-up that allow them to bind to and being taken up by the tumour 
cells. The important benefit of BG drug delivery is the increased bioavailability due to the 
bioadhesive nature of BG envelope surface targeting tumour tissue and the unique intracellular 
release mechanism of the drug. 
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The Bacterial Ghost (BG) platform technology is an innovative system for vaccine, drug 
or active substance delivery and for technical applications in white biotechnology. BGs are cell 
envelopes derived from (recombinant) Gram-negative bacteria that are devoid of all cytoplasmic 
content but have a preserved cellular morphology including all cell surface structures. Using 
BGs as delivery vehicles for subunit or DNA-vaccines the particle structure and surface 
properties of BGs are targeting the carrier itself to primary antigen-presenting cells. 
Furthermore, BGs exhibit intrinsic adjuvant properties and trigger an enhanced humoral and 
cellular immune response to the target antigen. Multiple antigens of the native BG envelope and 
recombinant protein or DNA antigens can be combined in a single type of BG. Antigens can be 
presented on the inner or outer membrane of the BG as well as in the periplasm that is sealed 
during BG formation. Drugs or supplements can also be loaded to the internal lumen or 
periplasmic space of the carrier. BGs are produced by batch fermentation with subsequent 
product recovery and purification via tangential flow filtration. For safety reasons all residual 
bacterial DNA is inactivated during the BG production process by the use of staphylococcal 
nuclease A and/or the treatment with ?-propiolactone. After purification BGs can be stored 
long-term at ambient room temperature as lyophilized product. The production cycle from the 
inoculation of the pre-culture to the purified BG concentrate ready for lyophilization does not 
take longer than a day and thus meets modern criteria of rapid vaccine production rather than 
keeping large stocks of vaccines. The broad spectrum of possible applications in combination 
with the comparably low production costs make the BG platform technology a safe and 
sophisticated product for the targeted delivery of vaccines and active agents as well as carrier of 
immobilized enzymes for applications in white biotechnology.
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Introduction
Bacterial ghosts (BGs) are envelopes from Gram-negative bacteria which have been 
produced by controlled expression of the cloned lysis gene E. After the essential role of gene E
in the lysis of Escherichia coli after infection with bacteriophage ?X174 was discovered in 
1966 [1] and after the eve of genetic engineering 16 years later it could subsequently be shown 
that after cloning its sole expression is sufficient to cause lysis of E. coli [2-3].  E was the first 
lethal gene for bacteria which could be silenced enough on plasmids to be established in non-
host range bacteria of the phage and converts Gram-negative bacteria into BGs whereas Gram-
positive bacteria are killed without lysis.  
Gene E codes for a 91-aa polypeptide [4-5]. In contrast to lytic proteins from other 
phages protein E has no inherent enzymatic function [6-7] but represents a membrane protein 
[8-9]. Analysis of the primary structure of protein E revealed a hydrophobic region at its N-
terminal end suggesting it is membrane-associated [8] and integrates into the cytoplasmic 
membrane of E. coli [10]. The observation that stationary phase host cells do not respond to E-
lysis induction but lyse upon provision of fresh medium as well as the inhibitory effect of non-
physiological pH-values on the E-lysis process indicated that E-mediated lysis is dependent on 
the physiological state of the host cells [11-12] triggers the host cell's autolytic system [9, 13-
15]. 
E has the ability to oligomerize and analysis of the hydropathicity of protein E indicated 
an E-specific lysis tunnel spanning the inner (IM) and outer membrane (OM) which most 
probably is located at membrane adhesion sites within the host cell [16]. E-mediated lysis 
releases all cytoplasmic content to the environment while periplasmic components remained 
associated with the empty cell envelope [9]. The collapse of the bacterial membrane potential 
precedes the onset of E-lysis [17]. The E-specific lysis tunnel could be visualized by high-
magnification scanning and transmission electron microscopy of E-lysed E. coli (Fig. 1, a). Mo-
reover, the images illustrated that E- lysis of E. coli was accompanied by a fusion of the inner 
and outer membrane (Fig. 1, b) sealing the periplasmic space (PPS) [18]. Several electron-
microscopic investigations of E-lysed E.coli cells revealed that in more than 90% of the cases 
the E-specific lysis tunnel is located either at the centre or the poles of the bacteria both of 
which are potential division zones [19]. Recalling that protein E-mediated lysis is dependent on 
the physiological state of the host bacterium [11-12] and analysis of E-lysis in E. coli mutants 
with defects in cell division  indicated that mechanisms involved in cell division are mandatory 
for lysis [19-20].  
The observed lysis tunnel diameter varies between 40 to 200 nm and does not show any 
regular structure. The driving force for the rapid discharge of the cell content is the osmotic 
pressure difference between the cytoplasm and the surrounding medium. However, the native 
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structure of the peptidoglycan within the envelope complex remains intact and rigid [21]. The 
observed stimulation of peptidoglycan turnover by about 10% [21] could be in accordance with 
genetic evidence that protein E inhibits MryA translocase A [22]. Based on these findings and 
extended experiments using a E-streptavidin fusion protein (E-FXa-StrpA) Schön et al. [23] 
described the process of E-mediated tunnel formation with a three-phase model: 1. integration 
of protein E into the IM with the C-terminus facing the cytoplasm - 2. conformational change of 
protein E translocating the C-terminal domain to the PPS accompanied by oligomerization and 
targeting of the division initiation complex via lateral diffusion - 3. fusion of IM and OM at 
membrane adhesion sites induced by exposition of the C-terminus of protein E to the cell surfa-
ce. This model implies that the lysis tunnel is note solely edged by protein E oligomers but its 
formation requires protein E-triggered fusion of the inner and outer membrane [23]. A 
schematic drawing of this model is shown in Figure 2 (b).
Upon discovery of the remarkable features of protein E-mediated lysis in E.coli the 
principle of E-lysis could be shown with other Gram-negative bacteria [24-25] but not for 
Gram-positive bacteria [26]. So far, BGs of numerous Gram-negative strains (different E. coli
strains, Salmonella typhimurium, Salmonella enteritidis, Klebsiella pneumoniae, Bordetella 
bronchiseptica, Heliobacter pylori, Vibrio cholerae, Actinobacillus pleuropneumoniae, Hae-
mophilus influenzae, Mannheimia haemolytica, Pasteurella multocida, Pseudomonas aerugino-
sa, Pseudomonas putida, Ralstonia eutropha, Pectobacterium cypripedii and others) have been 
generated successfully suggesting the BG platform might be extended to any Gram-negative 
bacterium [25]. The idea of utilizing BGs derived from different Gram-negative bacteria as 
candidate vaccines emerged due to the demand for both potent and safe new vaccines [27-31]. 
The BG system offers many advantages over traditional vaccination techniques such as targe-
ting and the intrinsic adjuvant properties of the BG particles. In addition, recombinant DNA 
technology facilitates the development of multivalent protein or DNA vaccines. Another great 
feature of BGs is the fact that no denaturing effects occur during E-lysis and hence all antigenic 
determinants are preserved throughout BG generation. The use of BGs as candidate vaccines 
and advanced drug carriers can be found in several recent reviews [24, 27, 29, 32-36].  
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BG - Production Process 
Initial cloning and expression studies with gene E used the inducible lac 
promoter/operator system with an over-expression of the lacI repressor gene (lac PO-lacIq1) [2-
3]. Later the temperature sensitive ?-system (?pL/?pR-cI857) has proven to be more suitable for 
quick and efficient lysis without the need of any addition of chemical inducers [11]. Since the ??-
repressor cI857 shows incipient expression of downstream gene E at temperatures above 30°C 
the temperature sensitivity of the system was optimized to meet more favourable fermentation 
temperatures of 35°C or higher. Mutations in the OR2 operator region of the ?pR promoter 
resulted in tight repression of downstream genes up to 36°C and 39°C, respectively [37-38]. 
These temperature-inducible E expression cassettes are widely used in current BG production 
processes since they are robust enough to allow fermentation of the bacterial culture at 35°C and 
induction of protein E-mediated lysis at 42 or 44°C. 
In standard fermentations of various bacteria the quality criterion for a successful E-lysis 
process is a BG formation of at least 99.9% of the bacterial culture within a time window of 2 h. 
Depending on the host organism E-lysis efficiencies of more than 99.99% and higher can be 
achieved in this time frame. In Figure 3 the time-point of E-lysis induction is defined as time-
point zero (0 min) with the preceding growth phase denoted in negative minutes. 
BG production has been established in fermentation volumes up to 20 l using Labfors-3 
and Techfors-S fermenters (Infors HT, Bottmingen, CH). Starting with a pre-culture that is 
growing exponentially the production fermenter is inoculated with the inoculum at a volume ra-
tio of 1:10. The standard fermentation process can be divided into three major stages: growth 
phase (90 min), E-lysis phase (120 min) and downstream processing.  
The overall timeline for the production process is designed in a way that from the 
automatic inoculation of the pre-culture to the final concentration of the product the whole 
process takes 18 h and can be performed in one working cycle. The key events of the BG pro-
duction process (Fig. 4) are discussed in more detail below. 
Growth phase: 
The growth phase in an example fermentation with E. coli harbouring plasmids for 
temperature-inducible E-lysis is conducted at 35°C, pH 7.20 and aeration parameters sufficient 
for exponential growth. To maintain a level of dissolved oxygen (dO2) of approximately 20% 
saturation both stirring and aeration rate are adjusted gradually over the course of the growth 
phase. After 90 min E-lysis of E. coli is induced at cell densities of  approximately 1-2 (109) 
cells/ml.  
When recombinant proteins are expressed to be incorporated into the envelope complex 
before E-mediated lysis expression of the corresponding genes is induced chemically 30 min af-
ter inoculation (e.g. lac-, arabinose induction system). In case that the synthesis of the foreign 
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proteins slows down the growth rate slightly lower cell densities are reached before normal in-
duction of E-lysis and to compensate for BG yield the growth phase may have to be prolonged 
to 120 min. 
E-Lysis phase:
E-lysis of the culture is induced by temperature up-shift from 35 to 42°C (Fig. 3, (a)). in 
our system it takes roughly 10 min to reach the new temperature in the fermenter. At the same 
time stirring and aeration control is locked to prevent foaming during BG formation. The dO2-
level subsequently drops below 5% and so remains for about 30 min. In the fermentation log vi-
sual evidence for E-lysis onset is a sudden signature up-shift of dO2 (Fig. 3, (b)). The E-lysis 
phase continues for a total of 120 min with its end being characterized by the dO2 reaching a 
stationary value of > 95% saturation (Fig. 3, (c)).
Down-stream processing:
The BG product is harvested from the fermenter via tangential flow filtration (TFF) in a 
0.2 μm hollow fibre module at a temperature of at 15°C. In a first step the fermentation broth 
(20 l) is concentrated to 2.0 l (Fig. 5 (a)) and transferred to a stirred reservoir. Then the con-
centrate is inactivated with ?-propiolactone (BPL). For more detail on BPL see chapter 3. In a 
second step the BPL-treated broth is washed with sterile, de-ionized water (dH2O) by diafiltrati-
on in a smaller 0.2 μm hollow fibre module. A total of 5.0 l dH2O displaces the remaining 
medium and all residual ctoplasmic content. During the non-steady-state diafiltration the 
product suspension is further concentrated to 400 ml (Fig. 5 (b)). The overall concentration 
factor is 50 while virtually all medium (> 99%) is withdrawn. The final BG concentrate is divi-
ded into aliquots and lyophilized. As freeze-dried product BGs are stable at room temperature 
for many years. 
The TFF procedure as described above is an alternative to harvesting and washing BG via 
centrifugation. Contrary to the filtration process this procedure is more laborious, time-
consuming and might lead to BG aggregation because of difficulties with a proper re-suspension 
of the BG pellet. Furthermore, the implementation of TFF for harvesting and washing of BGs 
keeps all processes in a closed system and reduces the risk of cross-contamination during the 
handling procedure. 
Process and quality control:
During fermentation all relevant process parameters (T, pH, dO2, aeration, stirring) are 
monitored and controlled. Starting from the time-point of inoculation (Fig. 3: A, -90 min) sam-
ples are taken every 30 min over the course of the fermentation (Fig. 3: B - H) and analyzed for 
optical density (OD600) and cfu. All samples are also examined by light-microscopy and flow 
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cytometry. Optionally, the biomass is also investigated for DNA content by real-time PCR and 
the level of protein E expression.  
In standard fermentations with E. coli the onset of E-lysis is linked to a sudden drop in 
OD600 of the culture broth and this simple determination is one important indicator of 
successful E-lysis induction. BG formation can also be observed as the appearance of translu-
cent bacterial bodies in light microscopy. Both methods are good indicators for the quality of E-
mediated lysis of E. coli but contain no quantitative information. The actual E-lysis efficiency is 
determined by cfu counting a day after sample collection. Flow cytometry, however, has been 
established as a reliable real-time tool for the assessment of E-lysis onset and the progress of 
BG formation [39]. For flow cytometry diluted samples of the culture broth are stained with two 
fluorescent dyes and run through a CyFlow analyzer (Partec, Münster, Germany). The first dye 
(RH414) stains phospholipid membranes and with its fluorescence signal defines a gate for the 
exclusion of all non-cellular background. The discrimination of living cells, dead but non-lysed 
cells and BGs is obtained by a combination of the forward scatter signal (FSC) and the fluores-
cence signal (FL1) of the second dye (DiBAC4(3)) which is able to penetrate and stain only cells 
that have lost their membrane potential. DiBAC-negative cells with a high scatter signal repre-
sent living cells, DiBAC-positive cells with a similar scatter signal represent the dead cell frac-
tion. DiBAC-positive cells with a diminished scatter signal are identified as BGs. The general 
procedure for online monitoring E-lysis of E. coli by flow cytometry has been developed by 
Haidinger et al. [39-40] and was adapted recently. The flow cytometry result for a given sample 
is available in less than 10 min after sampling. Representative dot-plots of an E .coli culture 
during the E-lysis process is shown in Figure 6 for the time-points induction (a), course (b) and 
end of the E-lysis phase (c). 
After lyophilization the dry powdery BG product is investigated with respect to sterility 
and re-suspensibility. For sterility investigations 10 mg of BGs are re-suspended in rich medium 
and aliquoted for plating as well as for enrichment cultures. All sterility tests are performed in 
triplets to ensure that the final product does not contain any viable cells. The re-suspensibility is 
evaluated via flow cytometry with a lyophilized sample that has been re-suspended in dH2O.
Since lyophilized BGs generally are well re-suspensible the sample should give a similar picture 
and corresponding particle counts as the original sample before lyophilization.  
BG – Inactivation 
As a new quality criterion set in the last two years the harvested BG product should be 
free of any living cells before lyophilization. Although the efficiency of BG formation reaches 
three to five orders of magnitude during the time window of E- lysis (Fig. 3, 4) remaining live 
cells must be inactivated subsequently. The presence of protein E in the envelope complex of 
bacteria does not necessarily kill all bacteria by E-lysis. However, protein E in the membrane 
36
renders all bacteria more sensitive to killing by lyophilization and in the past no living cell 
counts could be detected in the lyophilized BG samples. In applications where nucleic acid-free 
BGs are produced inactivation can be accomplished by the expression of an additional kill gene 
in the host cells in combination with E-lysis [41]. For this the staphylococcal nuclease A 
(SNUC) is used which reduces the DNA content below the detection limit of real-time PCR. 
SNUC activity is also responsible for cleaning up residual DNA in BGs and can lead to comple-
te inactivation of the culture as it degrades the host DNA into fragments no longer than 100 base 
pairs [41]. Activation of the positive effect of SNUC expression on minimizing both cell viabili-
ty and residual DNA-content in the BG product is dependent on the addition of Mg2+ and Ca2+
as well as a shift in pH to 8.0 [41]. Figure 7 shows a Shigella flexneri 2a culture harbouring 
plasmid pGLNic for co-expression of temperature-inducible protein E and IPTG-inducible 
SNUC.
In combination with or as an alternative to SNUC addition of the alkylating agent ?-
propiolactone (BPL) after harvesting is effective to fully inactivate all viable cells. BPL is 
known to react with nucleic acids, mainly guanine. BPL is widely used for the inactivation of 
viruses and further to sterilize vaccines, human tissue implants and plasma [42]. The presence 
of BPL causes alterations (transition mutations, cross-linking, nicks) in nucleic acids. Besides 
its reaction with nucleic acids in the presence of water BPL fully hydrolyses at room-
temperature into non-toxic ?-hydroxypropionix acid [42]. In BG production the amount of BPL 
for complete inactivation of the BG product suspension depends on three parameters: the a-
mount of DNA present in the suspension, the application time and the application temperature. 
Due to the expulsion of the cytoplasmic content most DNA in the BG suspension is present in 
the liquid phase which makes it reasonable to apply BPL in the BG concentrate after harvesting 
and before diafiltration. At this point approximately 97% of the original fermentation liquid - 
and therefore 97% of the free DNA - have been withdrawn from the product. Two equal dozes 
of BPL given at 30 min intervals are sufficient for total inactivation of all surviving cells at 
42°C within 60 min. The final BG product is washed with another 5.0 l dH2O by diafiltration 
before distribution for lyophilization.   
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BGs - Applications 
BGs solo:
Immunization against pathogenic Gram-negative bacteria can be achieved with the 
corresponding BGs and has been studied in various animal models [24, 36]. Some of the 
investigations should be mentioned briefly as they are examples for superior mucosal 
applications and cross-protection conferred to other subtypes of the pathogens used.  
In model investigations for human lung pathogens and for the development of veterinary 
vaccine candidates vaccination of swine with A. pleuropneumoniae (App) BGs not only resulted 
in protection against aerogenic infection with the potentially lethal pathogen but also prevented 
colonization of the lungs and tonsils indicating that immunization with BGs is superior to 
treatment with bacterins [43]. More importantly, no clinical side-effects have been reported. The 
mucosal application of App BGs as oral immunization [44] or as aerosols [43, 45] induced 
sterile immunity and cross-protection against other serotypes in pigs [45] whereas intramuscular 
immunization [46] fully prevented the vaccinated pigs against the disease after lethal challenge 
but did not confer to the superior sterile immunity as the challenge bacteria could be re-isolated 
from the tonsils from the vaccinated pigs.  
BG produced from P. multocida and M. haemolytica (formerly: P. haemolytica) were 
used in rabbit and mice models resulting in the production of antibodies effective not only 
against the strain used for immunization but also against other Pasteurella strains [47]. M. hae-
molytica BG immunization of cattle offered protective immunity comparable to commercially 
available vaccines [48].  
For V. cholera pre-clinical studies have been completed. The ilea loop challenge model 
revealed full protection of rabbits and more interestingly partial cross-protection between the 
classical O1 strain and the new upcoming O139 strain [49]. In most models mucosal application 
has proven to be a favourable route for administration of BG candidate vaccines inducing both 
humoral and cellular immune response [29, 36].  
BGs as adjuvants:
The BG morphology is not subject to denaturation during the lysis process and thus all 
major immune stimulating constituents are preserved. Those constituents are referred to as pa-
thogen-associated molecular patterns (PAMPs) comprising lipopolysaccharides (LPS), mo-
nophosphoryl lipid A (MPL), peptidoglycan or flagellants. As PAMPs are recognized by toll-
like receptors (TLR) they trigger the innate immune response. Consequently, independent of the 
bacterial strain from which the BGs are derived all BGs induce innate immune reactions (Abtin, 
Koller, Lubitz, personal communication) as first response and also carry intrinsic adjuvant 
properties which makes them extremely versatile to strengthen the general and specific immune 
status of the application [29].
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BGs as carriers of foreign protein antigens:
Using recombinant DNA technology foreign antigens (AGs) can be incorporated into or 
associated with the envelope complex of the bacteria before lysis and thus are constituents of 
the latter BGs (Fig. 2 (a)). AGs may be presented on the cell surface via fusion with outer 
membrane proteins (e.g. ompA) [50] or on the IM as membrane anchor fusions with N-, C- or 
N/C-terminal targeting [30]. It has been shown that fusion with these membrane anchors does 
not affect proper folding and assembly or diminish the functionality of enzymes leading to the 
assumption that AGs are also presented in their proper conformation. In addition to directly fu-
sing the target AG to the membrane anchor a system for subsequent loading of BGs with AGs 
was developed. In this approach the BGs are equipped with membrane-anchored streptavidin. 
After lyophilization such streptavidin BGs  can be loaded with a desired biotinylated compound 
[51].  
Another method of incorporating foreign proteins into BGs is the directed export to the 
PPS via MalE fusion proteins or with PPS signal sequences. As the PPS is sealed during lysis 
and the vast majority of all periplasmic components is retained within the envelope complex [9, 
18] the target AG can be expressed as a soluble protein and exported to the PPS. The membra-
ne-derived oligosaccharides [52] of the PPS provide a protective environment against inactiva-
tion during lyophilization [34].   
Also, for presenting protein AGs in BGs fusion of the target antigen with bacterial 
surface layer (S-layer) proteins can be used. Genes sbsA and sbsB of Bacillus
stearothermophilus code for the corresponding S-layer proteins SbsA and SbsB that form sheet-
like self-assembling superstructures within the cytoplasmic space (CPS) when expressed 
heterologous in Gram-negative bacteria [53-54]. Since S-layers are made up of several 100,000 
subunits they are not expelled with the cytoplasm during lysis. Both S-layer genes accept 
insertion of foreign sequences coding for large foreign proteins [54-55]. Linking MalE to SbsA 
the protein subunits can also be exported to the PPS prior to S-layer formation [56]. It was 
further suggested that multiple S-layer subunits each carrying a different AG could be expressed 
together within the same superstructure [36]. All different options of AG presentation in BG en-
velopes are summarized in Figure 2 (a) as a schematic drawing. 
BGs as carrier of biologically active substances:
The BG system provides a new promising platform for the delivery of drugs and other 
biologically active substances. Since BGs are devoid of any cytoplasmic content attention has 
been paid on the carrier capacity of the inner cytoplasmic lumen which provides an intracellular 
space of approximately 250 femtoliter per BG where drugs of interest can be filled as liquid or 
independent of the inner volume absorbed to the lipid compartment or specifically attached to 
receptors presented in the BGs. 
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BGs produced from the colonic commensal to pathogenic M. haemolytica were used for 
the in vitro delivery of the moderate hydrophilic cytostatic drug doxorubicin (DOX) to human 
colorectal adenocarcinoma (Caco-2) cells. Endogenous drug release was confirmed and enhan-
ced cytotoxic and antiproliferative activities in the Caco-2 cells were observed with DOX-
loaded BGs as compared to the substance per se with a difference of 2-3 orders of magnitude 
[57]. The water soluble substance calcein was used in another delivery model, whereby the for-
mer lysis holes were plugged with bacterial membrane vesicles [58]. BGs from P. cypripedii
were used as pesticide delivery systems with the lipophilic fungizide tebuconazole. The investi-
gations demonstrated that this formulation conferred a higher resistance to rainfalls due to adhe-
rence of the BGs to the plant with protective and curative effects towards agricultural plant pa-
thogens [59].  
It is assumed that organic ring structures bind unspecifically to the membrane 
compartments of BGs. Recent investigations of loading BGs with polyphenolic compounds, like 
resveratrol, are in agreement with this presumption. Currently, the modulating ability of such 
substances bound to BGs on the induction of components of the innate immune system, i.e. i-
NOS, was examined (Koller and Lubitz, personal communication). Furthermore, advanced drug 
cytotoxicity due to stabilization and protection of the UV-labile resveratrol derivates, namely 
Digalloylresveratrol and M8, by adsorption to the BG-interior could be demonstrated recently 
(Koller and Lubitz, personal communication). 
In a model investigation, in which a substituted matrix on the inner membrane of BGs for 
an enhanced binding of drugs is created, has been shown by Huter et al. [51]. Membrane ancho-
red streptavidin bound the coupling partner to the inside of the cytoplasmic membrane and al-
lowed biotinylated substances to be targeted. Studies with biotinylated alkaline phosphatase or 
biotinylated fluorescence-labelled dextrans as an additional matrix displayed successful binding 
within the inner lumen of BGs [51]. 
BGs as carriers of DNA vaccines:
Several viral and bacterial delivery systems with high transfection efficiencies bear a risk 
of reversion to their original pathogenic forms and "safer" non-viral systems such as attenuated 
bacteria, polycation/DNA complexes, nucleoporation have reduced transfection efficiencies 
[60-67]. The BG system represents a new highly efficient gene delivery platform as an alterna-
tive to current viral and bacterial methods in vaccine development. One of the biggest demands 
for the new DNA-carrier system is the safety of BGs. Recent investigations proved that BGs 
have no cytotoxic or genotoxic impact on various histological types of human cells after mutual 
co-incubation independently of the used BG species (manuscript in preparation).  
Recently, DNA vaccines got approval for use in veterinary practice [68]. DNA vaccines 
still require intensive research and improvements to be considered safe for use in human medi-
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cine. One reason for this slow pace in development and licensing approval of DNA vaccines is 
the requirement of high plasmid dosages and low immunogenicity, most commonly attributed to 
the absence of efficient delivery system [69-70]. Many experiments have been carried out in or-
der to deliver DNA vaccines using BGs as carriers, and a simple procedure for loading BGs 
with plasmid DNA has been standardized. Lyophilized BGs are re-suspended in DNA solutions 
followed by a couple of washing steps to remove unbound plasmid DNA from inside the BGs. It 
is further observed that the amount of DNA loaded inside the BGs is directly related to the con-
centration of DNA solution used. This loading procedure proved to be very efficient and upto 
6,000 midsize plasmid copies per BG can be loaded [71].  
The main advantage of BGs is their non-living character, while still retaining all of the 
surface morphological, structural and antigenic components of their living counterparts, and 
their outstanding loading capacity [72]. The inner space of BGs empty envelope can be loaded 
with a combination of peptides, drugs or foreign DNA which gives us an opportunity to design 
new types of polyvalent vaccines [57, 71, 73-74]. We have shown that BGs loaded with plasmid 
DNA encoding green fluorescent protein (GFP) are efficiently internalized and phagocytized by 
both professional antigen presenting cells (APCs) and tumor cells. BGs were able to deliver the 
heterologous genes to both non-dividing cells (monocyte-derived dendritic cells) and dividing 
cells (macrophages and melanoma) with study results showing that up to 82% of cells 
expressing the plasmid encoded reporter gene delivered by BGs and importantly with no 
cytotoxic impact on target cells [32, 71, 74-75]. Furthermore, intradermal and intramuscular 
immunization of Balb/c mice with BGs loaded with pCMV encoding beta-galactosidase stimu-
late more efficient both humoral and cellular AG-specific immune responses than naked DNA. 
Moreover, beta-galactosidase-specific immune response was detected after intravenous immu-
nization of mice with autologous dendritic cells (DCs) transfected ex vivo with pCMVbeta-
loaded BGs [32]. An increase of IFN-gamma producing AG-specific CD8+ T cells was obser-
ved in animals vaccinated with DNA loaded BGs in response to restimulation by APCs pulsed 
with peptide containing the immunodominant MHC class I epitope. Furthermore, BGs enhanced 
expression of MHC class I molecules and costimulatory molecules on DCs [32]. Cross-
presentation of AGs delivered to DCs by BGs could activate both CD4+ and CD8+ T cells and 
stimulates immune system to enhance immune response against AGs expressed by target cells. 
Bacterial LPS enhances maturation of DCs, affects endosomal acidification of DCs and also 
improves cross-presentation of AGs [76-77]. Inner and outer membrane structures of BGs 
including LPS remain intact in BGs and the surface LPS effectively stimulates the AG-cross-
presentation by DCs [19, 72]. 
In general the production and loading of BGs with plasmid DNA are two separate tasks. 
With the introduction of our new self immobilizing plasmids (pSIP) this multistep procedure 
was simplified into one step in-vivo, cost effective procedure. During this process the plasmid 
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DNA carrying an operator sequence is bound to a specific DNA binding protein present on the 
IM of the bacteria [78].  
For DNA vaccination and plasmid DNA used in gene therapy the bacterial backbone 
sequences and antibiotic resistant genes are considered to be a biological safety risk. To over-
come this hurdle new more sophisticated versions of pSIP BG-DNA-vaccines are based on mi-
nicircle (mc) DNA devoid of such biologically risky remains. This improved version of pSIP is 
based on the ParA resolvase system to produce mcDNA which is bound to the IM receptor whi-
le the sisterpair miniplasmid produced during this process is expelled to the culture media du-
ring the gene-E mediated lysis [79]. A modified system for minicircle production, based on en-
donuclease activity of I-SceI gene encoded from parent plasmid, digesting the miniplasmid has 
been reported [80]. In the new modified pSIP generation currently under construction 
endonuclease activity is also encoded to digest non-recombinant mother plasmids and the ParA 
produced miniplasmids.  
The main benefit of DNA vaccines is based on the induction of both cellular and humoral 
immune responses caused by processing of AG through both endogenous and exogenous 
pathways followed by AG epitopes presentation in the context of both MHC class I class and II 
molecules [81-83]. Well designed and applied gene therapy should provide successful delivery 
of desired AG DNA to the APCs followed by its expression, naturally processing and presenta-
tion of AG-derived epitopes. T-cells raised against delivered, naturally processed and presented 
AGs by APCs might be more effective in recognition of the same epitopes presented by cells 
expressing identical AGs. The expression of a delivered gene should induce strong immune res-
ponses or change the behavior of targeted cells.
BGs with their intact envelope structures including peptidoglycan and LPS are not only 
"waking up" professional phagocytic APCs but are also providing stimulatory impulses to tumor 
cells. It is known that e.g. melanoma cells have the capacity to behave as non-professional 
APCs and can phagocyte both apoptotic and live cells [84-87] and as recently shown respond to 
the challenge by BGs [73]. Despite the high DNA loading capacity of BGs relatively low con-
centrations of DNA are sufficient for effective gene delivery and its expression by melanoma 
cells. High transfection efficiencies obtained after incubation of BGs with melanoma cells and 
with monocyte-derived DCs using the identical type of BGs encourage us to design BGs carry-
ing selected immunogenic and immunodominant AGs usable at the same time for gene transfer 
to both professional APCs and tumor cells what might lead to induction and/or to increase of 
AG-specific immune response. 
White biotechnology - BGs as micro-bioreactors for enzymatic reactions:
As already mentioned above another possible application for the BG platform is the use 
of BGs as carrier of enzymes. The lack of cytoplasm and of a membrane potential due to E-
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mediated lysis of the bacteria is not accompanied by a total loss of enzymatic activities. The 
enzymatic activities of membrane-bound ?-galactosidase and chloramphenicol acetyl 
transferase have been described in BGs [88-89]. It has also been shown in BGs that membrane 
associated enzymes like ATPases are still functionally active. Moreover, even though the cy-
toplasmic content is expelled during lysis the inside of the cytoplasmic membrane as well as its 
associated products are retained. As the IM and OM are fused at the border of the E-specific 
lysis tunnel enzymes from the PPS like alkaline phosphatase and ?-lactamase are largely 
retained and active [9, 19]. As compared to their viable counterparts ATPase and ?-lactamase 
sustained decent activities in suspended BGs after one week storage at 4°C. Furthermore, 
enzyme activities were also detectable in long-term, ambient temperature stored lyophilized 
BG-batches. The obtained activities were similar to recently produced freeze-dried samples, e.g. 
concerning ATPase activity no significant differences were observed within five years of stora-
ge (Koller, Lubitz - personal communication). These data show that enzymes of BGs per se stay 
functionally preserved for long time of storage indicating the potential of BGs as reservoirs for 
biological functions to be used as dietary enzyme substitution or for other use.   
Pursuing the idea of Pfründer et al. of producing enantiopure fine chemicals such as e.g. 
asymmetric synthesis of a 3,5-dicarboxyhydroxylate in biphasic ionic liquid/water systems [90-
91] BGs shall act as micro-reactors. Anchoring potent enzymes like specialized alcohol de-
hydrogenases (ADHs) to the IM the internal lumen of the BG becomes the reaction volume. Re-
suspension of the BGs in an aqueous solution with a suitable reduction equivalent allows for 
proper function of the desired enzyme. Since both product and educts in those kinds of reactions 
are often poorly water-soluble the use of a non-polar solvent - in this case a suitable ionic liquid 
(IL) - becomes mandatory. IL are organic salts which are liquid at ambient temperatures; due to 
their low vapour pressure they are considered as safe ("green solvents") and also feature good 
in-situ extraction properties for product recovery [92]. Hence, BGs loaded with the reduction 
equivalent solution are dispersed in the ionic liquid which provides the substrate and receives 
the product. It was shown that the enzyme activity of ?-galactosidase could be vastly increased 
in an IL environment [93]. Preliminary studies of our lab have demonstrated that ?-
galactosidase was active when BGs were re-suspended in the IL [Bmim]PF6.
Qualitative determinations showed successful hydrolysis reactions of the substrates which 
were delivered in the ionic liquid. These findings give a first estimation for feasibility and attai-
nable enzymatic activity in such approaches. It is suggested that a limited series of reactions 
could be performed within one BG when a multi-step enzyme system is introduced offering the 
BG system as a versatile vehicle in white biotechnology.  
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Figures
 (a)  (b) 
Figure 1 (a): Lysis tunnel formation and expulsion of the cytoplasmic contents - reproduced 
from Ebensen et al. [32].(b): Lysis tunnel formation, accompanied by the fusion of IM and OM 
(arrow) - reproduced from Witte et al. [18] 
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Figure 2 - (a): different methods for AG presentation in the BG envelope complex - BG 
themselves carry native AG (LPS, OMP, IMP, TCP, flagella, pili) - TA may be presented on 
the cell surface via fusion with OmpA - the PPS can be loaded with TA via MBP-SbsA-fusion 
proteins (1), by fusion of the TA with MBP (2) or as sole TA using the gene III signal sequence 
(3) - Protein TA may be incorporated into the IM via E', L' or E'/L'-anchoring, biotinylated AG 
can be attached to E'-FXa-StrpA membrane anchors, DNA carrying the lac operator site can be 
attached to L'-anchored lacI repressor molecules - TA fused with SbsA-/SbsB proteins form S-
layers in the PPS. (b): Model of lysis tunnel formation according to Schön et al. [23]. 
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Figure 3: Fermentation protocol (growth/lysis phase) monitoring all relevant process 
parameters; (a) lysis induction, (b) lysis onset as indicated by dO2 up-shift, (c) stationary dO2 
plateau indicating end of lysis phase. 
Figure 4: Process timeline for the production of BG including the pre-culture (ON) and down-
stream processing. 
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Figure 5 (a): Harvesting of the BG product via TFF; concentration from 20 to 2 l in the 
fermenter (b) Washing of the BG product with 5.0 l dH2O via diafiltration; concentration from 
2.0 l to 400 ml in a stirred reservoir. 
(a)  (b)  (c) 
Figure 6: Flow cytometry pictures following the progress of lysis in an E.coli NM522 culture 
(pGLysivb); R1: living cells, R2: dead but intact cells, R3: lysed cells (BG); RN6: exclusion of 
non-cellular background with RH414 (not shown); FSC - forward scatter, FL1 - fluorescence 
intensity by DiBAC4(3); (a) sample D (0 minutes, lysis induction), (b) sample E (30 minutes), 
(c) sample H (120 minutes, end of lysis phase). 
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Figure 7: Standard fermentation for a S. flexneri 2a culture harbouring plasmid pGLNic: (a) 
IPTG-addition at -45 min to induce biosynthesis of SNUC, (b) temperature up-shift to 42°C at 
0 min to induce lysis, (c) pH up-shift to 8.0 and addition of Mg2+ and Ca2+ at +90 min to 
activate the enzymatic function of SNUC . 
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Bacterial ghosts (BGs) are empty bacterial envelopes of Gram-negative bacteria produced 
by controlled expression of cloned gene E, forming a lysis-tunnel structure within the envelope 
of the living bacteria. BGs are devoid of cytoplasmic content and possess all bacterial bio-
adhesive surface properties in their original state while not posing any infectious threat. BGs are 
ideally suited as an advanced drug delivery system (ADDS) for toxic substances in tumor 
therapy. The inner space of BGs can be loaded with either single components or combinations 
of peptides, drugs or DNA which provides an opportunity to design new types of (polyvalent) 
drug delivery vehicles. Uptake of BGs loaded with Doxorubicin (Dox) by CaCo2 cells led to 
effective DOX release from lysoendosomal compartments and accumulation in the nucleus. 
Viability and proliferative capacity of the cells were significantly decreased (2 to 3 orders of 
magnitude) after internalization of Dox loaded BGs as compared to cells incubated with free 
Dox. The same effect was observed with leukemia cells. Melanoma cells also revealed a high 
capability to internalize BGs. These results indicate that BGs are able to target a range of types 
of cancer. BGs have also been investigated as DNA delivery vectors.  Studies showed DNA 
loaded BGs are efficiently phagocytosed and internalized by both professional APCs and tumor 
cells with up to 82% of cells expressing the plasmid encoded reporter gene. Our studies with 
BGs as an ADDS system contribute (i) to optimize drug delivery for the treatment of cancer; (ii) 
define specific conditions for selection and preparation of BG formulations; (iii) and provide a 
background for the clinical application of BGs in cancer therapy. 
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1. Introduction 
Identification of optimal antigen (Ag) forms that are therapeutically effective for the 
vaccination of patients with cancer opens the door for using new strategies in vaccine 
development. The competent DNA vaccine should be able to efficiently deliver specific DNA 
(Ag) to the target cells e.g. DCs in order to elicit strong cellular and humoral immune responses, 
and a long term immune memory, and should consist of a non-specific adjuvant capable to 
increase the vaccine immunogenicity. The expression of a delivered gene should either induce 
strong immune responses or change the behavior of the targeted cells. Several delivery systems 
have been described, including viral vectors with high transfection efficiencies and “safer” non-
viral systems, such as attenuated bacteria, polycation/DNA complexes, nucleoporation, but with 
reduced transfection efficiencies [1-6]. Although viral vectors provide efficient gene transfer, 
safety concerns are still present due to the immunogenicity of most viruses which limits the 
duration of gene expression and the ability to re-administer the genes. Similarly, live bacterial 
vaccines have been successfully used as carriers for vaccine Ag but their use carries a risk of 
reversion to their original pathogenic forms [7, 8]. For many different types of tumors the 
usefulness of highly cytotoxic chemical agents as chemotherapeutics to inhibit fast tumor cell 
replication is diminished by a number of serious toxic side effects caused by these drugs 
including increased risk of cardiovascular diseases [9-11]. Many of these toxic effects which are 
mostly dose-related plus non-specific killing limit repeated drug application in the treatment of 
cancer patients. Incorporation of highly tumoricidal agents into a non-toxic delivery system 
capable of transferring the drug to the target cells without modification of the drugs function 
might lead to improved therapy and significant reduction of toxic side effects. Development of 
new delivery systems with no cytotoxicity and high efficiency of drug and/or gene medicine 
delivery as alternatives to current methods is very much needed. 
2. Bacterial Ghost System 
The bacterial ghost (BG) system developed during the past few years represents a new 
platform in vaccine development [12]. BGs, empty bacterial shells of Gram-negative bacteria, 
have been developed as a novel potent carrier and adjuvant system for the delivery of DNA 
vaccines [13-17]. BGs are produced by protein E-mediated lysis of Gram-negative bacteria. 
Inducible expression of the E gene causes the fusion of the inner and outer membranes of the 
bacterial cells to form intermembrane tunnel through which all the cytoplasmic contents of the 
bacteria is expelled, whilst the inner and outer membrane structures are preserved and remain 
intact  [18] (Fig.1). In contrast to attenuated bacteria there is absolutely no risk of reversal to 
pathogenic form. Safety profile studies concerning BGs and additional investigations showed 
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that BGs have no cytotoxic or genotoxic impact on various histological types of human cells 
(monocyte-derived dendritic cells, macrophages, conjunctival cells, keratinocytes, colon 
carcinoma cells, melanoma cells, hepatocellular carcinoma cells, promyeloblasts-acute 
promyelocytic leukemia cells, monocytes-acute monocytic leukemia cells) after mutual co-
incubation, independent of the used BG species (Kudela, Koller and Lubitz, manuscript in 
preparation), and that endotoxicity does not limit the use of BGs as a candidate vaccine [19]. 
The main advantage of BGs is their non-living character, while still retaining all of the surface 
morphological, structural and antigenic components of their living counterparts [12]. BGs have 
been produced from various non-pathogenic, pathogenic and probiotic strains including E. coli
K12, enterotoxigenic E. coli, enterohemorrhagic E.coli, E. coli Nissle 1917, Mannheimia 
haemolytica, Shigella flexneri, Vibrio cholerae, Salmonella enterica, Helicobacter pylori, and 
Actinobacillus pleurepneumoniae demonstrating the broad potential of the BG system in 
vaccine development and tumor therapy (Table 1). 
Because of the unique structure of the BG’s envelope with intact and preserved pathogen-
associated molecular patterns (PAMPs), BGs can be used in biomedicine alone as an adjuvant 
or as a delivery vehicle for drug or gene medicine. The inner space of BG’s empty envelope can 
be loaded with a combination of peptides, drugs or foreign DNA which gives us an opportunity 
to design new types of polyvalent vaccines and to use BGs in advanced drug delivery [13] 
(Fig.2). Uptake of BGs loaded with the anti-neoplastic drug (Doxorubicin) led to its efficient 
release from lyso-endosomal compartments and accumulation in the nucleus [20] (Fig.3). BGs 
have excellent DNA-loading capacity varying from 4000 to 6000 plasmids per BG depending 
on the concentrations of DNA solution used [21-24]. We have shown that BGs loaded with 
plasmid DNA are efficiently internalized and phagocytized by both professional antigen-
presenting cells (APCs) and tumor cells. Cross-presentation of Ag delivered to dendritic cells 
(DCs) by BGs can activate both CD4+ and CD8+ T cells and stimulate the immune system to 
enhance the immune response against Ag expressed by target cells. The presence of bacterial 
lipopolysaccharide (LPS) on the outer membrane of Gram-negative bacteria enhances 
maturation of DCs, affects endosomal acidification of DCs and also improves cross-presentation 
of Ag [25]. Inner and outer membrane structures of BGs including LPS and other PAMPs 
remain intact after protein E-mediated lysis of Gram-negative bacteria, therefore as well as BGs 
possessing a high loading capacity; they also carry on their surface highly effective molecules 
for the stimulation of cross-presentation by DCs [12, 18]. BGs with their intact envelope 
structures are not only immunostimulatory to professional phagocytes but are also capable of 
providing stimulatory signals to tumor cells. It is known that melanoma cells have the capacity 
to behave as non-professional APCs and can phagocyte both apoptotic and live cells [26-28], 
and we have recently shown that melanoma cells actively respond to exposure to BGs by 
increasing their rate of phagocytosis. Thus the BG system is an effective DNA carrier with BGs 
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shown to be very attractive targets for uptake by melanoma cells [21]. Using BGs for gene 
delivery to the immunocompetent cells, in particular DCs as well as tumor cells, could initiate 
or restore the immune response against the delivered tumor-associated antigens (TAA) as well 
as induce and increase expression of target gene by APCs and tumor cells. 
2.1  BGs-advanced drug delivery system 
A delivery system that transports chemotherapeutic drugs directly to the cytosol and 
nuclear area of target cells at levels sufficient to inhibit tumor cell proliferation would allow the 
use of decreased drug dosages, and thus lessen the negative impacts on people already 
challenged with serious diseases. Recent investigations confirm the recognition of BGs by 
various types of tumor cells and the capacity of BGs to efficiently target and be internalized by 
melanoma, leukemia and colorectal carcinoma cells. This phenomenon might be related to the 
presence of the LPS on the intact and preserved envelope of BGs leading to the activation of 
tumor cells. Some tumor cells like melanoma cells respond to LPS through the Toll-like 
receptor-4 (TLR-4), a receptor that is constitutively expressed by this type of tumor cell. 
Activation of melanoma cells by LPS results in enhanced production of IL-8, cell adhesion and 
might also play an important role in immune escape [29]. Although it has been reported that 
TLR-4 is not involved in cellular LPS uptake by monocyte or endothelial cells, the connection 
between TLR-4-mediated melanoma cell activation by LPS and their phagocytic activity 
remains to be defined [30]. Several studies reported increased tumor progression due to the 
activation of TLRs expressed on tumor cells with specific ligands, such as LPS [31, 32]. In 
contrast, other reports showed a protective role of TLR-4 inhibiting lung carcinogenesis [33]. 
Moreover, in vitro activation of tumor cells through TLR-4 promotes an anti-tumoral effect and 
inhibits tumor growth in vivo [34]. Furthermore, systemic administration of attenuated bacteria 
stimulates a potent immune response in the tumor area and polarizes T cell immune response 
toward Th1 dominant immunity through TLRs [35]. In general, recent reports indicate both 
positive and negative influences of tumor cell activation through TLRs but until now without 
any final clear consensus regarding their role in tumor progression or regression. Therefore, the 
exact role and the mechanisms involved during both positive and negative activation of TLR 
signaling in tumor cells has to be determined.  
PAMPs present on the surface of BGs help to increase targeting of tumor cells with BGs 
loaded with chemotherapeutic substances. Our results revealed that melanoma cells have a high 
capability to bind and internalize BGs without significant effect on their viability and 
proliferation [21]. Efficient endocytosis of BGs was also observed after incubation with colon 
carcinoma and leukemia cells (Fig.3 and Fig.4). Doxorubicin (Dox) loaded BGs made by simple 
resuspension and incubation of lyophilized BGs in Dox solution, were used as a model system 
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for BGs and drug delivery. It is assumed that Dox binds non-covalently to the inner membrane 
structure through the interaction of Dox-amine sugar parts and charged membrane proteins or 
with the antraquinone part of Dox with BG’s inner membrane [20]. Attached Dox is slowly 
released in water from BGs within a period of 8 days, with a detection of approximately 40% 
release within the first day and then constant release within the remaining days (~10% per day). 
Incubation of Dox loaded BGs with colon carcinoma cells led to efficient internalization of 
BGs, their degradation, the release of BG’s content to the cytoplasm of target cells and 
accumulation in the nuclear area. Incubation of tumor cells with Dox loaded BGs led to 
significantly higher inhibition of target cell proliferation (at least two orders of magnitude) in 
comparison to results obtained after incubation with pure Dox at the same concentration levels 
(Fig.5). To achieve the same level of inhibition, the Dox dose could be reduced to 100th when 
associated with BGs (16 h of co-incubation). The difference in the inhibition of target cell 
proliferation was even more dramatic when the free Dox and Dox loaded BGs were removed 
from the cell culture system already after 10 min of incubation in order to simulate a clinical 
condition which might occur in the medical application of Dox loaded BGs, because it is more 
likely that the targeting vehicles pass through the target cells or tissues within several minutes 
than that they remain at the targets for several hours [20]. 
Similar results were detected in both solid tumors (colon carcinoma) and dispersed 
tumors (monocytic and myeloid leukemia). Delivery of Dox bound to the inner membrane of 
BGs enhanced its intracellular concentration within tumor cells (CaCo2) up to 42 times higher 
than incubation of tumor cells with an equivalent concentration of Dox solution (Winter, Mader 
and Lubitz, manuscript in preparation). These results also indicate the loading and delivery 
capacities of BGs may be sufficient to effictively transport chemotherapeutics to cells that 
highly express P-glycoprotein and MDR1 and overcome Dox resistance [36, 37]. Detailed 
analysis of Dox loaded BG’s cytoxicity showed that drug (Dox)-filled BGs reduced cell 
proliferation with inhibitory concentrations of the drug (EC50 obtained by MTT-assay) up to 
300 times more effectively than when free drug was added to the cell culture system (Winter, 
Mader and Lubitz, manuscript in preparation). This phenomenon might be caused by 
degradation of Dox loaded BGs within the endo-lysosome of target cells allowing Dox to 
bypass the MDR efflux pumps and resulting in enhanced accumulation of Dox in the cytoplasm 
and then in the nuclear area of target cells. Activation of tumor cells by LPS present on the 
surface of BGs could also have increased the number of tumor cells in S-phase enhancing DNA 
intercalation by Dox delivered by BGs to cause a higher cytotoxic effect. However, the exact 
mechanism of the cytotoxic effect of chemotherapeutic drugs delivered to the tumor cells by 
BGs and use of this strategy in prospective cancer immunotherapy requires to be further 
investigated. Together, our results showed that BGs are able to deliver chemotherapeutic drugs 
without modification of its pharmacological properties. Drug incorporation to the BG’s 
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envelope significantly reduced the concentration necessary to efficiently inhibit tumor cell 
proliferation [20]. These facts support the potential of the BG system in tumor therapy to 
provide a desirable reduction in the toxic side effects of current chemotherapeutic agents and 
hence lead to the improvement and extension of the therapeutic window for patients undergoing 
chemotherapy. 
2.2 BGs-efficient non-toxic DNA delivery system 
Gene therapy applications in human medicine focused on delivery of DNA to the target 
cells may play an important role in the development of effective therapies and vaccines for 
major human diseases. Precisely designed and applied gene therapy requires a well defined Ag 
and simple but non-toxic and effective delivery system that successfully delivers the desired 
DNA (Ag) to the target cells-prefessional APCs e.g. DCs in order to prime effective Ag-specific 
CD4+ and CD8+ T cells. These induced T cells may be more effective at recognizing the same 
epitopes presented by cells expressing identical Ag. The expressed genes should induce strong 
humoral and cellular immune responses or change the behavior of targeted cells. The 
development of an optimal DNA Ag delivery system that has a suitable safety profile, low 
production costs and the capacity to positively affect the immune system, opens the door for the 
use of new strategies in vaccine development and tumor therapy. The efficient delivery of DNA 
(Ag) to the target cells e.g. DCs needs to elicit a robust immune response. The main benefit of a 
DNA vaccine is based on its ability to induce both cellular and humoral immune responses due 
to processing of Ag through both endogenous and exogenous pathways, followed by Ag epitope 
presentation in the context of both MHC class I and class II molecules [38, 39]. 
Prospective carrier-adjuvants for gene therapy should be able to deliver functional DNA 
to the target cells, and combine the capacities to both stimulate cells of immune system and help 
to increase specific immune response against delivered specific Ag. The selected delivery 
system should not represent any potential hazard for horizontal gene transfer and must 
demonstrate a suitable safety profile. Furthermore, in the case of DCs the selected carrier also 
has to promote cell maturation and the development of both humoral and cellular immune 
responses [40].  
A number of delivery systems with high transfection efficiencies have been successfully 
used as carriers for DNA-based vaccine Ag but their use bears a risk of reversion to their 
original pathogenic forms [7, 8]. The development of new delivery systems with no cytotoxicity 
and high efficiency of gene delivery as an alternative to current viral and bacterial methods is 
very much needed. The greatest requirement of any new delivery system for vaccine 
development against human diseases is the safety of the prospective DNA carrier. The BG 
system offers a new platform that would meet the required safety needs.  The safe profile of 
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BGs was confirmed using a Limulus-assay, where purified LPS (E. coli O26:B6) expressed 
endotoxic activity values 100-times higher than the BGs [19]. Furthermore, recent 
investigations of our group proved that BGs have no cytotoxic or genotoxic impact on various 
histological types of human cells (monocytes, macrophages, monocyte-derived dendritic cells, 
endothelial cells, keratinocytes) after mutual co-incubation independent of the used BG species 
(Kudela, Koller and Lubitz, manuscript in preparation). Therefore, endotoxicity does not limit 
the use of BGs as a candidate vaccine [19].  
The major benefit of BGs in vaccine development consists of their non-living character, 
their ability to retain all of the surface morphological, structural and antigenic components 
(PAMPs) of their living counterparts as well as their outstanding loading capacity [12]. The 
inner space of BG’s empty shell can be loaded with either single Ag or with a combination of 
various Ags which opens the possibility to devise and create new types of vaccines [13]. 
Intensive study of the BG system by our group in the past years concerning also its application 
as a DNA delivery system revealed that a simple procedure based on mixing of dried 
lyophilized BGs with a solution of plasmid DNA encoding required Ag followed by several 
washing steps is sufficient for generation of DNA loaded BGs which are immediately ready to 
use for gene delivery to different histological types of cells. Our studies confirmed the excellent 
loading capacity of BGs with final load depending on the concentration of DNA solution used 
[22-24]. We have shown that BGs loaded with plasmid DNA encoding heterologous gene 
(green fluorescent protein) are efficiently internalized and phagocytized by both professional 
mouse and human APCs and tumor cells. BGs were able to deliver the model genes to both non-
dividing cells (monocyte-derived DCs) and dividing cells (macrophages and melanoma cells) 
with study results showing that up to 85% of cells expressed the plasmid encoded reporter gene 
delivered by BGs (Fig.6 and Fig.7). Principally, incubation of BGs with all tested types of 
human and mouse cells including DCs, macrophages, epithelial cells and tumor cells caused no 
toxic impact on target cells [21-24]. Furthermore, intradermal and intramuscular immunizations 
of Balb/c mice with BGs loaded with pCMV encoding ?-gal (pCMV?) stimulate more 
efficiently both humoral and cellular ?-gal-specific immune responses than immunization with 
naked DNA. Moreover, increased ?-gal-specific immune response was also detected after 
intravenous immunization of mice with autologous DCs transfected ex vivo with pCMV?-
loaded BGs [24]. Production of IFN-? by Ag specific CD8+ T cells isolated from vaccinated 
animals was observed after coincubation and recognition of peptide containing the 
immunodominant MHC class I epitope presented by autologous APCs (Fig.7). Furthermore, 
stimulation with BGs enhanced expression of MHC class I and class II molecules and 
costimulatory molecules-CD40, CD54, CD80 and CD86 by DCs [24].  
Cross-presentation of Ag successfully delivered to DCs by BGs could activate both CD4+ 
and CD8+ T cells and thus stimulates the immune system to enhance Ag-specific immune 
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response leading to elimination of cells expressing target Ag. Bacterial LPS enhances 
maturation of DCs, affects endosomal acidification of DCs and also improves cross-presentation 
of Ag [41, 42]. Inner and outer membrane structures of BGs including LPS remain intact after 
protein E-mediated lysis of Gram-negative bacteria. Thus BGs also expressing LPS on their 
surface are likely to stimulate the cross-presentation of Ag by DCs [12, 18]. 
BGs with their intact envelope structures including PAMPs, e.g. peptidoglycan and LPS 
not only stimulate professional phagocytes but are also capable of providing stimulatory signals 
to the tumor cells. It is known that melanoma cells have the capacity to behave as non-
professional APCs and can phagocyte both apoptotic and live cells [26-28, 43]. Our recent 
studies showed that melanoma cells actively respond to the challenge by BGs by phagocytosis, 
thus BGs were shown to represent a very attractive target for melanoma cells [21]. Moreover, a 
study with melanoma cells revealed that even relatively low concentrations of DNA are 
sufficient for effective gene delivery and its expression by target cells. BGs loaded with 
approximately 50 plasmids per BG, when incubated with melanoma cells at the ratio BG:cell-
100:1, were sufficient for effective DNA delivery to the target cells and led to transfection 
efficiency of up to 80%. These observations suggest that BGs could be loaded by multiple 
plasmids (e.g. plasmids encoding various TAA expressed by certain types of tumor) and used to 
deliver heterologous genes to different types of cells in particular tumor types (i.e., proliferating 
and non-proliferating). High transfection efficiencies obtained after incubation of BGs with 
melanoma cells and with monocyte-derived DCs using the identical type of bacterial strain for 
preparation of BGs encourage us to design BGs carrying selected immunogenic and 
immunodominant Ag usable at the same time for gene transfer to both professional APCs and 
tumor cells. Applications of this type of BGs directly into the tumor microenvironment might 
lead to induction and/or to an increase of Ag-specific immune response and cytokine milieu 
alteration resulting in the attraction of the immunocompetent cells participating in the immune 
response against the tumor cells. 
In addition to the simple procedure used for loading of BGs with DNA mentioned above, 
a technique recently developed by our group showed that loading of BGs with DNA could be 
simplified even further using self-immobilizing plasmid which is retained by the carrier 
envelope due to a specific interaction between cytoplasmic membrane anchored proteins with 
minicircle DNA during and after protein E-mediated lysis. This technique allows the removal of 
plasmid sequences not required for vaccination, e.g., the origin of replication and the antibiotic 
resistance marker, resulting in production of BGs containing minicircle DNA with an increased 
safety profile [44, 45]. Additionally, the cytoplasmic space of BGs can be filled with various 
substances, e.g., water-soluble proteins, plasmids, drugs, further extending their utility as a 
potential therapeutic vehicle [13]. 
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3. Conclusions 
BGs combine features of the “ideal vaccine candidate and tumor therapy vehicle” (Table
2). The production of BGs can be easily and quickly undertaken either in disposable fermenters, 
small lab steel fermenters or in large scale fermenters from various types of Gram-negative 
bacteria including pathogens as well as probiotic strains. The production process requires 
standard technology which allows the use of this system in a broad number of differently 
developed countries. The BG’s high loading capacity, preservation of loaded compounds and 
stability at room temperature also permit their easy storage and handling in less developed 
countries. Furthermore, BG’s safe profile carries no risk of reversal to the native pathogenic 
form and no risk of horizontal gene transfer, and together with their ability to act as natural 
adjuvants due to the presence of all the surface morphological, structural and antigenic 
components of their living counterparts, especially designate this technology to be intensively 
studied for further vaccine development and tumor therapy. Altogether, the BG system 
constitutes a prospective safe and affordable multipurpose vehicle for the therapy of major 
human diseases including cancer. 
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Tables and Figures 
Fig. 1. Bacterial Ghost System. Inducible expression of E causes the fusion of inner and outer 
membranes of the bacterial cells and forms an intermembrane tunnel. The empty BG envelope 
is devoid of cytoplasmic content, whereas the inner and outer membrane structures including 
LPS and peptidoglycan are preserved and remain intact-reproduced from Ebensen et al. 2004. 
Arrow indicates E-specific lysis hole. 
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Table 2.
Bacterial Ghost System for vaccine development and tumor therapy. 
? Simple, high dose and low cost production in short time
? Stability at room temperature - loaded “merchandise” inside BGs is  very well 
preserved
? Safe profile - no risk of reversal to pathogenic form, not a hazard for horizontal gene 
transfer
? Non-living character, but still retaining all of the surface morphological, structural 
and antigenic components of their living counterparts for tissue and cell targeting
? Natural adjuvant - BGs provide direct  immunostimulatory effect on various cells of 
immune system
? Mucosal immunization with BGs induce strong humoral and cellular immune 
responses
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Fig. 2. Modified forms of Bacterial Ghost System. Schematic diagrams showing BG 
containing intact outer and inner membranes with sealed periplasmic space and inner space 
loaded with chemotherapeutic agent (A); inner membrane anchored streptavidin or in vivo
biotinylation C-terminal amino acid sequence (B); membrane anchored biotinylated or 
streptavidin coupled polymer(s) (C); DNA binding protein anchored to the inner membrane (D). 
Sealing of BG expressing streptavidin around lysis hole with biotinylated inside-out membrane 
vesicles from Gram-negative bacteria (E). Detailed view of the inside out vesicles closing E-
specific lysis tunnel, membrane anchored streptavidin or biotinylated membrane anchor are 
expressed either on the inside out vesicles or around lysis hole (F)-reproduced from Mayr et al. 
2008. 
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Fig. 3. Release of Dox within colon carcinoma cells after incubation with Dox loaded BGs.
The overlay of the transmission light microphotograph (A) and the confocal laser scanning 
microphotographs (B) show the location of the Dox in the nuclear area or associated with the 
BGs (yellow as a result of a direct overlay of red and green fluorescence)-reproduced from 
Paukner et al. 2004. 
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Fig. 4. Release of Dox within leukemia cells after incubation with Dox loaded BGs. 
Increased fluorescence of leukemia cells caused by incorporation of Dox in the nuclear area 
after incubation with Dox loaded BGs corresponds to increased concentration of Dox present 
inside the BGs.  
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Fig. 5. Inhibition of tumor cell proliferation after incubation with Dox loaded BGs, free 
Dox and BGs alone. Colon carcinoma cells were incubated with 10, 100 or 1000 ng/ml Dox 
either free or associated with ghosts (corresponding to ghost/cell ratios of 5, 50, 500) for 16 h or 
for 10 min followed by removal of free Dox, BGs alone or Dox loaded BGs and incubation for 
16h. Subsequently, the BrdU proliferation assay was performed to determine the viability of 
tumor cells-reproduced from Paukner et al. 2004.  
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Fig. 6. Bacterial Ghost System as DNA delivery system. Release of fluorescently labeled 
DNA after incubation of mouse macrophages with BGs loaded with nonhomologous FITC 
labeled linear double strand DNA (A). Efficient gene delivery and expression of model Ag-GFP 
48h after incubation of mouse macrophages with BGs loaded with plasmid DNA pEGF-N1 at 
the ratio of 500 BGs per cell for 2h (B)-reproduced from Paukner et al. 2005. 
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Fig. 7. DNA loaded BGs stimulate Ag-specific immune response. Gene transfer by BGs 
loaded with pEGFP into human monocyte-derived DCs (A). Immune responses stimulated by 
DC transfected ex vivo with DNA-loaded BGs- Ag-specific serum IgG responses 11 days after 
vaccination (B), increased number of IFN-gamma producing splenocytes after restimulation 
with immunodominant MHC class I Ag derived peptide (C)-reproduced from Kudela et al. 2005 
and Ebensen et al. 2004. 
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Chapter 2.1.1. 
Cytotoxic impact of resveratrol and
resveratrol analogues loaded bacterial ghosts (BGs)  
on the human derived colon cell line HT-29 
Verena Juliana Koller 1,2, Michaela Böhmdorfer3, Walter Jäger3, Thomas Szekeres4 and Werner 
Lubitz1,2,* 
1 University of Vienna, Department of Medicinal Chemistry, Vienna, Austria 
2 BIRD-C GmbH & CoKEG, Hauptstraße 88, 3420 Kritzendorf, Austria 
3 University of Vienna, Department of Clinical Pharmacy and Diagnostics, Vienna, Austria 
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Colorectal cancer is still the third most common cancer worldwide and new treatment 
strategies are needed. The aim of the present investigation was to develop a drug delivery model 
for the polyphenolic compound resveratrol (RV) as well its analogues 3,3’,4,4’,5,5’-
hexahydroxystilbene (M8) and  digalloylresveratrol (DIG) which exert anti-tumor activity in a 
variety of cell lines. For this purpose the bacterial ghost (BG) technology was used. BGs are 
non-living envelopes that are produced by the plasmid encoded gene E mediated lysis from 
Gram-negative bacteria. E coli BGs were filled with the chemotherapeutic substances and their 
impact on the colon cell line HT29 was investigated. In a comparative study with the free 
compounds, it was shown that DIG was quite more potent than M8 or RV. This cytotoxic 
pattern was also observed when the compounds were entrapped into BGs. Our findings show 
that the application of loaded BGs  significantly reduced the cell viability (up to 80 % with 
DIG). On the basis of the RV-status of HT29 cells, we were able to prove that the obtained 
cytotoxic effects were caused by intracellular drug delivery by BGs. Furthermore, more 
pronounced effects and sustained RV-levels were found after coincubation with RV-BGs than 
compared to the substance alone. These results indicate that BGs are an effective delivery 
system for the hydroxystilbene RV and its analogues DIG and M8 and can be used to target 
diseased human colon cells.  
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Introduction
The polyphenolic compound resveratrol (RV) is one of the most studied plant derived 
chemical. The hydroxystilbene shows beside antioxidative properties many chemopreventive 
activities in various cell lines e.g. leukaemia, breast and colon [1-3]. The exact mechanism of 
action of its cytostatic and cytotoxic effects is yet unknown. However, it was shown that RV 
mediates apoptosis through activation of the cell death receptor Fas or via depolarizing 
mitochondrial membranes followed by activation of caspase 9 [1, 2]. RV was also demonstrated 
to induce apoptosis via NF-?b inhibition and downregulation of Bcl-2 and promotes p53
dependent apoptotic responses [2]. Moreover, RV was shown to inhibit the enzyme 
ribonucleotide reductase (RR) which is found to be highly upregulated in rapidly proliferating 
tumor cells and catalyzes the rate limiting step of the de novo DNA-synthesis [4].  
Even though impressive in vitro effects are described, RV gives only limited anti-tumor activity 
in vivo [1, 2, 5]. Therefore, new substances have been developed to enhance the RV-related 
effects. Among these, higher hydroxylated RV-analogues like the 3,3’,4,4’,5,5’-
hexahydroxystilbene (M8), have been synthesized [6]. It has been demonstrated that M8 
induced apoptosis in HL-60 human promyelocytic leukemia cells [6, 7] and impaired melanoma 
progression was found in a metastatic mouse model [8]. Digalloylresveratrol (DIG) which 
represents a synthesized resveratrol ester composed of two gallic acid molecules and one RV 
molecule, showed dose-dependent apoptotic effects in the colon cell line HT29 [9]. Moreover, 
additive growth inhibition by combinatorial application with the standard chemotherapeuticum 
5-fluorouracil and DIG was observed. Increased pro-apoptotic effects of DIG were also found 
for HL-60 cells [10].  
Likewise RV, both chemicals (M8 and DIG) were shown to cause substantial imbalance 
of deoxyribonucleoside triphosphates (dNTPs), the products of RR, and to inhibit transition 
from the S- phase of the cell cycle to the G2/M phase [7, 9]. However, these studies 
demonstrated that both RV-analogues induced more apoptotic effects at lower concentrations 
than compared to the naturally occurring hydroxystilbene RV.  
Because RV as well as M8 and DIG are very UV-labile and are known to be rapidly 
metabolized, stabilization and enhancement of the bioavailability is desirable. Even though 
microencapsulation techniques have been developed for RV to solve some of the problems of 
oxidation and of controlled drug release [11-15], the implementation of the bacterial ghosts 
(BGs) system would provide new aspects for therapeutic applications.
Over the last decades, the BG system has become an extensive vaccine platform 
technology for a wide area of applications. BGs are produced from Gram-negative bacteria by 
controlled expression of the cloned bacteriophage PhiX174 gene E, resulting in empty cell 
envelopes which are devoid of any cytoplasmic content and contain only minimal amounts of 
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residual DNA. E-mediated lysis has been achieved for a variety of Gram negative bacteria [16, 
17]. Retaining immune stimulating compounds like LPS and peptidoglycan as well as antigenic 
epitopes, like their living counterparts, BGs are endowed with intrinsic adjuvant properties for 
boosting innate and adaptive immune responses [18]. This system can be extended by 
modifying the bacterial envelope prior to lysis or by entrapping various compounds in different 
compartments of the hosts so that they can be used as Advanced Drug Delivery Systems 
(ADDS) [17]. Besides the ability to present multiple epitopes due to expression of diverse 
foreign proteins by BGs, e.g. zona pellucida antigens [19], another advantage is given by the 
inner cytoplasmic lumen which can be filled with protein, DNA or drugs [17]. Loading and cell-
directed delivery of water-soluble substances and emulsions by BGs was demonstrated in cell 
culture and plant models [20, 21]. The use of BGs as carrier vehicles for cytostatic drugs, like 
doxorubicin (DOX) was shown with Caco2 cancer cells [22]. It was demonstrated that lower 
concentrations of this compound, delivered endogenously by BGs, was at least two orders of 
magnitudes more effective than the free substance.  
As recent investigations confirmed that organic ring structures, especially polyphenolic 
compounds, bind unspecifically to the membrane compartments of BGs [16], we aimed to load 
E. coli BGs with the chemotherapeutic drugs RV, M8 and DIG. The intention of the present 
study was to determine the cytotoxic impact of the entrapped compounds and to compare their 
efficiency in the human epithelial colon cell line HT29. To investigate further, whether the 
obtained effects were caused by endogenous drug delivery by BGs, additional experiments were 
conducted. For this purpose HT29 cells were treated with RV-loaded BGs and after different 
coincubation times, intra- and extracellular RV-concentrations were measured by HPLC. Also, 
the stabilizing and protection properties of RV by the BGs interior were examined. 
Additionally, long term incubation experiments (6 and 24 hrs) were conducted in which the 
amount of BG-delivered RV was compared to the free applied compound. 
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Materials and methods 
Cell culture 
HT29 cells were cultured under standard conditions (37°C moist atmosphere of 5% CO2)
in RPMI 1640 medium (Sigma Chemical Co., St. Louis, MO) supplemented with 10 % heat 
inactivated fetal calf serum (FCS, Sigma), 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA), 
100 U/ml penicillin (Invitrogen), 10 mM HEPES buffer (Lonza, Verviers, Belgium), 2 mM L-
glutamine (Invitrogen), 0.1 mM MEM Non-Essential Amino Acids (NEAA, Lonza) and 5 
μg/ml plasmocin (Lonza). The medium was changed every 2-3 days and cells were grown until 
they reached confluency. Subculturing was done by detaching the cells with TrypLE Express 
(Gibco, Invitrogen). Cell numbers were determined by use of a Bürker-chamber. Test media 
contained only antibiotics. 
Loading of E. coli NM522 BGs with RV,DIG and M8 
RV was purchased by Sigma and DIG as well as M8 were kindly provided by Dr. Walter 
Jäger. BGs were produced as described elsewhere [19, 21]. Lyophilized E. coli NM522 
(pGELys /AB; 071218; 5.4x109 particles/mg) BGs were loaded with different concentrations of 
RV (1-150 mM), DIG (1-100 mM) and with M8 (1-50 mM) by simple resuspension in the 
loading solutions. The samples were incubated at 28°C under soft shaking (600-800 rpm) for 30 
min. Thereafter, the samples were centrifuged (8 min, 13000 rpm) and washed 5 times with 
PBS. The BG pellets were stored at -20°C until use. Preparations of M8 and DIG stock solution 
as well as further loading concentrations were prepared by subsequent dilutions in 
dimethylsulfoxid (DMSO). RV stock solution and all other dilutions were prepared in methanol. 
BGs, which were resuspended in DMSO or in methanol and have been treated the same way as 
the BGs used for loading, served as BG-controls.  
Determination of viability by use of the neutralred assay 
The neutral red assay has been commonly used for the estimation of vital cells in culture. 
It is based on the uptake and lysosomal accumulation of the dye in living cells [23]. Prior to 
treatment, 1*105 cells were seeded in 96-well plates and were allowed to attach overnight. After 
one washing step with PBS, the cells were treated with 200 μl serum-free (sf) medium 
containing BGs (either loaded in the solvent control or in different RV, M8 or DIG 
concentrations) in a BG to cell ratio of 1000:1 (5x108 particles/ml) or with 50 μM of the 
substances (RV and RV-analogues) alone. After 24 hrs (37°C, 5% CO2), the cells were washed 
twice with PBS and were incubated with 100 μl neutralred dye (80 μg/ml final concentration; 
Roth) for another two hrs. Subsequently, the cells were washed again and the dye was extracted 
from the viable cells by use of 100 μl destaining solution (1 ml acetic acid, 73 ml 96 % ethanol 
and 26 ml deionized water). Absorbance was read with a microplate reader (Opsys MR, 
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DYNEX Technologies) at wavelength 570 nm (ref. 690 nm). Values, obtained from cells which 
were treated with serum free medium served as 100 % viability-level. The tests were performed 
in triplicate and mean values from three independent plates were determined. Data are 
represented as means + SD. 
Determination and quantification of RV extracted from E. coli NM522 BGs and HT29 cells  
RV was extracted from E. coli NM522 BGs by two times addition of 500 μl ethanol and 
shaking for 30 min (1000 rpm). After centrifugation (13000 rpm; 8 min), the obtained 
supernatants were collected and measured by HPLC. 
In order to assess the concentration of RV which will be delivered by endogenous uptake 
of RV-loaded BGs, 2x106 HT29 cells were seeded into 6-well plates and were allowed to attach 
overnight. The colon cells were incubated either with 2 ml 15 μM serum-free RV-solution or 
with 2 ml serum-free medium containing RV-BGs in a BG to cell ratio of 500 (5x108 particles 
ml-1). Based on the theoretical delivery rate of 40 % (obtained from microscopic studies) of the 
applied BGs, concentrations of t12 μM for BGs loaded in 100 mM RV were calculated. Cells 
which were treated with RV-BGs (t12 μM) were harvested after different incubations periods 
(20 min coincubation of BGs followed by harvesting after 4 hrs, 2, 4, 6 and 24 hrs 
coincubation). At each endpoint, also the according media were collected to determine the RV-
content which was extruded by the cells to the medium through transport proteins during these 
time periods. For comparison studies, the external as well as internal RV-concentrations were 
determined after application of 15 μM of pure RV for 6 and 24 hrs. 
Immediately after collection of the medium, a centrifugation step (13000 rpm; 10 min) 
was performed to remove RV-BGs and other cell debris. The obtained supernatants were stored 
at -20°C until use. Cells were harvested by trypsinization and enzyme activity was stopped by 
addition of 10% FCS-containing medium. After two washing steps with PBS (15 min, 1100 
rpm) the pellets were stored also at -20°C. Cell numbers and viability were determined by 
trypan blue staining in a Bürker chamber in triplicate.  
Methanolic RV-extraction was performed by the freeze-thawing method in liquid 
nitrogen (three times) and the determination of RV and its metabolites by HPLC was performed 
using a Dionex “UltiMate 3000” system (Dionex Corp., Sunnyvale, CA). The column oven was 
set at a temperature of 15°C, and the UV-detector was set at a wavelength at 307 nm. 
Chromatographic separation of resveratrol and its metabolites was performed on a Hypersil 
BDS-C18 column (5 μm, 250 x 4.6 mm I.D., Thermo Fisher Scientific, Inc, Waltham, MA), 
preceded by a Hypersil BDS-C18 precolumn (5 μm, 10 x 4.6mm I.D.), at a flow rate of 1 
ml/min. The mobile phase consisted of a continuous linear gradient, mixed from 5 mM 
ammonium acetate/acetic acid buffer, pH 7.4 (mobile phase A), and methanol (mobile phase B), 
to elute RV and its metabolites according to their lipophilicity. The mobile phase was filtered 
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through a 0.45 μM filter (HVLP04700, Milipore, Vienna, Austria). The gradient ranged from 
10% methanol (0 min) to 20% B at 10 min and linearly increased to 35% B at 22 min, followed 
by another increase to 60% B at 25 min, where it remained constant until 30 min. Subsequently, 
the percentage of methanol was decreased within 2 min to 10% in order to equilibrate the 
column for 8 min before application of the next sample. Calibration of the chromatogram was 
accomplished using the external standard method. Linear calibration curves were performed 
from the peak area of RV and its metabolites to the external standard resveratrol using standard 
solutions of RV to give a concentration range of 0.1 - 100 μg/ml. 
Statistical analysis 
All results were analysed by use of GraphPad Prism (version 5, GraphPad Software, Inc; 
San Diego; CA, USA). Statistical significance was determined by Student’s t-test. P-values < 
0.05 were considered statistically significant. 
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Results
Impact of pure and BG-entrapped RV, DIG and M8 on the viability of HT29 cells 
It has been already demonstrated that RV loaded BGs have an impact on the viability of 
murine macrophages (Koller and Lubitz, to be published elsewhere). In this study, analyses 
were conducted to investigate whether BGs, loaded with RV or its analogues DIG and M8, 
diminish the viability of the human colon cells HT29. Also the impact of the compounds (RV, 
M8 and DIG, Fig. 1) alone was examined at a concentration of 50 μM, which significantly 
reduced cell viability (Fig. 2). Our findings show that at this concentration RV and M8 
significantly decreased the cell viability to a similar extend (20% on average). However, higher 
effects were obtained after treatment with DIG which caused on average 80 % cell death after 
24 hrs..
In order to determine the cytotoxic impact of BG-delivered RV, DIG and M8 (lyophilized 
E. coli  NM522 BGs were loaded with the compounds up to the highest possible concentration: 
RV 150 mM, M8 50mM, DIG 100mM), experiments were conducted with HT29. The cells 
were treated with the loaded BGs in a MOI (multiplicity of infection) of 1000 for 24 hrs and cell 
viability was assessed with the neutralred assay. Results are depicted in Fig. 3A-C. It can be 
seen that the viability of the cell line was not impaired after treatment with the ghosts per se.
However, treatment of HT29 cells with BGs loaded with the three compounds resulted in a dose 
dependent loss of viability after 24 hrs. The cytotoxic pattern confirm with the results obtained 
from determination of the effects of the pure substance where the highest impact was found with 
DIG. Whereas no differences were seen after treatment with 50μM RV and M8 alone (Fig. 2),
significant differences were observed after delivery by BGs. Comparative investigations of BGs 
loaded in 50 mM of the adequate solution resulted in the following ranking: RV (91.1+5.6 % 
viability) <M8 (80.8+11.5 % viability) <DIG (45.6+9.0 % viability).  
Quantification of RV extracted from loaded BGs and HT29 cells 
Different experiments were conducted in order to investigate the stabilization properties 
of the BGs envelope for UV-labile chemicals like RV and to examine the extent of RV-delivery 
into HT29 cells by BGs. 
E. coli NM522 BGs revealed after loading (by resuspension in 100 mM RV) and extraction 
136.9 + 15.8 μg RV per 1*1010 BGs respectively. Under the conditions used in the present 
study, it has been determined that 1-0.5 % of the total amount of RV was bound in 1010 BGs. A 
representative HPLC-chromatogram of the BG entrapped RV is shown in Fig. 4A. It can be 
seen that no other substances than the pure compound could be determined, indicating that no 
metabolizing action occurred within the BG and that the substance was protected from UV-
damage during handling and storage since no cis-RV was detectable. 
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As uptake was demonstrated for E. coli BGs in the human colon cell line HT29 (Winter 
and Lubitz to be published), the cells were examined for the delivery of BG-bound RV. The 
colon cells were incubated with RV-loaded E. coli NM522 BGs for different time periods and 
were further treated as described in materials and methods. Subsequently, the extracted RV-
solutions were analysed by HPLC. A representative HPLC-diagram for serum-free media 
treated control cells is given in Fig 4B. Because of the fact that RV was rapidly metabolized by 
the investigated cells after incubation, the sum of RV and six metabolites (M1-M6) was 
calculated. No differences could be seen in the representative diagrams which were obtained 
after incubation with RV (Fig. 4C) or RV-BGs (Fig. 4D). RV and all metabolites are marked 
according to their retention time. 
From microscopic investigations it has been calculated that after 24 hrs coincubation 
roughly 40 % of the BGs are taken up by HT29 cells which would give a theoretical 
concentration of t12 μM for BGs loaded in 100 mM RV. 
Short time incubation of HT29 cells with BGs for 20 min, followed by further incubation 
in sf-medium for 4 hrs until harvesting, showed already detectable concentrations of RV and its 
metabolites in the cells (1.7+0.7 ng/1x106 cells). Increasing intracellular amounts of RV and its 
metabolites were found after 2 hrs (20.5+1.8 ng/1x106 cells) and 4 hrs (29.3+3.7 ng/1x106 cells)
incubation (Fig. 5A).
Since it can be excluded that RV is released from BGs without any uptake by the cells 
(data not shown), the supernatants of the HT29 cells were investigated. As RV-metabolites can 
be pumped out from the cells, a time dependent increase in concentration was measured in the 
medium (Fig 5B). After 4 hrs incubation with RV-BGs, 4 times more RV metabolites were 
detectable in the supernatant medium (4.1+0.8 μg/ml) than found after treatment with BGs for 
20 min, followed by further incubation in serum-free medium for four hours until harvesting 
(1.1+0.1 μg/ml). 
Comparative investigations of 6 and 24 hrs treatment either with RV-loaded E. coli
NM522 BGs (t12 μM) or with 15 μM RV solutions were conducted and results are represented 
in Fig. 5C-D. High significant differences of the intracellular RV and metabolite levels were 
obtained after treatment with t12 μM BGs when compared with the substance alone after 6 hrs 
(P=0.0138) and 24 hrs (P=0.0412). On average, 30.5+6.0 ng /1x106 cells RV and RV-
metabolites were detectable in the BG treated cells after 6 hrs. This represents more than 4-fold 
of the obtained values by 15 μM RV (7.2+0.8 ng / 1x106 cells).
Results obtained from measurements of the supernatant medium of the cells after treatment with 
15 μM RV or RV-BGs for 6 and 24 hrs are depicted in Fig. 3D. Significant higher 
concentrations were found with BGs compared to the substance per se after 6 hrs incubation 
(P=0.0001) and after 24 hrs (P=0.0327)..  
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Our findings show that RV delivery by BGs caused sustained levels of intra- and 
extracellular concentrations of the chemical and its metabolites. Furthermore, we could 
demonstrate a drug release profile in the HT29 cell line depending on the coincubation time of 
BGs. Moreover, better effects were found with RV when delivered by BGs than with the free 
applied substance. High differences were also found in regard to the cytotoxic impact of the 
compound. While neutralred assays as well as trypanblue staining of the cells showed that 15 
μM of free RV did not cause reduction of cell viability (data not shown), RV-loaded BGs 
decreased cell viability about 15 %. 
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Discussion
More than 655,000 deaths are recorded worldwide per year which are related to colorectal 
cancer [24]. Therefore, new targeted agents are designed and used in various therapeutic 
treatments. Several studies showed that RV suppresses the proliferation of various colon cancer 
cells in vitro and that tumor formation was significantly reduced in mice [1].  Also the 
proapoptotic potential of the RV analogues M8 and DIG has been demonstrated for a variety of 
rapid proliferating cell lines, including colon and leukaemia cells  [9, 10, 25]  
To date, there is a high demand for developing a drug delivery system that accounts for 
substance protection and sustained drug-release. Therefore, encapsulation techniques are now 
under progress to overcome this problem and researches with diverse biodegradable carrier 
systems have been conducted. RV has been demonstrated to incorporate into liposomes [13] and 
the compound was loaded into calcium-pectinate beads having 1-2 mm in diameter [12] or into 
mPEG-PCL based nanoparticles smaller than 100 nm in size [14]. 
In the present study, the potential of BGs as a drug delivery system for RV and its 
analogues M8 and DIG was investigated in the colon cell line HT29. The experiments showed 
that the cell viability was not affected after long term incubation with E. coli BGs per se but was 
reduced in a dose dependent manner when the compounds were entrapped.
As HPLC is a reliable method and was already used for the determination of RV-
concentrations in biological systems [26], different experiments were conducted with RV-
loaded BGs to investigate if the obtained cytotoxic effects were caused by intracellular delivery. 
However, first we examined the stabilization capacity of the BGs interior towards the 
photosensitive chemical. Comparisons between the standard trans-resveratrol and the extract of 
the BG-entrapped chemical clearly demonstrate, that no UV-induced alteration had occurred 
during the encapsulation process as no cis-resveratrol was detectable. This is in analogy to a 
study in which RV was incorporated into lypophylized S. cerevisiae cells which were 
plasmolyzed before the freeze drying process [15]. As by this method, the cytoplasmic material 
is mostly removed from the cell, similar to BGs, the encapsulation yield (EY) can be compared 
with our results. Recalculating for one mg loaded vehicles, the yeast EY was on average 0.0450 
+ 0.005 % compared to an entrapping efficiency of 0.3007 + 0.0344 % by BGs. Since the 
common beaker’s yeast sizes in its spherical form 5-10 μm in diameter in contrast to E. coli
BGs which show on average 1 μm in length, a higher entrapping rate could be assumed. 
However, a direct opposite can be demonstrated as more than 6 times less RV could be 
incorporated into S. cerevisiae. This can be mainly explained by the efficacy of the lysis 
process. Compared to cell treatment with a plasmolyser, the ghost production technique 
represents a controlled lysis system. As nearly all of the cytoplasmic content is expelled in more 
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than 99.99% of the population through the generated lysis hole (up to 200 nm), the full capacity 
of the intracellular ghost lumen can be used for the loading of chemicals. 
 Because of the fact, that some enzymes of the BGs were found to be still active, even 
after lyophilization, we investigated if any chemical changes take place after BG-encapsulation. 
Since only high purity peaks were obtained under the chromatographic conditions, we can 
certify the metabolic inactivity of BGs towards resveratrol.   
RV is known to be rapidly metabolized and glucuronidated in the small intestine of rat 
[27] as well as in the human GI tract and liver [5, 28]. Because sulfotransferase activity was 
reported to be higher in gut than in liver [29], the GI tract can be considered as the major side 
for RV metabolism. 
To investigated the uptake of RV-loaded BGs and their total-RV metabolite content, the 
metabolic active HT29 colon cell line was used which expresses multigenic families of enzymes 
such as sulfotransferases and UDP-glucuronosyltransferases [30, 31]. Furthermore, these cells 
possess transport proteins like multidrug resistance protein 3 (Mrp3) and ABCG2 (also named 
BCRP), which have been shown in cell culture studies to mediate the extrusion of metabolites 
from the cells [30, 32]. Therefore, we examined the intracellular and the extracellular 
concentrations of RV and their metabolites after applications of RV-loaded BGs in comparison 
to an equivalent dose of free RV after long term treatment. Due to the high metabolic rates of 
the used HT29 cells mostly only metabolites were detectable in the cytosolic fractions. 
However, a higher and sustained release profile could be found, after internal RV delivery by 
BGs than compared with the substance alone. More than 5 times higher intracellular RV 
concentrations, mainly metabolites, were detected after 6 hrs application of RV-loaded ghosts 
than with RV per se. After 24 hrs coincubation also differences concerning the cell viability 
were detectable. In contrast to the free RV solution, drug delivery by BGs caused cytotoxic 
effects in HT29 cells. Such findings were also obtained in a former study in which increased 
cytotoxic and antiproliferative activity of the cytostatic drug doxorubicin was found after 
endogenous release by BGs than compared to the chemical per se [22]. In another investigation 
with glia cells it was shown that formulation of nanoparticle-bound RV resulted in significant 
higher cytotoxicity than the free drug in an equivalent dose [14].  
Even though RV is known to be metabolized within 8-14 min [12], beneficial effects of 
dietary RV have been demonstrated in mice [33, 34]. Therefore, it is speculated that its 
metabolites may still retain some of their pharmacological activities or that due to deconjugation 
of these metabolites, the pharmacologically active parent compound could be released again. 
The latter assumption is in agreement by a human study in which new RV plasma peaks were 
observable again after 6 hrs after intestinal hydrolysis [35]. Furthermore it was shown that the 
compound interferes with serum albumins in vitro [36] and in vivo that up to 50 % of RV-
metabolites, which were transported into plasma, were noncovalently bound to proteins [37] 
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However, a previous in vitro study demonstrated that RV induces apoptosis only after 
long term treatment for up to 24 hrs [38] and as we also did not observe any acute toxic events 
after shorter exposure times, we presume that the cytotoxic effects are mainly related to the 
originated metabolites.  
The results of the present study confirm that BGs represent an effective delivery system 
for the compounds RV, DIG and M8 by BGs. As RV has been shown to have potential 
therapeutic efficacy on lower gastrointestinal diseases like colitis and colorectal cancer it could 
be assumed that the BG bound chemical or its analogues M8 and DIG might enhance the 
effectiveness of therapy. 
88
Figures
Hexahydroxystilbene (M8) Resveratrol (RV)Digalloylresveratrol (DIG)
Fig 1. Chemical structures of the 3,3’,4,4’,5,5’-hexahydroxystilbene (M8, left), 
digalloylresveratrol (DIG, middle) and resveratrol (RV, right). 
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Fig. 2. Comparative cytotoxic effects of RV and RV-analogues M8 and Dig are shown. HT29 
cells were treated for 24 hrs. All compounds significantly reduced the cell viability at a 
concentration of 50 μM. Values are means + SD obtained after 4-6 measurements which were 
performed in triplicate. 
89
Medium 0 50 100 150
0
50
100
150
* * *
RV-BGsBGs
RV loading solution [mM]
Vi
ab
ili
ty
 [%
]
Medium 0 10 25 50
0
50
100
150
* *
M8-BGsBGs
M8 loading solution [mM]
Vi
ab
ili
ty
 [%
]
Medium 0 25 50 100
0
50
100
150
*
*
*
DIG-BGsBGs
DIG loading solution [mM]
Vi
ab
ili
ty
 [%
]
Fig. 3. Impact on the viability of the colon cell line HT29 after treatment with loaded BGs for 
24 hrs. Metabolic activity was assessed by neutral red assays. Bars represent mean values + SD 
of 4-6 determinations measured in triplicate. Asterisks indicate values which were considered 
significant different from the medium treated controls.  
90
0 5 10 15 20 25 30 35 40
0
500
1000
1500
2000
2500
RV
Retention time (min)
In
te
ns
ity
 (m
V)
0 5 10 15 20 25 30 35 40
0
1
2
3
4
Retention time (min)
In
te
ns
ity
 (m
V)
0 5 10 15 20 25 30 35 40
0.0
0.5
1.0
1.5
2.0
M1
M2
M3
M4 M5
M6
RV
Retention time (min)
In
te
ns
ity
 (m
V)
0 5 10 15 20 25 30 35 40
0
1
2
3
4
M1
M2
M3
M4 M5 M6
RV
Retention time (min)
In
te
ns
ity
 (m
V)
A B
C D
Fig. 4. Representative HPLC chromatograms of RV measurements are depicted. An example 
for the quantification of RV extracted from BGs is shown (A). It can be seen that no 
metabolization of the drug occurred within the BG’s lumen and that only trans-RV was 
detected. A diagram of serum-free medium treated HT29 cells is shown in (B). Since RV is 
rapidly metabolized within the colon cells, also its metabolites were considered for 
quantification. Representative diagrams after treatment of colon cells with RV alone (C) or 
delivered by BGs (D) are depicted. 
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Fig. 5. Time dependent RV delivery by BGs into the colon cell line HT29. RV and its 
according metabolites were detectable after short term treatment with RV-loaded E. coli
NM522 BGs for 20 min, followed by further incubation in serum-free medium for 4 hrs 
until harvesting. Further increase of the concentrations was found after 2 and 4 hours 
coincubation with BGs in a MOI of 500 (5x108 BGs/ml). Intracellular RV and RV-
metabolite levels are depiced in (A) and concentrations which were extruded by the cells 
into the medium are shown in (B). Comparative quantification HPLC analyses were 
performed to investigate the internal content (C) and the extracellular amount (D) of RV 
and its metabolites after 6 and 24 hrs incubation with 15 μM free RV (white bars) or with 
RV-loaded BGs (black bars). Cells were coincubated with RV-BGs in a MOI of 500 (5x108
BGs/ml, t12 μM). Asterisks indicate values which were statistically significant different 
from those obtained with 15 μM RV per se.
Bars represent means + SD measured either in triplicate (internal concentration) or duplicate 
(external concentration).
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Chapter 2.2.1. 
Bacterial Ghosts (BGs) as potential antigen and drug 
delivery system for ocular diseases: Effective endocytosis of 
BGs by human conjunctival epithelial cells 
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The purpose of the presented investigation was to examine the efficiency of bacterial 
ghosts (BGs) - empty bacterial cell envelopes of Gram-negative bacteria retaining all the surface 
morphological, structural and antigenic components in the same quality as in their living 
counterparts - to target human conjunctival epithelial cells, as well as to test the endocytic 
capacity of conjunctival cells after co-incubation with BGs generated from different bacterial 
species, and to foreclose potential cytotoxic effects caused by different types of BGs. The 
capacity of conjunctival cells to endocyte BGs was investigated using the Chang conjunctival 
epithelial cell line and primary human conjunctiva-derived epithelial cells (HCDECs) as in vitro
model. The efficiency of endocytic activity of conjunctival epithelial cells was measured by 
uptake of fluorescence-labeled BGs and determined by flow cytometry. Potential cytoxicity of 
BGs was monitored by the WST-1 Proliferation Assay. A high capacity of HCDECs to 
functionally internalize BGs was detected with the level of endocytosis depending on the type 
of BG species. Further analysis showed that BGs have no cytotoxic effect on HCDECs after 
mutual co-incubation, independently of the used bacterial species. Moreover, BGs alone did not 
enhance expression of both MHC class I and class II molecules, but increased expression of 
ICAM-1. The high endocytosis rates of BGs by HCDECs with no BG-mediated cytotoxic 
impact designate this bacterial carrier system to be a promising candidate for an ocular surface 
drug delivery system. BGs could be useful for future therapeutic ocular surface applications and 
eye-specific disease vaccine development including DNA transfer. 
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Introduction
The ocular surface epithelium plays a fundamental role in the protection of the eye from 
environmental factors and pathogens. First acting as a physical barrier it defends the eye from 
injury and invasion of pathogens and allergens, and second as part of the eye-associated 
lymphoid tissue (EALT) it contributes to the homeostasis of the ocular surface [1-2]. This front 
line role of the ocular surface epithelial cells is supported not just with the capacity to form 
physical obstacle against microbes or drug agents but also with their capability to produce pro-
inflammatory cytokines, chemokines and antimicrobial peptides, and thus to enhance 
elimination of pathogens, and to protect the eye from uncontrolled inflammatory responses [3-
6]. Conjunctival epithelium is about three layers thick and covers vascularized connective tissue 
built from bone-marrow derived cells which form conjunctiva-associated lymphoid tissue [7-8]. 
In addition to the presence of CD4+ and CD8+ T cells in conjunctival epithelium; macrophages 
and Langerhans dendritic cells are also present as numerous populations in the conjunctiva [9-
10]. Professional antigen-presenting cells (APCs) capture and process antigens, express 
lymphocyte co-stimulatory molecules, migrate to the lymphoid organs and secrete cytokines to 
initiate immune responses [11]. Extracellular antigens present in the conjunctiva are processed 
by APCs and presented in the context of MHC class II molecules to the lymphocytes in the local 
lymphoid follicles [9, 12]. Furthermore, intraepithelial T lymphocytes are capable to recognize 
glycolipids derived from bacterial pathogens which are associated with nonpolymorphic class I 
MHC-like molecules, and by production of cytokines to activate professional phagocytes [13-
14]. 
Due to the conjunctival epithelium barrier function delivery of drugs/antigens is 
challenging. Tight intercellular junctions and the constant state of flux of the tear fluid not only 
hinder the penetration of harmful but also of therapeutic agents. Therefore platforms that 
overcome this shield enabling effective administration of drugs or antigens to the ocular tissues 
and EALT would help to progress the development of prospective generic drugs/vaccines/gene 
therapy against various ocular surface diseases.  
Bacterial ghosts (BGs) represent empty bacterial cell envelopes of Gram-negative 
bacteria which have been developed in the last years as a novel carrier and adjuvant system for 
the delivery of mucosal vaccines [15-17]. BGs are produced by protein E-mediated lysis of 
Gram-negative bacteria. Protein E fuses the inner and outer membranes forming a specific small 
hole in the bacterial envelope through which all the cytoplasmic content is expelled. The empty 
shell of BGs is devoid of nucleic acids, ribosomes and other constituents, whereas inner and 
outer membrane structures including the outer membrane proteins, adhesins, LPS, and 
peptidoglycan are well preserved and remain intact [18].  
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The main advantage of BGs is their non-living character, while still retaining all of the 
surface morphological, structural and antigenic components in the same quality as in their living 
counterparts [19]. The different spaces of BGs can be loaded with a combination of protein 
antigens, drugs or foreign DNA which gives an opportunity to design new types of polyvalent 
vaccines or to use BGs as advanced drug delivery system [16]. LPS-lipopolysaccharide (i.e., 
lipid A, endotoxin) - content of the Gram-negative bacteria cell envelopes presented on the 
BG’s shell does not represent a risk for using of BGs as a vaccine candidate. Previous 
immunological studies have shown that BGs induce dose-dependent antibody responses against 
bacterial cell components and LPS without inducing fever. Safe profile of BG was confirmed 
using a Limulus-assay, where purified LPS (E. coli O26:B6) expressed endotoxic activity 
values 100-times higher than the BGs. Moreover, there is no risk of reversal to pathogenic form 
in contrast to attenuated bacteria used as bacterial delivery system [20].  
Our previously published studies have shown that BGs loaded with plasmid DNA 
encoding green fluorescent protein are efficiently internalized and phagocyted by both 
professional antigen-presenting cells and tumor cells. BGs were able to deliver the heterologous 
genes to both non-dividing cells (monocyte-derived DCs) and dividing cells (macrophages and 
melanoma) with study results showing that up to 85% of cells expressed the plasmid encoded 
reporter gene delivered by BGs [21-24].  
The purpose of the present study was to examine the capacity of BGs generated from 
different bacterial species to target primary human conjunctiva-derived cells (HCDECs) and 
their potential effect on cell viability, as well as to test the endocytic capacity of primary 
HCDECs after co-incubation with BGs. 
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Material and methods 
Cells and reagents
A human conjunctival cell line (Wong–Kilbourne derivative of Chang conjunctiva, clone 
1-5c-4, ATCC CCL-20.2) kindly provided by Prof. Bernd R. Binder (Medical University 
Vienna, Centre of Biomolecular Medicine and Pharmacology; Department of Vascular Biology 
and Thrombosis Research, Vienna, Austria) was maintained in Dulbecco’s modified Eagle’s  
medium (Lonza, Verviers, Belgium) supplemented with 10% FCS (Sigma Chemical Co., St. 
Louis, MO), 2 mM glutamine (Invitrogen, Carlsbad, CA), 100 U/mL penicillin (Invitrogen), 
100 ?g/mL streptomycin (Invitrogen), 10 mM HEPES (Lonza), and 0.1 mM MEM Non-
Essential Amino Acids Solution (Lonza) in a 5% CO2 humidified incubator at +37°C. Human 
conjunctiva specimen biopsies were obtained from patient donors undergoing eye surgery. 
Informed consent was obtained in accordance with the Declaration of Helsinki from all subjects 
prior to surgery. The study was approved by Ethics committee of the Medical University of 
Vienna (EK-Nr. 598/2008). Primary human conjunctiva-derived epithelial cells (HCDECs) 
were obtained from biopsy specimen with small modifications of previously described methods 
[25-27]. Briefly, conjunctival tissues were cut into small pieces and incubated for 1h at +37°C 
with 1.2 IU/mL dispase II (Invitrogen). Cells were detached, collected and cultured in complete 
culture medium- Dulbecco’s modified Eagle’s medium and Ham’s F12 (1:1 mixture)(PAA 
Laboratories GmbH, Vienna, Austria) supplemented with 10% FCS, penicillin/streptomycin, 
HEPES, MEM Non-Essential Amino Acids Solution, 1 μg/mL bovine pancreas insulin (Sigma), 
2 ng/mL epidermal growth factor-EGF (R&D Systems, Inc., Minneapolis, MN), 5 μg/mL 
hydrocortisone (Sigma), and 0.1 μg/mL cholera toxin (Sigma). The cultures were fed with fresh 
medium and supplements every 2 to 3 days. 
Production of BGs  
BGs from Mannheimia haemolytica A23, Escherichia coli Nissle 1917, Escherichia coli
NK9373, and Escherichia coli NM522 were produced by the controlled expression of the 
phage-derived lysis protein E, as described previously [18, 28-30]. For safety reasons, to avoid 
presence of potential non-lysed, non-culturable but viable cells, the BG’s preparations were 
inactivated with gentamycin (50 mg/mL; Invitrogen) and streptomycin (100 mg/mL; 
Invitrogen). Subsequently the BGs were washed three times with phosphate-buffered saline 
(PBS, pH~7.4; Lonza), resuspended in distilled water and lyophilized. Lyophilized BGs were 
stored at +4°C. 
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FITC-labeled BGs uptake
The efficiency of endocytic activity of conjunctiva cells was measured as described 
previously [22-23].  Briefly, 5 mg of BGs were resuspended in 500 ?L 0.1 M Na2CO3 (pH~9.0; 
Sigma). Stock solution volume of 25 ?L FITC (1 mg FITC; Sigma, in 1 mL DMSO; Sigma) 
was added to the BGs suspension and shaken for 2 h at room temperature. Afterward the BGs 
were carefully washed with PBS and stored at +4°C protected from light. HCDECs cultured in 
24 well plates (2x105 cells/well; Sarstedt, Nümbrecht, Germany) were incubated with FITC-
BGs (1000 per cell) for 10 and 40 min at +37°C. After incubation the cells were washed three 
times with PBS to remove the excess of BGs. Finally the cells were detached using TrypLETM
Express (Invitrogen), washed 3 times with PBS, fixed in cold 1.5% PFA (Sigma) in PBS and 
analyzed on BD FACSCanto™ Flow Cytometer (BD Biosciences, Pharmingen, San Jose, 
USA). Dead cells were excluded according to their forward and side scatter properties. Obtained 
data were analyzed using FlowJo Software version 7.5 (Tree Star, Inc., Ashland, OR). 
Cell proliferation and viability assay  
Metabolic activity and viability of HCDECs after incubation with BGs were assessed 
using premixed WST-1 cell proliferation assay following the manufacturer’s instructions 
(Clontech Laboratories, Inc., Mountain View, CA). HCDECs cultured in 96 well flat-bottom 
plates (2x105/well, Sarstedt) were incubated with BGs (1000 per cell) for 40 min at +37°C. 
After co-culture with BGs the HCDECs were washed to remove the excess of BGs followed by 
incubation in complete culture medium. After 24 h premixed WST-1 cell proliferation reagent 
was added to each well and cells were incubated for additional 4h at +37°C in a 5% CO2
humidified incubator as recommended by the manufacturer. After 1 min of thorough plate 
shaking, the absorbance was measured at 450 nm (reference wavelength 690 nm) using a 
DYNEX Opsys MR plate reader (Dynex Technologies, Chantilly, VA). Cytotoxic agent Triton 
X-100 (0.005%; Sigma) was used as a control. 
Flow cytometry analysis of human conjunctiva derived cells  
The capacity of BGs to elicit expression of MHC molecules and ICAM-1 on the surface 
of responding cells was assessed by incubation of HCDECs with BGs (1000 per cell) for 10 and 
40 min at +37°C in a 5% CO2 humidified incubator. After incubation the cells were washed 
three times with PBS to remove the excess of BGs and fresh complete culture medium was 
added for additional incubation. Cells were collected 24h, 36h and 72h after stimulation, 
resuspended in FACs buffer (0.1% BSA (Sigma), 0.01% NaN3 (Sigma) in PBS) and stained 
with panel of mAb – FITC conjugated mouse anti-human HLA-ABC (BD Biosciences), PE 
conjugated mouse anti-human HLA-DR (BD Biosciences), PE-Cy™5 conjugated mouse anti-
human CD54 (ICAM-1) (BD Biosciences), and isotype controls (BD Biosciences). 
101
Unstimulated cells incubated without BGs stained with isotype controls and with a panel of 
described mAbs served as controls. After incubation for 30 min at +4°C the cells were washed 
with FACs buffer, fixed in cold 1.5% PFA in PBS and analyzed on BD FACSCanto™ Flow 
Cytometer (BD Biosciences). Dead cells were excluded according to their forward and side 
scatter properties. Obtained data were analyzed using FlowJo software (Tree Star). 
Statistical analysis
Obtained results were analyzed by GraphPad Prism version 5 (GraphPad Software, La 
Jolla, CA). The statistical significance of the difference between two groups was evaluated by 
Student's t-test and between more than two groups by the one-way ANOVA. Differences were 
considered to be significant with p < 0.05. 
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Results
Effective endocytosis of BGs by human conjunctival cells  
The endoytosis of BGs by primary HCDECs and conjunctival epithelial cell line CCL-
20.2 was determined by flow cytometry after extensive removal of non-internalized BGs by 
washing with PBS. The detection of efficiently internalized BGs within human conjunctival 
cells was also confirmed by confocal laser scanning microscopy (data not shown). The obtained 
results showed that the uptake rates were dependent on the bacterial species from which BGs 
were prepared and length of co-incubation. The highest internalization of BGs was observed 
after incubation of human conjunctival cells (HCC) with BGs derived from M. haemolytica
(Fig.1). Up to 80% of conjunctival cells CCL-20.2 effectively internalized M. haemolytica BGs 
at the ratio BG:HCC - 1000:1 after 40 min of co-incubation. Detectable endocytosis of BGs was 
observed already 10 min after adding of BGs to the culture system. BGs derived from E.coli
NK9373 revealed approximately the half efficacy to stimulate endocytic capacity of human 
conjunctival cells compare to M. haemolytica derived BGs (~43%). Significant internalization 
of BGs was also detected after incubation of human conjunctiva cells with BGs derived from 
E.coli Nissle 1917 (~24%). The number of cells with increased fluorescence as a result of 
endocytosis of FITC-labeled BGs rose with extended time of co-incubation. E. coli NM522 
derived BGs showed modest positive impact on the capacity of human conjunctival cells to 
endocyte BGs after 40 min of co-incubation when part of conjunctival cells (~13%) efficiently 
bound and internalized FITC-labeled empty bacterial shells (Fig.1A). Similar results confirming 
the hierarchy of BG types capable to stimulate endocytic capacity of 6 different human primary 
conjunctival cells were observed after co-incubation of BGs with HCDECs obtained from 
various human conjunctival specimen biopsies. The results presented in Fig.1B are the average 
of 6 different primary cells (HCDEC 1-6) tested and thus it is obvious that the standard 
deviation is higher than the one given for the Wong–Kilbourne derivative of Chang conjunctiva 
cells (Fig. 1A). In the following, all investigations are performed with the 6 different primary 
conjunctival cells to exclude unspecific effects due to the prolonged culture of the CCL-20.2 
cell line resulting in alterations of cell surface properties. 
BGs have no cytotoxic impact on primary HCDECs 
Analysis of BGs uptake by primary HCDECs revealed various levels of their endocytic 
capacity depending on the type of bacterial species used for generation of BGs. Cytotoxicity test 
using premixed WST-1 cell proliferation reagent was performed to investigate if the different 
types of BGs would affect the viability and metabolic activity of primary HCDECs. Enzymatic 
cleavage of the tetrazolium salt WST-1 (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-
tetrazolio]-1,3-benzene disulfonate) to water soluble formazan dye by viable cells was analyzed 
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24 h after incubation of primary HCDECs obtained from different donors (n=6)  with BGs 
(1000 per cell) for 40 min. Released formazan dye was quantitated spectrophotometrically by 
the measurement of the absorbance at 450/690 nm. The results showed no cytotoxic effects of 
all the analyzed types of BGs on the viability of primary HCDECs. We detected no significant 
difference in metabolic activity of analyzed cells incubated with BGs in comparison with the 
cells incubated without BGs. Significant decrease of viability was detected only after incubation 
of cells in the presence of cytotoxic agent (Triton X-100) (Fig. 2).
BGs stimulate expression of ICAM-1 on HCDECs, but not HLA-ABC and HLA-DR 
Human conjunctival cells constitutively express HLA class I antigen-presenting 
molecules and ICAM-1, but not HLA-DR (HLA class II) without IFN-gamma stimulation.[25] 
Primary HCDECs were incubated with different types of BGs for 10 and 40 min and after 
removal of BGs from culture incubated for additional 24h-72h. Increased expression of ICAM-1 
molecule on the surface of primary HCDECs was detected already 24h  after stimulation with 
BGs for both 10 and 40 min co-incubation, but no significant changes in HLA class I and class 
II molecules expression by primary HCDECs were observed after stimulation with BGs (Fig.3).
The same results for all markers tested were observed 48h and 72h after stimulation of primary 
HCDECs with BGs (data not shown). Further, no fold change of HLA-ABC and HLA-DR mean 
fluorescence intensity (MFI) values were noticed 24 h after co-incubation of primary HCDECs 
with the four different types of BGs for both 10 and 40 min (Fig. 4A,B). Stimulation of primary 
HCDECs generated from different donors (n=6) with  the different types of BGs resulted in 6.1, 
5.5, 6.4, and 6.4-fold change increase of ICAM-1 (CD54) MFI values after 10 min co-
incubation with E. coli NK9373, M. haemolytica, E.coli Nissle 1917, and E. coli NM522, 
respectively. Extended co-incubation of HCDECs with BGs for 40 min did not cause significant 
changes in expression of ICAM-1 (CD54) compared to results observed after 10 min of co-
culture with study results showing 5.9, 5.1, 6.2, and 5,6-fold change increase of MFI values 
after co-incubation with E. coli NK9373, M. haemolytica, E.coli Nissle 1917, and E. coli 
NM522, respectively (Fig. 4C). These results indicate that the stimulation of ICAM-1 
expression is independent from the number of BGs being internalized and the signal for the 
stimulation does not discriminate up to a factor  of 4 (M. haemolytica and E. coli NM522) of the 
total uptake. 
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Discussion
In the present study, we investigated the capacity of BGs derived from different bacterial 
species to target primary HCDECs by evaluating their capacity to endocyte BGs and the impact 
of BGs on their viability and metabolic activity. Our results demonstrate a high capacity of 
primary conjunctiva cells to bind and endocyte BGs. In this panel of BGs derived from 
pathogenic and non-pathogenic bacterial species, the most effective envelopes for uptake by 
primary HCDECs were determined and identified as BGs from M. haemolytica, E. coli
NK9373, E. coli Nissle 1917, and E. coli NM522. Subsequent studies revealed that BGs without 
restrictions to the bacterial species used for their preparation have no cytotoxic effects on 
conjunctival epithelial cells, but stimulate increased expression of the co-stimulatory molecule 
ICAM-1 on the surface of primary HCDECs. 
Conjunctival epithelial cells in addition to physical protection of the eye are also capable 
to respond towards bacterial pathogens by production of antimicrobial peptides and pro-
inflammatory cytokines [5, 8]. Sensing of pathogens with pattern recognition receptors -TLRs- 
expressed by conjunctival cells plays a key role in the ocular immune defense mechanism [31]. 
Probably minor molecular differences in structures of LPS and flagellin presented on the surface 
of various bacterial species would affect signaling through TLR receptors expressed by 
conjunctival cells and thus modulate production of proinflammatory cytokines and expression 
of surface molecules involved in immune response. Our findings about the uptake of different 
BGs by primary HCDECs presented in this study showed that the selection of bacterial species 
used for the generation of BGs have a significant role for future use of BGs as carriers for the 
ocular disease vaccine development and/or drug treatment. From the panel of tested BGs 
derived from various bacterial species we have observed strong abilities of BGs to be 
internalized by primary HCDECs (M. haemolytica), next we identified BGs with mediate 
capacity to stimulate endocytosis of primary HCDECs (E. coli NK9373), as well as BGs with 
moderate impact on endocytic capacity of primary HCDECs (E. coli Nissle 1917 and E. coli
NM522). Furthermore, we observed that BGs derived from other bacterial species including
ETEC, S. typhimurium, S. flexneri, and P. multocida were either ignored or minor recognized by 
primary HCDECs (data not shown). Entire specific mechanism or identification of BG’s surface 
molecules affecting the endocytic capacity of conjunctival cells and secretion of 
proinflammatory cytokines by primary HCDECs after co-incubation with BGs should be further 
investigated in details. Although not having the highest uptake rates, BGs derived from E. coli 
Nissle 1917 seem to have an advantage over the other tested BGs envelopes. E. coli Nissle 1917 
is a probiotic and therapeutic strain which has a good record for its use in preterm-infants and 
toddlers, and is registered as therapeutic agent in several European countries [32-33]. With these 
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findings the way seems to be open to use BGs as carrier of antigens or drugs for preventive and 
therapeutic use against infectious diseases of the eye. 
Besides, for prospective future application of BGs against various ocular surface diseases 
complete cytokine profile of HCDECs after incubation with BGs needs to be examined. We 
showed previously that DCs efficiently endocyte BGs derived from various bacterial species 
and produce high levels of IL-12 and TNF-alpha [34], cytokines very effective in the induction 
of Th1 type T cell immune response. These cytokines together with IL-6 and IL-8 secreted by 
conjunctival cells after stimulation with LPS as described Chung et al [35] have the capacity to 
induce IFN-gamma production by NK and T cells [36]. Moreover, capacity of BGs to stimulate 
secretion of IL-6 and IL-8 by epithelial cells was observed after incubation of BGs with primary 
human keratinocytes (Abtin and Lubitz, personal communication). IFN-gamma is critical factor 
affecting the degree of cellular pathogen infection; furthermore it has the capacity to stimulate 
expression of antigen-presenting molecules on both professional and non-professional APCs 
like conjunctival epithelial cells, fibroblasts etc. [25, 37-41]. 
ICAM-1 is typically associated with adhesion and transmigration of leukocytes, but it 
also plays an important role in providing of the second or costimulatory signal required for T 
cell activation and cytokine production after MHC-Ag-complex – TcR ligation [42]. Activation 
of T cells in ICAM-1/LFA-1 dependent manner stimulates CD8+ T cells with the phenotype of 
fully differentiated effector IFN-gamma producing cytotoxic T cells capable to lyse antigen 
specific target cells [43]. Furthermore, increased ICAM-1 expression by tumor cells correlate 
with increased cytolytic capacity of tumor infiltrating lymphocytes [44]. Besides the impact of 
ICAM-1 on T cells it was reported recently that cells from stromal microenviroment (fibroblast) 
are capable to induce maturation of DCs in ICAM-1/LFA-1 dependent manner [45]. These 
observations open the question if BGs related increased expression of ICAM-1 by human 
conjunctival cells might have an additional stimulatory effect on leukocyte populations 
presented in EALT and positive impact on induced antigen-specific immune response.  
We proved previously that BGs are able to deliver DNA and drugs to the target cells [21-
24, 29, 46]. Excellent BGs delivery capacity, ability to stimulate cytokine secretion by target 
cells, and capability to increase expression of co-stimulatory molecules on the surface of target 
cells emphasize BGs as a promising candidate for ocular surface disease treatment. We are 
aware that using Gram-negative bacteria LPS content of the cell envelopes presented on the 
BG’s shell does not represent a risk for using of BGs as a potential drug delivery candidate [16, 
20]. Moreover, we showed that endocytosis of empty bacterial shells did not stimulate increased 
expression of antigen presenting molecules on the surface of primary HCDECs, but we 
observed enhanced expression of ICAM-1, which is playing an important role in transmigration 
of leukocytes and is also capable to provide the activation signal for DCs, T cells and NK cells 
[43, 45, 47-48]. Future investigations will characterize cytokine production/alteration of primary 
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HCDECs challenged by BGs like modification of innate immunity markers. Optimization and 
improvement of the selected prospective model type of BGs would help to progress the 
development of microbial-mediated ocular disease vaccine and drug carriers, and their 
application in future clinical trials. However, this concept has to be investigated in details in 
future studies including in vivo models and investigations related to the impact of BGs loaded 
with DNA and/or drugs on all cell populations forming the target tissue and EALT. In our 
opinion, these results indicate that BGs have the potential to be used as a carrier for delivery of 
drugs/antigens/RNA/DNA to human conjunctival cells.  
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Figures
Fig. 1. Endocytosis of FITC-labeled BGs by human conjunctival cells. Human conjunctival cell 
line CCL-20.2 (A) and primary human conjunctiva-derived epithelial cells (HCDECs; n=6) (B) 
were incubated with FITC-labeled BGs derived from different bacterial species for 10 and 40 
minutes at +37°C. The endocytosis of BGs by conjunctival cells depends on the bacterial 
species from which the BGs were prepared. Values were calculated as the percentage of cells 
with increased fluorescence incubated with unlabeled BGs subtracted from the percentage of 
positive cells incubated with FITC-labeled BGs. Endocytic capacity of conjunctival cells was 
measured by BD FACSCanto flow cytometer (BD Biosciences). Data represents the mean of 
three independent experiments ? SD. 
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Fig. 2. Impact of BGs derived from different bacterial species on the viability and metabolic 
activity of the primary human conjunctiva-derived epithelial cells (HCDECs). HCDECs were 
incubated for 40 min with BGs (1000 per cell) generated from different bacterial species. The 
colorimetric WST-1 cleavage assay was performed to investigate possible toxic effects of BGs 
on primary HCDECs. Each bar represents the mean of three independent experiments 
performed in triplicates ? SD.
HCDEC-1
Tr
ito
n X
-10
0
no
BG
s
E. 
co
li N
K9
37
3
M.
 ha
em
oly
tic
a
E. 
co
li N
iss
le 
19
17
E. 
co
li N
M5
22
0
1
2
3
Ab
so
rb
an
ce
 (A
45
0n
m
/A
69
0n
m
)
HCDEC-2
Tr
ito
n X
-10
0
no
 B
Gs
E. 
co
li N
K9
37
3
M.
 ha
em
oly
tic
a
E. 
co
li N
iss
le 
19
17
E. 
co
li N
M5
22
0
1
2
3
Ab
so
rb
an
ce
 (A
45
0n
m
/A
69
0n
m
)
HCDEC-3
Tr
ito
n X
-10
0
no
 B
Gs
E. 
co
li N
K9
37
3
M.
 ha
em
oly
tic
a
E.
co
li N
iss
le 
19
17
E. 
co
li N
M5
22
0
1
2
3
Ab
so
rb
an
ce
 (A
45
0n
m
/A
69
0n
m
)
HCDEC-4
Tr
ito
n X
-10
0
no
 B
Gs
E. 
co
li N
K9
37
3
M.
ha
em
oly
tic
a
E.
co
li N
iss
le
19
17
E. 
co
li N
M5
22
0
1
2
3
Ab
so
rb
an
ce
 (A
45
0n
m
/A
69
0n
m
)
HCDEC-5
Tr
ito
n X
-10
0
no
BG
s
E. 
co
li N
K9
37
3
M.
ha
em
oly
tic
a
E.
co
li N
iss
le
19
17
E. 
co
li N
M5
22
0
1
2
3
Ab
so
rb
an
ce
 (A
45
0n
m
/A
69
0n
m
)
HCDEC-6
Tr
ito
n X
-10
0
no
BG
s
E. 
co
li N
K9
37
3
M.
 ha
em
oly
tic
a
E. 
co
li N
iss
le 
19
17
E. 
co
li N
M5
22
0
1
2
3
Ab
so
rb
an
ce
 (A
45
0n
m
/A
69
0n
m
)
109
B)
A)
Fig. 3. Representative flow cytometry analysis of HLA-ABC, HLA-DR and CD54 (ICAM-1) 
expression by the primary human conjunctiva-derived epithelial cells after incubation with BGs. 
Cells HCDEC-3 were incubated for 10 (A) and 40 (B) min with BGs (empty histograms-dotted 
line) prepared from E. coli Nissle 1917 (1000 per cell) and stained with a panel of monoclonal 
antibodies. Unstimulated cells incubated without BGs stained with a panel of monoclonal 
antibodies (full histograms) or isotype control (empty histograms-full line) as described in 
Material and Methods served as controls. 
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Fig. 4. Incubation of BGs with the primary human conjunctiva-derived epithelial cells 
(HCDECs) elicits increased expression of ICAM-1 (CD54), but has no impact on the expression 
of HLA-ABC and HLA-DR by primary HCDECs. Fold  change of the MFI  of primary 
HCDECs (n=6)  stimulated for 10 and 40 min at +37°C with BGs derived from different 
bacterial species and stained with mAbs 24h after stimulation as described in Material and 
Methods. Unstimulated cells incubated without BGs stained with a panel of Abs served as 
controls. Fold change of BGs-induced HLA-ABC, HLA-DR and ICAM-1 (CD54) MFI values 
were calculated and shown as the mean of 3 independent experiments. 
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Bacterial ghosts (BGs) are non-denaturated bacterial envelopes obtained from Gram-
negative bacteria produced by E-mediated lysis. In the present study the safety aspects in regard 
to cytotoxicity and genotoxicity of BGs were examined in the human derived conjunctival cell 
line CCl 20.2. Further, the toxicity of benzalkonium chloride (BAC), a preservative of 
numerous medical preparations, was investigated in combination experiments with BGs.  
Results obtained from earlier investigations in single cell gel electrophoresis (SCGE) 
assays showed that bacteria can cause DNA-damage in human derived cells. However, the 
findings from the present study demonstrate that BGs per se no not trigger any toxic effects in 
CCL 20.2 cells.
In addition, we found that BGs are protective against the acute toxic and genotoxic effects 
caused by BAC. Presence of BGs increased the viability of the cells after short and long term 
BAC treatment by 60 %. Furthermore, also the induction of DNA migration by the quaternary 
ammonium compound was significantly reduced. The protective properties could be partly 
explained by inactivation of BAC-generated H2O2 due to peroxidase activities of BGs. Results 
of agar diffusion assays in which bacteria were tested with BAC in presence or absence of BGs, 
showed that the bactericidal nature of the preservative was not affected.  
These findings show that BGs are “safe” vehicles that could be used as drug carriers for 
treatment of conjunctival diseases coevally providing a protection against preservative induced 
toxicity.  
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Introduction
BAC is widely used as disinfectant, stabilizer and preservative of a variety of 
prescriptions as well as over-the-counter-drugs and can be found in cosmetics, infant care 
products as well as nasal sprays, otic drops and ophthalmic solutions [1]. It is the most 
commonly used preservative in ophthalmological medications and is added at concentrations 
ranging between 40 and 250 mg/l to various preparations to prevent bacterial contaminations 
and disintegration of the active drug [2].  
The cytotoxic effects of BAC is well documented with ocular tissues like the cornea, 
conjunctiva and retina, especially associated with long-term use [3]. Induction of necrosis and 
apoptosis has been demonstrated in conjunctival cells [4] and  it was shown that cell death was 
caused by direct disruption of the cell membranes [5] or by interaction with membrane G-
proteins (Guanine nucleotide triphosphate binding proteins) thereby effecting signal 
transduction causing apoptotic stimulation [6, 7].  
Bacterial ghosts (BGs) are non-degraded bacterial cell envelopes devoid of any 
cytoplasmatic content produced from Gram-negative bacteria by controlled expression of the 
plasmid encoded gene E of bacteriophage PhiX174 [8, 9]. These non-living bacterial envelopes 
maintain the full cellular morphology with preserved peptidoglycan, lipopolysaccharide (LPS) 
and outer membrane proteins. Furthermore, the inner lumen provides a huge filling volume for 
drugs, coevally providing a protected environment from outside influences. The uptake and 
phagocytosis of BGs has been investigated in various cell lines eg. dentritic cells, different 
human melanoma cells, macrophages and colon cells and the capacity of BGs as drug targeting 
and delivering vehicles has been demonstrated [10, 11]. BGs can be used for immunization 
against their own structure, as antigen delivery systems [12] or they can be filled with DNA [13] 
or drugs [14]. Despite the fact, that BGs were proven to be non-cytotoxic to melanoma cells and 
macrophages in vitro [15, 16], nothing is known about the safety aspects of BGs concerning 
epithelial conjunctiva cells.
Aim of the present study was to examine whether BGs themselves cause acute or 
genotoxic effects in the Wong-Kilbourne derivative of Chang conjunctiva cell line (CCl 20.2). 
These cells have been widely used for BAC-induced toxicological and functional in vitro
studies [4, 17, 18] and possess characteristics that are typical for normal tissue and primary 
cultures [19]. Furthermore, experiments were conducted to find out if the use of ghosts may 
reverse the toxic effects of BAC and if this has an impact on its bactericidal properties.  
The acute toxicity of the drug and of different BGs, prepared from different bacterial 
species, was determined by use of the neutralred assay and DNA-damage was assessed with the 
SCGE (single cell gel-electrophoresis) technique. The alkaline SCGE assay is one of the most 
commonly used methods for identifying substances with genotoxic activity at the single cell 
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level and is highly sensitive towards ROS [20-22]. This test system is based on the 
measurement of DNA-migration in an electric field and the size of the comets serves as a 
measure of the extent of DNA-damage. The SCGE assay has been used in earlier investigations 
to demonstrate the DNA-damage caused by bacteria [23]. Recent findings showed that BAC 
causes positive results in SCGE assays with nasal [24] and bronchial cells [25] as well as with 
primary hepatocytes [26]. 
Since it has been shown that BAC produces at concentrations in a the range of 50-100 
mg/l intracellular reactive oxygen species (ROS), in particular H2O2, and leads to cell death of 
conjunctival cells [17, 18] we examined BAC in solution and determined the possible 
participation of the bacterial peroxidase in the detoxification. Finally we conducted additional 
measurements to elucidate if the bactericidal activities of the drug, which we examined by agar 
disc diffusion assays, are affected by the BGs.  
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Materials and methods 
Cell culture 
The American Type Culture Collection (ATCC Manassas, VA) certified cell line (CCL) 
20.2 (Wong-Kilbourne derivate of Chang conjunctival cells, clone 1-5c-4) was kindly provided 
by Prof. Bernd Binder (Medical University Vienna, Center of Biomolecular Medicine and 
Pharmacology; Department of Vascular Biology and Thrombosis Research, Vienna, Austria). 
The cells were cultured under standard conditions (37°C moist atmosphere of 5% CO2) in RPMI 
1640 medium (Sigma Chemical Co., St. Louis, MO) supplemented with 10% heat inactivated 
fetal calf serum (FCS, Sigma), 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA),  100 U/ml 
penicillin (Invitrogen), 10 mM HEPES buffer (Lonza, Verviers, Belgium), 2 mM L-glutamine 
(Invitrogen), 0.1 mM MEM Non-Essential Amino Acids (NEAA, Lonza) and 5 μg/ml 
plasmocin (Lonza). The medium was changed every 2-3 days and when cultures reached 
confluency, the cells were washed with phosphate buffered saline (DPBS, Lonza), detached 
with TrypLE Express (Gibco), centrifuged and subcultured. 
Production of bacterial ghosts 
The following BGs were produced as described earlier [14, 27] and were used in the 
present study: Escherichia coli NM522 (pGELys), Escherichia coli Nissle 1917 (pGLysivb), 
Enterotoxigenic Escherichia coli (ETEC) H10407 (pGLysivb), Shigella flexneri CVD1203 
(pAW12), Shigella flexneri CVD1203-CFAI-CS3 (pGLysivb / pJGX15A / pACCS3), Shigella 
flexneri ATCC700930 (pGLNIc / SNUC), Salmonella typhimurium ATCC14028 (pGLysivb) 
and Pasteurella multocida (pSR2). 
Cytotoxicity assays 
The viability of the cells was determined in neutralred assays. This method is based on 
the accumulation of the dye in the lysosomes of living cells [28]. To investigate the impact of 
BGs towards the conjunctival cell line CCl 20.2, 5x104 cells were seeded in 96-well plates and 
were allowed to attach. Then the cells were treated with 200 μl of different types of BGs 
(resuspended in serum free medium) in a MOI (multiplicity of infection) of 1000 for 24 hrs. 
TritonX-100 (0.005 %) served as a positive control and cells treated with serum free medium 
represent the negative control. 
In combination experiments with BAC and BGs, the cells were treated with 200 μl of 
different BAC-concentrations (ranging from 0.01-0.0001 %) and with BGs (MOI of 1000). For 
short time incubation experiments (5 min), the cells were divided into two groups: the first were 
treated only once and the second were re-exposed to BAC 60 min after the initial treatment to 
mimic a repetitive character of drug treatment. The cell viability was determined after a 24 hrs 
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recovery period in complete medium. The recovery phase was included to simulate the clinical 
conditions in which the conjunctival tissue may recover after topical eye drop administration. 
Long term treatment lasted 24 hrs.  
After each treatment, two washing steps with PBS were performed. Subsequently, the 
cells were incubated with 100 μl of NR (80 μg/ml final concentration; Roth) for two hrs (37°C; 
5 % CO2). After the dye had been discarded, the wells were washed two times with PBS and 
dye was released by the addition of 100 μl of the destaining solution (1 ml acetic acid, 73 ml 96 
% ethanol and 26 ml deionized water). After shaking, the absorbance was measured at 570 nm 
(reference wavelength 690 nm) with a microplate reader (Opsys MR, DYNEX Technologies). 
The tests were performed in triplicate and mean values from 3 independent plates were 
determined. Data are represented as means + SD. Values obtained with medium treated cells 
were considered as control and were set as 100 % viability.  
SCGE assays 
The single cell gel electrophoresis (SCGE) assays were performed according to the 
guidelines described by Tice at al [22]. In order to test the impact of different BGs on the DNA-
stability, 1x105 CCl 20.2 cells were cultured in 6-well plates for 45-48 hrs (37°C; 5% CO2).
Thereafter, the culture medium was replaced by one ml serum free-medium containing BGs 
(1000 particles / cell) and the cell were incubated for 40 min in the dark (37°C; 5% CO2).
Analyses, in which the effects of different concentrations of H2O2, BAC and BAC in 
combination with ETEC BGs (MOI of 1000) were investigated, were performed with 48-well 
plates. 2x105 cells were allowed to attach and after removal of the culture medium, the cells 
were treated with 400 μl of the compounds with or without BGs. Incubation was either 
performed for 10 min (H2O2) or for 5 min and 20 min with the preservative BAC (also in 
combination with ETEC BGs).Thereafter, the medium was discarded and the cells were washed 
twice with PBS and detached with TripleEx. After two washing steps (1600 rpm, 8 min, 21°C), 
the pellets were resuspended and viability was determined by trypan blue exclusion [29]. Only 
cultures in which the viability of the cells was > 80% were used for further analyses. Thereafter, 
the cells were pelleted (1600 rpm, 8 min, 21°C) and were resuspended in low melting agarose 
(LMA, 0.5%). Then the cells were spread onto precoated agarose slides (1.5 % normal melting 
agarose) and lysed in the dark for 1 hour at 4°C. After 20 min of unwinding in electrophoresis 
buffer, the electrophoresis was carried out for 20 min (300 mA, 25 V) and neutralization was 
performed twice for 8 min. Air dried slides were stained with ethidium bromide (20 μg/ml) and 
the percentage of DNA of tail was measured by the use of a computer aided image analysis 
system (Comet IV, Perceptive Instruments Ltd., Haverhill, UK).For each experimental point, 
three cultures were made in parallel. From each culture one slide was prepared and from each 
slide 50 randomly distributed cells were evaluated.  
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Qualitative determination of H2O2-generation by BAC 
In order to determine if H2O2 is released by BAC, the qualitative method described by 
Liszkay et al. was used [30]. The assay is based on the development of a blue reaction product 
when tetramethyl benzidine (TMB) is oxidized by peroxidase in the presence of hydrogen 
peroxide. For this purpose, three BAC solutions (4, 20 and 40 mg/ml), containing 0.37 % citric 
acid, 3.5 mM TMB and 1 μg horseradish peroxidase (HRP, Type VI-A from Sigma) were 
incubated at 37°C. After 3 days, the generation of H2O2 was monitored photometrically and 
absorbance was read at 370 nm. For each point, three experiments were conducted. 
Peroxidase activity measurements of BGs  
To determine the peroxidase activity of selected BG strains, colorimetric enzyme 
measurements were conducted as described by Rafii et al. [31]. The enzyme assay was 
performed in 1 ml PBS containing 1mM TMB, 0.37 % citric acid, 0.3 % H2O2 and 10 μl 
sample. The mixture was incubated for 10 min, centrifuged and the produced oxidized TMB 
was measured at OD 370 nm. 
HRP was used as an internal standard and units were defined as arbitrary units, whereby 
one mg solid corresponds to 1000 AZBTS units (see information from sigma). Peroxidase 
activity of BGs was determined from obtained peroxidase activity/used particles*factor. The 
factor was calculated as μg lyophilized particles per μg protein of the respective BGs. Protein 
contents were measured with the Bradford protein assay kit (Bio-Rad Laboratories GmbH, 
Munich, Germany)  
Agar disc diffusion assays 
To monitor the bactericidal effect of BAC, disc diffusion assays were performed with 
minor modifications [32, 33]. Briefly, overnight cultures of the E. coli strain NM522 were 
spread onto agar plates. After drying, sterile drug-free paper discs (diameter 7.0 mm; No. 2668;
Schleicher and Schüll, Dassel, Germany) were placed to the surface. Thereafter, 30 μl of 
different solutions (BAC alone or in combination with 5x109 ETEC-BGs / ml) were spotted onto 
the discs. Then the plates were incubated at 37°C for 48 hrs. The diameter of the growth 
inhibition zones was determined in triplicate and the obtained area in mm2 was considered for 
evaluation.
Statistics
All results were analysed by use of GraphPad Prism (version 5, GraphPad Software, Inc; 
San Diego; CA, USA). Data are expressed as means + SD. Statistical analysis between more 
than two groups was performed by the one-way ANOVA and the Dunnett's multiple comparison 
test as post-test. Difference between two groups was evaluated by the Student’s t-test. P-values 
< 0,05 were considered statistically significant. 
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Results
Genotoxic and cytotoxic impact of BGs on CCL 20.2 cells 
The cell viability was assessed in neutralred assays and no differences were found 
between the negative controls which were exposed to serum free medium compared to BGs 
derived different bacterial species (MOI of 1000) after treatment for 24 hrs (Table 1.).
Exposure of the cells to the same BGs as used in the cytotoxicity assays, also did not 
affect the DNA-stability of the cells after 40 min (Table 1).
Determination of viability with BGs and BAC 
Considering that ophthalmological medications contain up to 250 mg/l BAC and that eye 
drops are quickly further diluted after application in its environment, e.g. through the tear fluid, 
different BAC concentrations ranging from 10-100 mg/l were chosen to investigate the impact 
on the conjunctiva cells after 5 min exposure followed by a 24 hr recovery period (Fig. 1A). As 
it was demonstrated that BAC can be found in the ocular tissues after a single topical 
application even after a few days [5, 34], experiments were conducted in which the long term 
application (24 hrs) was studied. Results obtained after 24 hr treatment with ten-fold lower BAC 
concentration 1-10 mg/l are depicted in Fig. 1B. Significant cytotoxic effects were obtained 
with 50 mg/l BAC after short-term incubation and with 5 mg/l BAC after long-term treatment. 
To investigate whether BGs have an impact on the BAC-induced cytotoxicity in CCL 
20.2 cells, simultaneous treatment experiments with the preservative and different BGs were 
conducted. To simulate the situation of multidose application of BAC, further experiments were 
performed in which the cells were treated twice with the preservative (5 min; 1 hr break) 
followed by a 24 hr recovery time. It can be seen that double treatment with the chemical alone 
led to significant decrease in the viability of the cells. As shown in Fig. 2A, the percentage of 
viability dropped from 53 % for the single dose application to 4 % cell viability for 50 mg/l 
BAC.
However, compared to BAC-treated cells, increased numbers of the cells stayed alive by 
the presence of BGs. High beneficial effects could be found with BGs after double applications 
of 50 mg/l BAC. Differences were seen between the E. coli BGs and Shigella and Salmonella
BGs. Enhanced viability from 17-fold was found for one of the Shigella samples and 5 to 12-
fold for E. coli BGs (Fig. 2A).
Due to the strong effects seen after double treatment with 50 mg/l BAC, the impact of 10-
fold diluted BAC samples for long term exposure (24 hrs) with and without BGs was 
investigated (Fig. 2B). Exposure of CCL 20.2 cells to 5 mg/l BAC for 24 hrs resulted in about 
80 % decrease of the viability. Protective effects were found when BGs were present in the 
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preservative solution. Cytotoxicity was significantly lowered in combination with all different 
BGs (MOI of 1000) to a similar extent. On average 85 % of the cells survived.
Determination of H2O2-generation by BAC and measurement of BG peroxidase acitivity  
Experiments were conducted to qualitatively investigate the generation of H2O2 by BAC. 
The development of a blue colour in TMB/HRP supplemented BAC-solution indicated the 
formation of H2O2. Results are depicted in Fig. 3.
One explanation of the beneficial effects of BGs towards BAC-induced cytotoxicity (Fig. 
2) could be the detoxification of ROS due to hydrolysis of H2O2 by BG-associated peroxidase. 
As depicted in Fig. 4, all BGs oxidized TMB. The highest enzyme activities were obtained with 
ETEC and S. flexneri BGs.
Comparative agar diffusion assays 
The mode of cytotoxic action of BAC as preservative and disinfectant is the 
permeabilization and solubilization of bacterial membranes leading to release of the cell 
contents [35]. Since Gram-negative bacteria are known to be quite more resistant towards BAC 
due to their outer membrane than Gram-positives [36], high concentrations of BAC (5, 15 and 
40 mg/ml) have been tested with the E. coli NM522 strain. For the coincubation of the different 
BAC solutions with BGs, ETEC ghosts have been chosen, as they exhibited good effects on cell 
viability (Fig. 2) and for their peroxidase activity associated with the BGs themselves (Fig. 4).
A dose dependent inhibition of the bacterial growth could be observed with the used BAC 
concentrations. The presence of ETEC BGs in the three different BAC concentrations had no 
effect on the inhibition zone, indicating that the peroxidase activity of ETEC BGs did not have 
an impact the bactericidal action of BAC (Fig. 5).
Genotoxicity assays with H2O2, BAC and combined BAC-ETEC BGs solutions 
As H2O2 was used as positive control in SCGE assays with BGs (Table 1), a dose-
response curve was established to investigate the sensitivity of this cell line. A clear dose 
dependent induction of DNA-damage was observed when cells were exposed to different H2O2
concentrations for 10 min. As shown in Fig. 6A, significant differences between the percentage 
of tail intensity were already found at concentrations > 50 μM.  
Furthermore, the genotoxic impact of BAC towards the conjunctiva cells CCL 20.2 was 
investigated after short term treatments. Significant DNA-damage was detected already after 5 
min incubation with 50 mg/l BAC. Extended time of coincubation of CCl 20.2 and BAC at the 
same concentration led to a 6-fold increase of percentage of DNA in tail compared to the 
respective control (Fig. 6B)
To elucidate whether BGs could also have an impact on BAC-induced DNA-damage, 
experiments were conducted with ETEC BGs, which already demonstrated protective effects 
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towards BAC-induced cytotoxicity (Fig. 2) and for which high peroxidase activities were 
obtained (Fig. 4). As depicted in Fig. 6C, our findings show that coincubation of BAC (50 
mg/l) with ETEC BGs significantly reduced DNA-migration. On average, the presence of BGs 
reduced the preservative caused DNA-damage 55% after 5 min and 35 % after 20 min 
coincubation. A simple explanation for the detoxification seen in the SCGE tests as well as in 
the cytotoxicity assays could be the possible loading of the BGs with the compound thereby 
reducing the concentration of BAC in the medium and / or the participation of the active 
peroxidase system could contribute to the elimination of BAC-generated H2O2.
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Discussion
This is the first report concerning the “safety” of BGs produced from different bacterial 
species, and their protective effects towards BAC induced cytotoxicity and genotoxicity in 
conjunctival cells CCl 20.2.  
It was shown that BAC concentrations from 1-100 mg/l led to delayed induction of cell 
death [4]. Cell proliferation and viability were altered in a dose-dependent time course which 
worked rapidly for 100 mg/l BAC (within 24 hrs) and gradually for concentration less equal 
than 50 mg/l. In agreement with the results obtained from their investigations we obtained 
similar viability values by use of the short time application and recovery model (Fig. 1).
Further, we conducted double treatment experiments with BAC to mimic a repetitive character 
as it is used in medical application as eye drop preservative. A strong inhibitory effect of BAC-
induced cytotoxicity could be demonstrated when the cells were simultaneously treated with 
BGs (Fig. 2A). More than 10-fold increase in cell viability could be observed when CCL 20.2 
cells were concomitantly exposed to the preservative when BGs (in particular E. coli or Shigella
BGs) were present. 
Animal studies demonstrated that the turnover of BAC in the eye is very slow and that the 
compound could be detected in the ocular tissues still after 48 hours up to 9 days after a single 
topical application [5, 34]. Therefore, experiments were conducted in which the long term 
application (24 hrs) of BAC was investigated. Findings of treatment experiments with BAC and 
BGs resulted in high beneficial effects as CCL 20.2 cell viability was 40-60 % enhanced in the 
presence of BGs (Fig. 2B).
The antiseptic effects of BAC at concentrations lower than 500 mg/l have been 
demonstrated already in 1930s [37, 38]. Resistance to quaternary ammonium chlorides has been 
reported to be mainly related to the adoption or hyperexpression of multi-drug efflux pumps in 
gram negative bacteria [39, 40]. Since a membrane potential is needed for functionally efflux 
systems, these mechanism can be excluded as an explanation for the diminished damage of 
BAC in combination with BGs.  
In former studies it was shown that membrane associated enzymes of BGs like ATPases 
[27] or enzymes from the periplasmatic space such as alkaline phosphatase and ?-lactamase [41] 
are vastly retained and active. Therefore, lyophilized BGs were investigated for their peroxidase 
activity and the enzyme was found to be still functionally active (Fig. 4). As generation of H2O2
by BAC was demonstrated (FIG. 3), we assumed that one mechanism of detoxification of BAC 
with BGs could be due to their peroxidase activity. 
BAC treatment has been demonstrated to induce internal ROS production in Chang cells 
and endogenous H2O2-generation was already found at concentrations higher than 10 mg/l BAC 
[17, 18]. Treatment of human corneal epithelial cells with H2O2 concentrations > 30 ppm caused 
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in vitro significant morphological and cytotoxic changes within 5 hrs [42]. Furthermore, a 
significant decrease in cell viability was shown after exposure to 300 μM H2O2 for 24 hrs [43]. 
To our knowledge, no genotoxic investigations were performed with H2O2 in this cell line. In 
the present study the impact of concentrations 4 to 6-times lower than mentioned above was 
examined after a short incubation period of 10 min. A dose-dependent induction of DNA-
migration could be observed and significant DNA-damage was monitored by use of SCGE 
already at concentrations > 50 μM (Fig. 6A)
Furthermore, results depicted in Fig. 4B indicate that BAC induces DNA-lesions at a 
significant level already with 50 mg/l after short term incubations (i.e. 5 min and 20 min). These 
findings can be confirmed since high DNA-fragmentation was also observed with an 
electrophoretic assay system after treatment of CCl 20.2 cells with 100 mg/l BAC for 10 min 
[4]. Significant DNA-migration caused by the preservative was also found in primary rat 
hepatocytes when cells were exposed to 1 mg/l for one hr [26]. Another study with the human-
derived bronchial epithelial cell line BEAS-2B showed clear cut induction of DNA-damage 
after 2 hrs treatment with 20-50 mg/l BAC [25].  
Since several in vitro studies indicated the generation of ROS, in particular H2O2 and 
superoxide anion, after BAC application in conjunctival cells [4, 17, 44], we assume that BAC-
induced DNA-migration could be also elicited by ROS, which encounters also a mayor key role 
in inflammation processes. However, no formation of oxidized DNA-bases was found in SCGE 
assays with the enzyme FPG in hepatocytes it and was stated that the observed genotoxic effects 
of BAC may not be related to oxidative stress [26]. Nevertheless, significant decrease of BAC-
induced DNA-damage was observed in presence of  ETEC BGs (Fig. 6C). One detoxification 
mechanism could be the participation of the enzymatic cleavage of BAC-generated H2O2 due to 
the bacterial associated peroxidase or the fact that BGs are loaded with the compound coevally 
depriving the toxic compound from the medium. Furthermore, as the uptake of BGs used in the 
present study by CCl 20.2 cells has been determined in a different investigation (Kudela and 
Lubitz, in press), it can be also assumed that the beneficial effect on cell viability originates also 
from the intracellular subset and not only from the presence of extracellular BGs. 
Due to advantage that BGs also possess intrinsic adjuvant properties, we plan to develop 
a BG-vaccine against the blindness causing Chlamydia trachomatis pathogen in the near future. 
As part of the SAFE program (S = Surgery, A = antibiotics, F = Facial cleanliness, Hygiene 
Promotion, E = Environmental Health Improvements), azithromycin represents the commonly 
used standard antibiotic which is recommended by the World Health Organization (WHO) to 
fight these infections [45]. 
To date a huge spectrum of delivery systems has been developed for ocular drugs [46] 
and liposomes, polymorphonuclear leukocytes as well as nanoparticles have already been 
demonstrated as carrier systems for azithromycin [47-49]. However, a recent in vivo study 
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showed that nanoparticles accumulate and induce additional inflammatory reactions due to 
radical generation causing DNA-damage [50]. 
As our findings indicate that neither the DNA-stability nor the viability of the 
conjunctival cells was impaired after treatment with various BGs, the examined strains represent 
optimal candidates as drug carriers for the treatment of intracellular infectious eye diseases. 
As we could further demonstrate that BGs perpetuate the antibactericidal action of the 
preserving agent (Fig. 5), it is conceivable that BGs can be loaded with azithromycin and 
formulated as eyedrops preserved with BAC. Such applications could have an additional 
beneficial impact as the ocular surface would be sheltered from preservative related side effects. 
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Tables and Figures 
Table 1 
Impact of BGs on the viability and on the DNA-stability of the conjunctival cell line CCL 20.2.1
Bacterial ghosts
Pos. control 4 + 1 17,690 + 3,359
Neg. control 105 + 2 5,952 + 1,364
E.coli  NM522 109 + 15 4,002 + 0,831
E.coli  Nissle 98 + 15 6,898 + 1,459
ETEC  H10407 97 + 3 4,196 + 0,716
S. flexneri 100 + 5 7,534 + 2,500
S. flexneri CS3 111 + 3 5,416 + 1,563
S. flexneri  SNUC 110 + 6 7,480 + 0,703
S. typhimurium 104 + 2 5,895 + 2,701
P. multocida 104 + 1 7,217 + 1,198
Viability + SD [%] 2 DNA in tail + SD [%] 2
1 The cells were incubated with different BGs (MOI of 1000) for 24 hrs. Thereafter, the viability 
was measured with neutralred, and DNA-stability was determined in SCGE assays.  
2 Values represent means + SD of three measurements in parallel. 
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Fig. 1. Impact of BAC on the viability of the conjunctival cell line CCL 20.2. Dose-dependent 
reduction of viability caused by the preservative BAC in the conjunctival cell line CCL 20.2 is 
shown after 5 min exposure followed by a 24 hour recovery period (A) and after 24 hours 
incubation (B). The viability of conjunctiva cells was determined in neutralred assays. Bars 
represent values of means + SD obtained from three independent experiments. 
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Fig. 2. Impact of BAC alone or in combination with different BGs on the viability of CCL 20.2 
cells. Figure (A) shows the acute toxic effects toward the conjunctival cell line after short term 
treatment with either 50 mg/l BAC in combination with different BGs for 5 min (single 
application white bars; double treatment black bars) followed by a 24 hr recovery period. Figure 
(B) shows the effects on the viability of the conjunctival cell line after long term treatment with 
5 mg/l BAC in combination with different BGs for 24 hrs. Cells were treated with BGs in a 
MOI of 1000 and the viability was determined by the use of the neutralred assay. Bars represent 
mean data + SD obtained from three independent measurements. Asterisks indicate values 
which differ significantly from BAC treated cells (p < 0.05). 
128
4 20 40
0.05
0.10
0.15
0.20
BAC [mg/ml]
O
D
 3
70
Fig. 3. Dose-dependent generation of H2O2 by BAC. The formation of the radicals was 
monitored by the production of the blue product with the TMB/HRP method. Bars represent 
mean values + SD of three measurements.  
E.
 c
ol
i N
M
52
2
E.
 c
ol
i N
is
sl
e 
19
17
ET
EC
 H
10
40
7
S.
 fl
ex
ne
ri
S.
 fl
ex
ne
ri 
C
S3
S.
 fl
ex
ne
ri 
SN
U
C
S.
 ty
ph
im
ur
iu
m
P.
 m
ul
to
ci
da
0
2
4
6
8
ar
bi
tr
ar
y 
un
its
 p
er
ox
id
as
e
 p
er
 p
ar
tic
le
Fig. 4. Determination of peroxidase activity of different BGs. Hydrolysis of H2O2 was 
monitored spectrophotometrically. Enzyme activities are depicted as arbitrary units. The 
measurements were performed in triplicate and data are depicted as mean values + SD. 
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Fig. 5. Comparison of growth inhibition of E. coli NM522 caused by different BAC 
concentrations with or without ETEC BGs. Values were obtained by agar disc diffusion assays. 
Bars indicate the effect caused by the substance alone (white) and in combination with ETEC
BGs (black).  
Data are shown as mean values + SD which were obtained with triplicate measurements.  
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Fig. 6. Dose dependent induction of DNA-damage by H2O2 (A) and BAC (B) in CCl 20.2 cells. 
The cells were either treated with different doses of H2O2 for 10 min, or with BAC for either 5 
min (white bars) or 20 min (black bars). In a further combination experiment, the impact of 
BAC (shaded bars) and ETEC H10407 BGs (dotted bars) on the DNA-migration was 
investigated (C).
Bars indicate mean values + SD obtained with three cultures. Asterisks indicate values which 
differ significantly from the controls and crosses mark statistical significant differences with 
and without BGs (p < 0.05). 
131
References 
1. Marple, B., P. Roland, and M. Benninger, Safety review of benzalkonium chloride used as a 
preservative in intranasal solutions: an overview of conflicting data and opinions. Otolaryngol 
Head Neck Surg, 2004. 130(1): p. 131-41. 
2. Xiong, C., et al., A rabbit dry eye model induced by topical medication of a preservative 
benzalkonium chloride. Invest Ophthalmol Vis Sci, 2008. 49(5): p. 1850-6. 
3. Baudouin, C., Detrimental effect of preservatives in eyedrops: implications for the treatment of 
glaucoma. Acta Ophthalmol, 2008. 86(7): p. 716-26. 
4. De Saint Jean, M., et al., Effects of benzalkonium chloride on growth and survival of Chang 
conjunctival cells. Invest Ophthalmol Vis Sci, 1999. 40(3): p. 619-30. 
5. Green, K., et al., Detergent penetration into young and adult rabbit eyes: comparative 
pharmacokinetics. Cutaneous and Ocular Toxicology, 1987. 6(2): p. 89-107. 
6. Patarca, R. and M.A. Fletcher, Effects of benzalkonium salts on eukaryotic and microbial G-
protein-mediated processes and surface membranes. Crit Rev Oncog, 1995. 6(3-6): p. 327-56. 
7. Guo, Y., et al., Benzalkonium chloride induces dephosphorylation of Myosin light chain in 
cultured corneal epithelial cells. Invest Ophthalmol Vis Sci, 2007. 48(5): p. 2001-8. 
8. Witte, A., et al., Endogenous transmembrane tunnel formation mediated by phi X174 lysis 
protein E. J Bacteriol, 1990. 172(7): p. 4109-14. 
9. Witte, A., et al., Effect of phi X174 protein E-mediated lysis on murein composition of 
Escherichia coli. FEMS Microbiol Lett, 1998. 164(1): p. 149-57. 
10. Mayr, U.K., VJ.; Lubitz, P. and Lubitz, W., Bacterial Ghosts as Vaccine and Drug Delivery 
Platforms, in Patho-Biotechnology, R.S.a.C. Hill, Editor. 2008, Landes Bioscience. 
11. Paukner, S., et al., Bacterial ghosts as a novel advanced targeting system for drug and DNA 
delivery. Expert Opin Drug Deliv, 2006. 3(1): p. 11-22. 
12. Tabrizi, C.A., et al., Bacterial ghosts--biological particles as delivery systems for antigens, 
nucleic acids and drugs. Curr Opin Biotechnol, 2004. 15(6): p. 530-7. 
13. Paukner, S., et al., DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and 
expression in macrophages. Mol Ther, 2005. 11(2): p. 215-23. 
14. Paukner, S., G. Kohl, and W. Lubitz, Bacterial ghosts as novel advanced drug delivery systems: 
antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J Control Release, 2004. 
94(1): p. 63-74. 
15. Kudela, P., et al., Effective gene transfer to melanoma cells using bacterial ghosts. Cancer Lett, 
2007. 
16. Mader, H.J., et al., Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines.
Vaccine, 1997. 15(2): p. 195-202. 
17. Brasnu, E., et al., Comparative study on the cytotoxic effects of benzalkonium chloride on the 
Wong-Kilbourne derivative of Chang conjunctival and IOBA-NHC cell lines. Mol Vis, 2008. 14:
p. 394-402. 
18. Debbasch, C., et al., Quaternary ammoniums and other preservatives' contribution in oxidative 
stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci, 2001. 42(3): p. 
642-52. 
19. De Saint Jean, M., et al., Comparison of morphological and functional characteristics of 
primary-cultured human conjunctival epithelium and of Wong-Kilbourne derivative of Chang 
conjunctival cell line. Exp Eye Res, 2004. 78(2): p. 257-74. 
20. Anderson, D. and M.J. Plewa, The International Comet Assay Workshop. Mutagenesis, 1998. 
13(1): p. 67-73. 
21. Moller, P., et al., The comet assay as a rapid test in biomonitoring occupational exposure to 
DNA-damaging agents and effect of confounding factors. Cancer Epidemiol Biomarkers Prev, 
2000. 9(10): p. 1005-15. 
22. Tice, R.R., et al., Single cell gel/comet assay: guidelines for in vitro and in vivo genetic 
toxicology testing. Environ Mol Mutagen, 2000. 35(3): p. 206-21. 
23. Koller, V.J., et al., Impact of lactic acid bacteria on oxidative DNA damage in human derived 
colon cells. Food Chem Toxicol, 2008. 46(4): p. 1221-9. 
24. Riechelmann, H., et al., Nasal toxicity of benzalkonium chloride. Am J Rhinol, 2004. 18(5): p. 
291-9. 
25. Deutschle, T., et al., In vitro genotoxicity and cytotoxicity of benzalkonium chloride. Toxicol In 
Vitro, 2006. 20(8): p. 1472-7. 
132
26. Ferk, F., et al., Benzalkonium chloride (BAC) and dimethyldioctadecyl-ammonium bromide 
(DDAB), two common quaternary ammonium compounds, cause genotoxic effects in mammalian 
and plant cells at environmentally relevant concentrations. Mutagenesis, 2007. 22(6): p. 363-70. 
27. Witte, A., et al., Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli. Arch 
Microbiol, 1992. 157(4): p. 381-8. 
28. Repetto, G., A. del Peso, and J.L. Zurita, Neutral red uptake assay for the estimation of cell 
viability/cytotoxicity. Nat Protoc, 2008. 3(7): p. 1125-31. 
29. Lindl, T. and J. Bauer, Zell und Gewebekultur. Vol. 169. 1989, New York: Gustav Fischer 
Verlag, Stuttgart. 
30. Liszkay, A., E. van der Zalm, and P. Schopfer, Production of reactive oxygen intermediates 
(O(2)(.-), H(2)O(2), and (.)OH) by maize roots and their role in wall loosening and elongation 
growth. Plant Physiol, 2004. 136(2): p. 3114-23; discussion 3001. 
31. Rafii, F., et al., Detection and purification of a catalase-peroxidase from Mycobacterium sp. 
Pyr-1. FEMS Microbiol Lett, 1999. 173(2): p. 285-90. 
32. Bauer, A.W., et al., Antibiotic susceptibility testing by a standardized single disk method. Am J 
Clin Pathol, 1966. 45(4): p. 493-6. 
33. Gaydos, J.M. and B.J. Harrington, Agar disk diffusion for the quality control testing of Autobac 
elution disks. Antimicrob Agents Chemother, 1982. 21(3): p. 516-8. 
34. Champeau, E.J. and H.F. Edelhauser, Effect of ophthalmic preservatives on the ocular surface: 
conjunctival and corneal uptake and distribution of benzalkonium chloride and chlorhexidine 
digluconate. The Preocular Tear Film in Health, Disease, and Contact Lens Wear., ed. F.J. 
Holly. 1998: Dry Eye Institute, Inc Lubbock, TX. . 292-302. 
35. Gilbert, P. and L.E. Moore, Cationic antiseptics: diversity of action under a common epithet. J 
Appl Microbiol, 2005. 99(4): p. 703-15. 
36. McDonnell, G. and A.D. Russell, Antiseptics and disinfectants: activity, action, and resistance.
Clin Microbiol Rev, 1999. 12(1): p. 147-79. 
37. Dunning, N., Leishmania vaccines: from leishmanization to the era of DNA technology.
BioscienceHorizons, 2009. 2(1): p. 73-82. 
38. Heineman, P., Antiseptic properties of alkyldimethyl-benzyl-ammonium chloride. J. Am. Pharm. 
Assoc. , 1937. 26: p. 711. 
39. Li, X.Z. and H. Nikaido, Efflux-mediated drug resistance in bacteria. Drugs, 2004. 64(2): p. 
159-204. 
40. Tikhonova, E.B. and H.I. Zgurskaya, AcrA, AcrB, and TolC of Escherichia coli Form a Stable 
Intermembrane Multidrug Efflux Complex. J Biol Chem, 2004. 279(31): p. 32116-24. 
41. Witte, A. and W. Lubitz, Biochemical characterization of phi X174-protein-E-mediated lysis of 
Escherichia coli. Eur J Biochem, 1989. 180(2): p. 393-8. 
42. Tripathi, B.J. and R.C. Tripathi, Hydrogen peroxide damage to human corneal epithelial cells in 
vitro. Implications for contact lens disinfection systems. Arch Ophthalmol, 1989. 107(10): p. 
1516-9. 
43. De Saint Jean, M., et al., Toxicity of preserved and unpreserved antiglaucoma topical drugs in 
an in vitro model of conjunctival cells. Curr Eye Res, 2000. 20(2): p. 85-94. 
44. Guenoun, J.M., et al., In vitro comparison of cytoprotective and antioxidative effects of 
latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest 
Ophthalmol Vis Sci, 2005. 46(12): p. 4594-9. 
45. Eko, F.O., T. Barisani-Asenbauer, and W. Lubitz, Development of a Chlamydia trachomatis 
bacterial ghost vaccine to fight human blindness. Hum Vaccin, 2007. 4(3). 
46. Gaudana, R., et al., Recent perspectives in ocular drug delivery. Pharm Res, 2009. 26(5): p. 
1197-216. 
47. Gladue, R.P. and M.E. Snider, Intracellular accumulation of azithromycin by cultured human 
fibroblasts. Antimicrob Agents Chemother, 1990. 34(6): p. 1056-60. 
48. Oh, Y.K., D.E. Nix, and R.M. Straubinger, Formulation and efficacy of liposome-encapsulated 
antibiotics for therapy of intracellular Mycobacterium avium infection. Antimicrob Agents 
Chemother, 1995. 39(9): p. 2104-11. 
49. Zhang, D., et al., Preparation of azithromycin nanosuspensions by high pressure 
homogenization and its physicochemical characteristics studies. Drug Dev Ind Pharm, 2007. 
33(5): p. 569-75. 
50. Trouiller, B., et al., Titanium dioxide nanoparticles induce DNA damage and genetic instability 
in vivo in mice. Cancer Res, 2009. 69(22): p. 8784-9. 
133
134
Chapter 2.3. 
Bacterial Ghosts as Triggers
of the Innate Immune System 
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Chapter 2.3.1. 
Bacterial ghosts promote innate immune
responses in human keratinocytes 
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Bacterial ghosts (BGs) as non-living bacterial envelopes devoid of cytoplasmic content 
have been used to study the ability of bacterial cell envelop components for the induction of 
antimicrobial peptides and pro-inflammatory cytokines in human primary keratinocytes (KCs). 
Quantitative real-time PCR (qRT-PCR) analysis revealed that incubation of KCs with BGs 
generated from Escherichia coli NM522 induced the mRNA expression of two antimicrobial 
peptides, psoriasin (S100A7c) and human ? defensin-2 (hBD-2), in a BGs particle 
concentration-dependent manner. Using immunoblot analysis we showed that BGs generated 
from a flagellin-deficient (?fliC) E. coli strain NK9375 were as effective as its isogenic wild-
type (wt) E. coli strain NK9373 to induce psoriasin protein expression when normalized to BG 
particles being taken up by KCs. However, results obtained from endocytic activity of BGs by 
KCs reflect that this uptake is greatly dependent on the presence of flagellin on the surface of 
BGs. Moreover, BGs derived from wt E. coli NK9373 strongly induced the release of the pro-
inflammatory cytokines interleukin (IL)-6 and IL-8, compared to ?fliC E. coli NK9375 BGs. 
Taken together, the data demonstrate that BGs have the capacity to induce the expression of 
innate immune modulators and that these responses are partially dependent on the presence of 
flagellin.
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Introduction
The innate immune system serves to protect the host from invading microorganisms and 
upon activation triggers a series of host defense responses (3). A central mechanism of these 
responses is the production of pro-inflammatory cytokines and antimicrobial defense molecules. 
Different components of microbial pathogens, referred to pathogen-associated molecular 
patterns (PAMPs) are recognized by pattern recognition receptors (PRRs) of the innate immune 
system. Among these receptors are the Toll-like receptors (TLRs), NOD-like receptors (NLRs), 
RIG-like receptors (RLRs) and peptidoglycan-like recognition proteins (PGRPs), all 
contributing to early host defense against pathogens (5,6,12). For example, the bacterial PAMP 
flagellin, a monomer subunit of the flagellum binds to TLR5 and activates the transcription 
factor NF-kappaB (10), ultimately leading to the expression of pro-inflammatory cytokines  and 
antimicrobial peptides including psoriasin (S100A7c) and human ?-defensin 2 (hBD-2) in 
human primary keratinocytes (KCs) (1,2,20).  
Bacterial ghosts (BGs) are cell envelopes devoid of cytoplasmic content which are 
produced by the controlled expression of plasmid-encoded lysis gene E of bacteriophage 
?X174 in Gram-negative bacteria. Gene E codes for a membrane protein, which is able to fuse 
inner and outer membranes and thus forming an E-specific lysis tunnel through which the 
cytoplasmic content is expelled (27,28). These non-living bacterial envelopes maintain the full 
cellular morphology of the native bacteria. All the cell surface structures, including the outer 
membrane proteins, adhesins, lipopolysaccharide (LPS) and peptidoglycan are preserved in BGs 
(18).
BGs can be used for immunization either against its own envelop structure or as an 
antigen delivery system for foreign target antigens (13,18). Immunization with Vibrio cholerae
ghosts protected against diarrhea and death following challenge with fully virulent V. cholerae
in a rabbit animal model (7) or incorporation of a core antigen of hepatitis B virus on the surface 
of E. coli BGs resulted in a significant immune response against this core antigen in mice (14). 
BGs can also be used as delivery vehicles for active substances such as doxorubicin (21) or as a 
carrier of DNA (15) and enzymes (11). Nevertheless, little is known about the capacity of BGs 
to induce the expression of innate immune modulators by epithelial cells especially human KCs. 
In the present study the ability of E. coli BGs to induce antimicrobial peptides and pro-
inflammatory cytokines expression in human primary KCs has been investigated. The results 
demonstrate that the presence of flagellin on the surface of BGs enhance the expression of the 
antimicrobial psoriasin and hBD-2, and the release of interleukin (IL)-6 and IL-8 by human 
KCs.
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Materials & Methods 
Cell culture 
Human primary KCs prepared from neonatal foreskin were obtained from Clonetics (San
Diego, CA, USA) and cultured in serum-free keratinocyte growth medium (KGM, Clonetics) as 
described previously (23). For stimulation, third passage KCs were cultured in 12-well tissue 
culture plates (Corning Incorporated, Corning, NY, USA) and used at a confluence of 60-70 %. 
Stimulation was performed in keratinocyte basal medium (KBM, Clonetics).  
RNA isolation and qRT-PCR 
After stimulation, cells were washed with phosphate-buffered saline (PBS) and RNA was 
isolated using TRIzol® Reagent (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. For cDNA synthesis RNA was reverse-transcribed with MuLV-
reverse transcriptase using the Gene Amp RNA PCR kit (Applied Biosystems, Foster City, CA, 
USA) and oligo dT primers (Roche Diagnostics, Basel, Switzerland). cDNA sequences of the 
genes under investigation were obtained from the GenBank. Primers were designed using the 
PRIMER3 software from the Whitehead Institute for Biomedical Research (Cambridge, MA, 
USA). The following forward (F) and reverse (R) intron-spanning primers were used for ?-2-
microglobulin (B2M): F, 5?-GATGAGTATGCCTGCCGTGTG-3?; R, 5?-
CAATCCAAATGCGGCATCT-3?; psoriasin: F, 5?-GGAGAACTTCCCCAACTTCCTT-3?; R, 
5?-GGAGAAGACATTTTATTGTTCCT-3?; hBD-2: F, 5?-ATCAGCCATGAGGGTCTTGT-3?;
R, 5?-GAGACCACAGGTGCCATTTT-3?; qRT-PCR was performed by the LightCycler 
technology using the Fast Start SYBR Green I kit for amplification and detection (Roche 
Diagnostics). In all assays, cDNA was amplified using a standardized program (10 min 
denaturing step and 55 cycles of 5 sec at 95°C; 15 sec at 65°C, and 15 sec at 72°C; melting 
point analysis in 0.1°C steps; final cooling step). Each LightCycler capillary was loaded with 
1.5 μl DNA master mix; 1.8 μl MgCl2 (25 mM); 10.2 μl H2O; and 0.5 μl of each primer 
(10 μM). Determination of the relative quantification of target gene expression and 
amplification efficiencies were performed using a mathematical model by Pfaffl (22). The 
expression of the target gene was normalized to the expression of the housekeeping gene ?-2-
microglobulin. All real-time PCRs were performed in triplicate. The specificity of PCR 
reactions was confirmed by sequencing of the PCR products. 
BGs production and KCs stimulation 
E. coli NM522 was obtained from Stratagene, Amsterdam, The Netherlands. E. coli 
NK9373 (wt) and E. coli NK9375 (?fliC), a flagellin-deficient strain having an in frame 
deletion within the fliC gene (4) were kindly provided by Dr. David Bates (Baylor College of 
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Medicine, Houston, Texas). E. coli strains harbouring the lysis plasmid pGLysivb (unpublished) 
were grown in animal free Lennox Broth (LBv; 10 g/l sojapeptone, 5 g/l yeast extract, 5 g/l 
NaCl) containing gentamycin (20 μg/ml) at 35°C. Two litre of medium were inoculated with 4 
ml glycerine stock, descending from one single transformant colony and used as a preculture for 
fermentation after over night incubation. Fermentations were performed in 20 l medium using a 
Techfors S fermenter (Infors Ag, Bottmingen, Switzerland). Following parameters were 
documented: temperature, flow, stirrer, pH, pO2, foaming and pumps for acid, base and 
antifoam. Growth and lysis of the bacteria were followed by measuring the optical density 
(OD600), by determination of the colony forming units using a spiral plater (WASP system, Don 
Whitley Scientific Limited, West Yorkshire, UK) and by microscopy of periodically taken 
samples. Bacteria were grown in LBv medium set to pH 7.2 with aeration and agitation (flow 
and stirring controlled by a programmed sequence) to mid-logarithmic stage. Expression of the 
lysis protein E was induced by temperature upshift to 42°C. After the completed lysis process 
(reaching a plateau in the pO2 level) the remaining intact bacteria were killed by addition of 
beta-propiolacton (BPL). A total of 0.075 % BPL was added in two equal doses with a time gap 
of 30 min. For incubation with BPL the stirring rate was set to 600 rpm. For harvesting by a 
seperator (CTC1, GEA Westfalia Separator GmbH, Oelde, Germany) the temperature was set to 
16°C and a flow rate of about 200 ml/min was used. The system was rinsed with 5 l sterile, 
distilled water before resuspension of the BG pellet and BGs were subsequently washed by 5 
resuspension/centrifugation cycles with distilled water in a total volume of 7.5 l using a Hermle 
ZK 401 centrifuge (Hermle Labortechnik GmbH, Wehingen, Germany) at 8,000 min-1, 4°C, 15 
min. The final pellet was resuspended in 200 ml distilled water, aliquoted into lyophilisation 
bottles and stored at -80°C. Samples were lyophilized for about 60 h using a Lyolab B (LSL 
Secfroid, Aclens, Switzerland) lyophilisator. 
Lyophilized BGs from E. coli NM522, E. coli NK9373 (wt) and E. coli NK9375 (?fliC)
were resuspended in KBM medium before applying on KCs. For in vitro assays recombinant 
IL-1? (R&D Systems, Minneapolis, MN, USA) were used. 
Cytokine measurement 
Culture supernatants of stimulated KCs were depleted by centrifugation of detached cells 
or cell fragments and stored at -20°C until analysis. Concentrations of IL-6 and IL-8 were 
determined by enzyme-linked immunosorbant assay (ELISA; R&D Systems) according to the 
manufacturer’s instructions.
Immunoblot analysis 
For analysis of protein expression, KCs were lyzed in SDS-PAGE loading buffer (50 mM 
Tris, pH 7.4, 2 % SDS). After sonication insoluble cell debris were removed by centrifugation 
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and protein concentration was measured by the BCA (bicinchoninic acid) method (Pierce, 
Rockford, IL, USA). Western blot analysis was performed as described previously (19). Equal 
loading of protein lysates was confirmed by Ponceau S staining of the membrane. The following 
first step antibody was used: mouse monoclonal IgG1 anti-psoriasin clone 47C1068 (dilution 
1:500; Abcam, Cambridge, UK). The membranes were developed using the Chemiglow reagent 
(Alpha Innotech, San Leandro, CA, USA) according to the manufacturer’s instructions. 
Fluorescein isothiocyanate (FITC)-labeled BG uptake  
The efficiency of the endocytic activity of the human primary KCs was measured as 
described previously (15,16). Briefly, human primary KCs cultured in 24 well plates (2x105
cells/well) were incubated with FITC-BG (1000 per cell) for 2 hours at +37°C. After the 
incubation cells were washed three times with PBS to remove the excess BGs. Finally the cells 
were detached using TrypLETM Express (Invitrogen), washed twice with PBS, fixed in cold 
1.5% paraformaldehyde (Sigma-Aldrich, St. Louis, MO) in PBS and analyzed on BD 
FACSCanto™ Flow Cytometer (BD Biosciences, Pharmingen, San Jose, USA).
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Results
Expression of antimicrobial peptides by BGs in human primary KCs   
It has been reported that E. coli culture supernatants induce the expression of the 
antimicrobial peptides psoriasin and hBD-2 in epidermal KCs (1,8). To investigate the capacity 
of BGs to elicit innate immune responses by epithelial cells, human primary KCs were 
stimulated for 24 hours with different particle concentrations of BGs generated from E. coli
NM522. The relative mRNA up-regulation of the antimicrobial psoriasin and hBD-2 were 
determined by quantitative real-time PCR (qRT-PCR). Stimulation of KCs by IL-1? (10 ng/ml) 
served as positive control for the up-regulation of the analyzed antimicrobial peptides (1). As 
can be depicted from Fig. 1 the mRNA expression of both peptides was up-regulated in KCs 
after incubation with BGs. The stimulated psoriasin and hBD-2 mRNA production was 
dependent on the BG particles and for both peptides the strongest up-regulation was observed at 
2x108 BG particles/ml. For psoriasin, BG concentrations below 2x108 particles/ml had minimal 
to no effect (Fig. 1A), whereas for hBD-2 a dose-dependent induction of mRNA was detected 
(Fig. 1B). These data indicate that KCs respond to BGs by the production of antimicrobial 
peptides in a particle-dependent manner.  
We have previously reported that the induction of psoriasin and hBD-2 in KCs is 
dependent on flagellin expression by E. coli (1). To investigate whether flagellin of BGs has a 
similar effect, we generated BGs from the wild-type (wt) NK9373 and the isogenic flagellin-
deficient (?fliC) NK9375 E. coli strains. KCs were stimulated for 48 hours and afterwards 
analyzed by immunoblot for psoriasin protein production. In contrast to the mRNA data a faint 
band of psoriasin was detected on the protein level at 2x107 BG particles/ml. Strong induction of 
psoriasin was observed at 2x108 particles/ml which was even stronger at 2x109 particles/ml by 
wt (NK9373) E. coli BGs. For the isogenic ?fliC (NK9375) strain a faint band of psoriasin was 
detected starting at 2x108 BG particles/ml with a prominent expression level at 2x109 BG
particles/ml (Fig. 2).
Expression of cytokines by BGs in human primary KCs   
The secretion of the pro-inflammatory cytokines IL-6 and IL-8 by KCs after incubation 
for 48 hours with BGs were investigated by ELISA. The release of IL-6 and IL-8 by KCs after 
the incubation with wt (NK9373) and ?fliC (NK9375) E. coli BGs was dependent on the BG 
source and particle numbers used (Fig. 3A, B). Obtained results showed that the effect of wt 
(NK9373) E. coli BGs on IL-6 and IL-8 release was detectable beginning at concentrations 
2x107 particles/ml. While concentrations below 2x107 particles/ml were almost ineffective, 
2x109 particles/ml strongly enhanced the secretion of IL-6 from 2 pg/ml (untreated) to 600 
pg/ml and IL-8 from 60 pg/ml (untreated) to 1350 pg/ml, respectively (Fig. 3A, B). However, 
142
?fliC (NK9375) E. coli BGs increased the secretion of both cytokines only when using 2x109
particles/ml to 134 pg/ml and 750 pg/ml of IL-6 and IL-8, respectively, whereas BGs 
concentrations below that had no effect on the release of both cytokines (Fig. 3A, B). The 
decreased response of KCs towards ?fliC (NK9375) E. coli BGs in psoriasin production and IL-
6 or IL-8 secretion reflects that flagellin is a major inducing component of these proteins in 
KCs. The question remains whether other components of the ?fliC (NK9375) E. coli BGs have 
signaling activities for the production of antimicrobial peptides or pro-inflammatory cytokines. 
For this purpose uptake studies for wt (NK9373) and ?fliC (NK9375) E. coli BGs by KCs were 
performed.
Endocytosis of wt (NK9373) and ?fliC (NK9375) E. coli BGs by human primary KCs  
As mentioned above, the up-regulation of antimicrobial peptides and enhanced release of 
pro-inflammatory cytokines by KCs is dependent on the presence of flagellin on the surface of 
BGs. To further investigate the role of flagellin in the uptake by KCs, endocytosis of wt 
(NK9373) and ?fliC (NK9375) E. coli BGs were compared and analyzed. Missing flagellin on 
the surface of BGs caused significant decrease (~6-fold less) of KCs capacity to bind and 
endocyte BGs (Fig. 4). Obtained results clearly indicate the important role of bacterial flagellin 
in the endocytosis of BGs by KCs as well as in the production of antimicrobial peptides and 
secretion of pro-inflammatory cytokines. 
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Discussion
BGs are nonliving cell envelope preparations from Gram-negative bacteria, devoid of 
cytoplasmic contents, while their cellular morphology and native surface antigenic structures 
remain preserved (18,24). In this investigation the effect of BGs on the regulation of innate 
immune modulators using human primary KCs was determined. Applying BGs of the non-
pathogenic E. coli strain MN522 on human KCs up-regulated the expression of the 
antimicrobial psoriasin and hBD-2. This was in agreement with earlier reports where cell 
culture supernatants or disrupted cells of E. coli strains enhanced the expression of these two 
antimicrobial peptides (1,8). Therefore, this investigation indicates that the envelop structure of 
BGs is recognized by KCs and promotes innate immune responses similar to bacterial 
compounds used in the former studies.  
As reported earlier, the responsiveness towards E. coli by KCs is mediated through TLR5 
and its ligand flagellin (1). Since we did not have a direct measure of the amount of flagellin 
present on BGs of E. coli NM522, BGs of two isogenic E. coli strains NK9373 (wt) and 
NK9375 (?fliC) were propagated under the same growth conditions and used in this study. The 
wt (NK9373) strain exhibited a BG concentration-dependent induction of psoriasin production; 
whereas the ?fliC (NK9375) strain showed the expression of psoriasin at BG concentrations of 
one order of magnitude higher than the wt strain (Fig. 2). Accordingly, the data obtained from 
the release of the pro-inflammatory cytokines IL-6 and IL-8 underlined the significance of the 
presence of flagellin in the BGs preparation when compared to the ?FliC mutant strain (Fig. 3).
From the previous studies with supernatants of E. coli as source of shad flagellin and/or purified 
flagellin, it is evident that flagellin is the major inducer of psoriasin in human KCs (1,8). 
However, since ?FliC BGs are capable of psoriasin induction there seems to be additional FliC-
independent pathways.  
Investigation of BGs uptake by KCs derived from wt (NK9373) and ?fliC (NK9375) E. 
coli strains showed that the flagella bearing strain is taken up roughly one order of magnitute 
better than the ?FliC strain (Fig. 4). This observation suggests that the presence of flagellin on 
the BG surface contributes to the binding and uptake of BGs into KCs. When the results of 
psoriasin production are normalized to the number of BG particles being taken up by KCs, the 
same concentration effects could be seen for the induction of the latter antimicrobial peptide. 
The release of IL-6 and IL-8 by KCs, however, were more sensitive to the presence of flagellin 
as no direct correlation with the BGs particle number could be detected (Fig. 3).
It is still possible that the acidic degradation of the flagella present in NK9373 BGs in the 
lysosomal compartment of KCs, monomeric flagellin is able to bind to TLR5 (10) and stimulate 
the expression of the cytokines IL-6 and IL-8 and the production of psoriasin. As flagellin 
144
binding to TLR5 cannot occur with the ?FliC BGs and consequently the signalling induced by 
this binding, other ways of internal signalling leading to NF-kappaB induced expression of 
psoriasin have to be induced by BGs in KCs. Possible intracellular receptors which might sense 
the presence of BGs or BGs constituents irrespective of flagellin expression are the NLRs such 
as NOD1 or NOD2. Recent investigations have reported the functional expression of NOD1 (9) 
and NOD2 (26) by peptidoglycan fragments in KCs. In particular, NOD1 mediates the sensing 
of peptidoglycan fragments containing the amino-acid meso-diaminopimelic acid and NOD2 
mediates the sensing of muramyl dipeptide (3), which both of these fragments are degradation 
products of the still intact peptidoglycan of E. coli BGs (29). For the NOD1/NOD2 dependent 
induction of hBD-2 (23) the above mentioned peptidoglycan fragments can only originate from 
the degradation of BGs in the endo-lysosome compartments of KCs. In this context it is 
worthwhile to note hat the BGs used in this study were all derived from non-pathogenic E. coli
strains, and thus a discrimination between pathogenic and non-pathogenic strains for their 
ability to induce hBD-2 via activation of NOD1 through peptidoglycan fragments transported 
into the effecter cells by a bacterial type IV protein secretion system (25) was not given. The 
connection between activation of NOD2 by muramyl dipeptde (MDP) and increased hBD-2 
production in primary KCs has been reported (23), and in our study the use of BGs to induce 
hBD-2 and psoriasin has been demonstrated. Therefore, it seems possible to use BGs in 
therapeutic approaches to enhance the innate immune defence system of the skin. Potential 
therapeutic effects of BGs can be combined by packaging drugs or other biological active 
substances into BGs which could also be delivered intracellular for the stimulation of additional 
beneficial health effects (17,21). 
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Figures  
 
 
 
 
Fig 1. BGs induce the expression of antimicrobial psoriasin and hBD-2 in human primary KCs. 
KCs were incubated for 24 h with IL-1α (10 ng/ml) or BGs (E. coli NM522) varying from 
2x106 to 2x108 particles/ml, thereafter total RNA was isolated and reverse-transcribed to cDNA. 
The relative expression of psoriasin (A) and hBD-2 (B) was determined by qRT-PCR. The 
mean values are displayed in relation to untreated cells. Relative gene expression levels were 
normalized to the expression of the housekeeping gene β-2-microglobulin. Data represent the 
mean ± SD of triplicate samples. 
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Fig. 2. Induction of psoriasin in KCs by wt (NK9373) and ΔfliC (NK9375) E. coli BGs. KCs 
were incubated for 48 h with wt (NK9373) and ΔfliC (NK9375) E. coli BGs from 1x106 to 
2x109 particles/ml. After stimulation cell lysates were subjected to immunoblot analysis for 
psoriasin (upper panel) as described in the Materials and Methods section. Ponceau S staining of  
the membrane served as loading control of protein lysates (lower panel). 
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Fig. 3. BGs induce the secretion of pro-inflammatory cytokines. KCs were incubated for 48 h 
with wt (NK9373) and ΔfliC (NK9375) E. coli BGs from 1x106 to 2x109 particles/ml. After the 
incubation period cell culture medium was collected and the concentrations of IL-6 (A) and IL-
8 (B) were determined by ELISA. Data represent the mean ± SD of triplicate samples. 
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Fig. 4. Comparative flow cytometric analysis of human primary KCs endocytic activity for 
BGs. KCs were incubated with FITC-labeled BGs (1000 per cell) - wt (NK9373) and ΔfliC 
(NK9375) E. coli BGs for 2 h at +37 °C. Cells incubated without BGs or with non-labeled BGs 
served as the controls. Values were calculated as the percentage of cells with increased 
fluorescence incubated without or with non-labeled BGs subtracted from the percentage of 
positive cells incubated with FITC-labeled BGs. Endocytic capacity of KCs was measured by 
BD FACSCanto™ Flow Cytometer (BD Biosciences). Each bar represents the mean of four 
independent experiments ± SD. 
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 Chapter 2.3.2. 
Modulation of Bacterial Ghosts (BG)-induced nitric oxide 
(NO) production in RAW 264.7 macrophages by BG-
delivered resveratrol 
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In the present study we show that coincubation of RAW 264.7 macrophages with bacterial 
ghosts (BGs) leads to a dose-dependent induction of the inducible nitric oxide synthase (iNOS).  
To determine whether BG-mediated delivery of the known iNOS inhibitor, resveratrol (RV) 
is an effective way to inhibit NO production in RAW264.7 macrophages we loaded BGs with 
RV and measured BG-induced nitrite accumulation. Indeed, NO formation was modulated in 
the presence of BGs loaded with RV and a significant decrease of BG-induced NO production 
was observed. RV-delivered by BGs was effective in a concentration as low as 0.48+0.25 µM. 
Externally added RV was still ineffective at a concentration 6-times higher (3 µM). BGs 
exhibited no cytotoxicity in RAW 264.7 cells even when coincubated for 24 hrs. However, cell 
viability decreased by about 10 % when macrophages were incubated with RV-loaded BGs 
dependent on the RV cargo. Since internal cell delivery of RV by BGs seems to increase the RV 
effect, we postulate an intracellular RV receptor for which we propose the abbreviation ERVR 
(endogenous resveratrol receptor). 
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Introduction 
 
The innate immune system consists of special types of cells and humoral factors that 
rapidly react on infectious agents by inactivation or killing mechanisms in a non-specific 
manner. Among others, this defense system leads to phagocytosis of bacteria, viruses or 
protozoa by macrophages, monocytes, neutrophils and dentritic cells resulting in the release of 
antimicrobial peptides, hydrolytic enzymes and/or reactive oxygen species (ROS) or reactive 
nitrogen species (RNS). An example of the latter one is given by the production of nitric oxide 
(NO) through the inducible nitric oxide synthase (iNOS). However, generation of iNOS-
dependent NO is not only a feature of phagocytes but also of epithelial cells or keratinocytes [1-
3]. 
NO has been shown to be a versatile molecule, exhibiting an ambiguous endogenously 
role, with a rapid half life and displays a crucial mediator molecule for various cellular 
functions [4]. This highly reactive molecule is implicated in the pathophysiology of many 
diseases and can cause cytotoxic and mutagenic effects when it is produced in excessive 
amounts, like under oxidative burst conditions [4]. However, due to various effector and 
immunoregulatory functions, e.g. antimicrobial, antitumorigenic and apoptotic activity or its 
modulating character of cytokines and T-cell differentiation, NO plays an important role in the 
immune system. Furthermore, this radical contributes to an antimicrobial activity against certain 
intracellular bacterial pathogens like Salmonella enterica, Trypanosoma musculi, 
Mycobacterium tuberculosis, Legionella pneumophila or Leishmania major [5, 6].  
There are three major nitric oxide synthase (NOS) isoforms known, the contitutively 
expressed neuronal NOS (also known as nNOS or NOS1) and endothelial NOS (eNOS or 
NOS3) as well as the inducible isoform (iNOS or NOS2). The latter is accountable for the NO 
production in macrophages and keratinocytes. All three types of NOS oxidize one molecule of 
L-arginine at a guanidine nitrogen to an intermediate which is oxidized to yield one molecule of 
NO and L-citrulline. [1-4].  
Bacterial lipopolysaccharide (LPS) is among the most important stimuli for murine iNOS 
induction after binding to toll-like receptor 4 (TLR4) [7]. 
Bacterial ghosts (BGs) are, in analogy to empty erythrocytes or bacteriophage ghosts, cell 
envelopes of Gram-negative bacteria which are devoid of cytoplamic content and free of nucleic 
acids. They are produced by controlled expression of plasmid-encoded lysis gene E of PhiX174 
that leads to fusion of inner and outer membranes. Thus, an E-specific lysis tunnel is formed 
and the cytoplasmic content is expelled due to the osmotic pressure difference between the 
cytoplasm and the exterior of the bacteria [8, 9]. These non-living, empty bacterial envelopes 
maintain the full cellular morphology of the native bacteria. The feature, that all the cell surface 
structures, including the outer membrane proteins, adhesins, LPS and peptidoglycans are well 
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preserved in BGs emphasizes them  as attractive natural adjuvants for vaccination [10]. The fact 
that BGs share the antigenic determinants from their living counterpart and that additional 
foreign proteins can be expressed on or within the cell envelope as well as DNA or drugs can be 
loaded inside the cytoplasmic lumen of the ghosts, highlights them as a novel vaccination 
system for animals and humans  [10-12].  
Resveratrol (RV) is a polyphenolic stilbene compound, naturally occurring either in trans- 
or cis-isomeric forms in various plant species, especially present in skins of grapes, peanuts and 
berries showing a broad spectrum of immunomodulating activities. Many studies allocate 
anticancer, antioxidant and cardioprotective properties as well as an extended life-span to this 
molecule [13-16]. Moreover, RV possesses great therapeutic potential in treatment of a variety 
of infectious diseases of animals and humans. Its activity has been demonstrated against 
dermatophytes [17] and viruses like Herpes simplex [18]. The growth inhibitory effect of RV 
has been substantiated for a broad range of bacterial species including intracellular Chlamydia 
pneumoniae that accounts for acute respiratory tract infections [17, 19]. Furthermore, decreased 
infectivity of protozoa species which cause diseases in fish [20, 21] was achieved and more 
recently the elimination of the intracellular skin pathogen L. major, responsible for cutaneous 
leishmaniasis, by RV was demonstrated [22, 23].  
As shown in earlier studies, BGs have quite an impact on the parameters of the innate 
immune system like the secretion of cytokines and expression of antimicrobial peptides (Abtin 
and Lubitz, to be published). Taken into consideration that iNOS-dependent production of NO, 
a key-player molecule in innate immunity, is stimulated by LPS we aimed, first, to examine the 
extent of BG-stimulated NO release in the model macrophage cell line RAW 264.7 and, second, 
to study the impact of RV-loaded BGs on this NO release since RV is reported to inhibit LPS-
induced NO production in macrophages [16, 24].  
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Materials & Methods 
 
Chemicals 
If not otherwise stated, all chemicals were obtained from Sigma Aldrich. 
 
Cell culture 
RAW 264.7 cells obtained from the American Type Culture Collection (ATCC, USA), 
were cultured in Dulbecco’s Modified Essential Medium with 4.5g/L glucose (Lonza, 
BioWitthaker®, Verviers, Belgium; DMEM without L-glutamine and phenol red) supplemented 
with 2 mM L-glutamine (Lonza) and with 10 % heat-inactivated fetal calf serum (FCS, Gibco; 
Invitrogen, Carlsbad, CA). Additionally, 100 U penicillin/streptomycin (Lonza) was added to 
the cultivation medium. For the experiments serum-free (sf-) media were used. The cells were 
grown under standard conditions (37°C, 5% CO2) and the medium was changed every 2-3 days. 
The cells were subcultured when they reached their confluent state.  
 
Bacterial ghost production 
BGs from E. coli NM522 (pGLysivb; 240106-5/6), were produced by the controlled 
expression of the phage-derived lysis protein E as described elsewhere [9, 25]. Inactivation of 
the non-lysed bacteria was done by addition of antibiotics. Lyophilized BGs were stored at 
room temperature (1 mg lyophilized weight contained 1.27x1010 particles). BGs were 
resuspended in sf-medium prior to treatment experiments.  
  
Loading BGs with resveratrol 
12-24 mg lyophilized BGs were suspended in different RV (Sigma Chemical Co., St. 
Louis, MO) concentrations (1-35 mg RV/ml methanol) and incubated under vigorous shaking 
(800 rpm) for 30 min at 28°C. The loaded BGs were collected by centrifugation at 11300 g for 
15 min and the pellets were washed three times with water. 1 mg BG aliquots were stored at -
20°C until use.  
 
Quantification of RV extracted from BGs 
The extraction of RV out of the BGs was performed using 500 µl ethanol 96% (Brenntag 
CEE GmbH, Vienna) per 1 mg of BGs. After 5 min of ultrasonification the ethanolic extract 
was diluted 1:1 with H2O and immediately centrifuged at 11300 g at 4°C for 15 min.  
The HPLC analysis was conducted with a PE 200 Series HPLC System, consisting of a 
pump, an autosampler, a diode-array detector, a column oven and a Turbochrom Navigator 
software for the control of the equipment and for data evaluation. A Lichrospher 100 RP-18e 
(5µm) Column (250x4mm) has been used for separation. 
156
The quantification was done by the peak area method applying RV as external standard. 
A gradient method was performed using diluted acetic acid (pH 2.8) as solvent A and methanol 
(HiPerSolv for HPLC, gradient grade) as solvent B at a flow rate of 1 ml/min at 25°C. The 
gradient profile started from 50% B to 60% B within 10 min and a final purge with 95% B. 10 
µl of all samples and dilutions were injected and the chromatograms were monitored at 305 nm. 
The relevant RV peak was identified by comparing the retention time (5.3 min) and the UV of 
the samples with those of the external RV standard.  
 
Nitrite assay 
RAW 264.7 cells were seeded in 96 well plates and cultured for two days. Approximately 
3x105 macrophages per well were then stimulated either with 200 µl of a defined concentration 
of empty BGs (positive control) or with resveratrol-loaded ghosts (4.6 fg RV/BG), or with 
empty bacterial ghosts plus defined RV concentrations given externally, for 20 min. Thereafter, 
the bacterial ghost suspensions were removed by washing cells with PBS twice. Then, cells 
were incubated for another 20 hrs in the dark at 37°C 5% CO2. In order to investigate the 
stimulatory impact of pure LPS (Fluka, Sigma Chemical Co., St. Louis, MO; E. coli serotype 
055:B5), long-term incubation experiments with various LPS concentrations were conducted for 
20 hrs.  
Based on the entrapped amount of RV in BGs (Fig.1A) and the number BGs which were 
associated with macrophages (adhered to and taken up by the cells) after 20 min treatment (Fig. 
1B), the BG-delivered RV particles have been calculated. As stimulation of NO induction in 
RAW 264.7 cells was performed with BGs having the highest RV-yield (4.6 fg RV/BG) in a 
multiplicity of infection (MOI) rate of 100 and 1000, calculated RV-delivery values by BGs 
correspond to 0.48+0.25 µM and 8.86+2.21 µM RV (1.21x107 RV molecules per single BG). 
As an indicator of NO production, nitrite concentration was measured in the supernatant 
of the macrophages by use of the Griess reaction [26]. Briefly, 100 µl of each supernatant was 
mixed with 90 µl 1% sulphanilamide (Fluka) in 5 % H3PO4 and 90 µl of N-(1-Naphthyl) 
ethylene diamine dihydrochloride in water. The absorbance was determined at 550 nm with an 
ELISA reader (Tecan Sunrise). 
 
Application and detection of FITC-labeled BGs  
As an indication for endocytic RV delivery, uptake of FITC-labeled BGs was determined 
in the analyzed cell line. For this purpose, lyophilized BGs (5-15 mg were resuspended in 1.5 
ml 0.1M Na2CO3; pH ~ 9.0. Thereafter, 25 µl of FITC stock solution (2 mg FITC in 1 ml 
DMSO) was added to the BG suspension and shaken for 2 hrs in the dark at 16°C. After five 
washing steps with PBS (5 min; 11300 g) and check for positive labeling, the BG pellets were 
resuspended again in sodium carbonate buffer and stored at -20°C until use. 
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Culturing and treatment of RAW 264.7 cells was the same as for the nitrite assay with 
minor modifications. After 20 min incubation with defined amounts of empty BGs the 
macrophages were washed twice with PBS and the washing solutions were collected in empty 
neighbouring wells. Fluorescence was then recorded with a GENios Pro plate reader (Tecan) at 
excitation and emission wavelengths of 485/535 nm (gain 40). Total fluorescence values were 
taken as 100% of the applied ghost amount and uptake was calculated from the resulting 
fluorescence per macrophage.  
Internalisation of the bacterial ghosts (BG) was veryfied by use of confocal laser scanning 
microscopy (CLSM). For this purpose cells were seeded in 8-well chamber slides (Falcon 
CultureSlide) and were allowed to attach. The medium was replaced by 200 µl sf-medium 
containing the appropriate FITC-labeled BG giving a BG to cell ratio of 1000 and the slides 
were further incubated for either 20 min or 40 min. Thereafter, cells were washed twice with 
PBS and 1% paraformaldehyde (PFA) was added for fixation (20 min, room temperature). In 
addition, experiments were conducted in which the attached BGs were removed from the cells 
by trypsinization. After two washing steps with PBS the cells were fixed onto glass slides by 
cytospin (800 rpm, 15 min) and were fixed with PFA as described before. Thereafter, the cells 
were washed again for two times with PBS and were permeabilized with 0.5 % Triton X-100 for 
20 min, followed by other two washing procedures. Then, 100 µl of freshly prepared 
PromoFluor 590 (Texas-Red)-conjugated Phalloidin (5 µl methanolic 100 U/ml dye-stock; PBS; 
1 % BSA) was added to visualize cell boundaries. After 45 min of incubation, slides were 
washed again twice with PBS and imaged by CLSM. 
 
Cytotoxicity assays 
The neutral red assay was used to test the impact of empty or RV-loaded BGs as well as 
RV per se on the viability of RAW 264.7 cells. Neutral red (3-amino-m-dimethylamino-
2methyl-phenazine hydrochloride) selectively accumulates in lysosomes of living cells [27] and 
provides therefore a quantitative assessment of viability. 
Individual wells of 96-well plates were inoculated with 1.25 x 105 cells and were allowed 
to attach overnight. Macrophages were treated with 200 µl medium containing RV-loaded and 
unloaded BGs (all resuspended in sf-medium) in different BG to cell ratios (10, 100, 1000) or 
with RV alone for either 20 min followed by a 20 hour recovery period or 24 hrs. The same 
conditions were performed with two RV concentrations (15 µM and 30 µM). Triton X-100 
(0.01 %) served as positive control and cells treated with sf-medium represent the negative 
control. After treatment, cells were washed twice with PBS and then incubated either with 
culture medium for 20 hrs or directly with 100 µl of neutral red (80 µg/ml final concentration) 
for another two hours (37 °C; 5 % CO2). Thereafter, the dye was discarded and the wells were 
washed two times with PBS. Extraction of the dye was accomplished by addition of 100 µl of 
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the acidic destaining solution (1 ml acetic acid, 73 ml 96 % ethanol and 26 ml deionized water). 
The plates were shaken for 10 min and the developed color was measured by a plate reader 
(Dynex OpsysMR) at 570 nm (reference wavelength 690 nm). 
 
Statistics 
  
All results were analysed by use of GraphPad Prism (version 5, GraphPad Software, Inc; 
San Diego; CA, USA). Data are expressed as means + SD. Statistical analysis was performed by 
the use of Student’s t-test. P-values < 0.05 were considered statistically significant. 
159
Results 
 
Loading of BGs with RV 
The loading of lyophilized E. coli BGs with RV was performed by resuspension of BGs 
in RV solutions of different concentrations (1-35 mg/ml RV). To determine the amount of RV 
in BGs, ethanolic extracts were performed and analyzed via HPLC. The results are depicted in 
Fig. 1A. A clear correlation between the loading concentration of RV and recovered RV was 
observed (correlation coefficient r2 = 0.9980). The highest loading efficiency was obtained after 
suspension of lyophilized BGs in a 35 mg/ml RV solution corresponding to 46 µg RV/1x1010 
BGs (4.6 fg RV/BG).  
 
Adherence and uptake of FITC-labeled BGs by murine macrophages 
Fluorometric quantification experiments were conducted in order to investigate the 
amount of BGs which are either attached and/or taken up by murine macrophages after a short 
time of coincubation. Fig. 1B depicts the result obtained by fluorometric measurements of 
RAW 264.7 cells coincubated with E. coli BGs for 20 min and two washing steps. The amount 
of associated BGs per cell (attached and intracellular) clearly depends on the ratio of BGs per 
cell (correlation coefficient r2 = 0.998). Furthermore, no differences where observed when the 
experiments were performed in 96 or 24 well plates (data not shown). An average of 25 % of 
the applied BGs were associated with the macrophage population after this short incubation 
time. 
To clarify whether BGs are taken up by murine macrophages within this period, confocal 
laser scanning microscopy (CLSM) studies were conducted in which the internalization was 
visually examined. For this purpose, z-stacks were performed after incubation of FITC-labeled 
E. coli BGs with RAW 264.7 cells after 20 and 40 min. Macrophages were stained with Texas-
Red Phalloidin, which selectively binds to the F-actin skeleton of cells. Images displaying 
representative single z-stacks of various optical sections are depicted in Fig. 2. It can be seen 
that FITC-labeled BGs which are already internalized by RAW 264.7 cells stained in red, 
appear yellow (roughly 65 %). Green colored BGs (less than 35 %) represent those which are 
not engulfed but attached to cells (Fig. 2A). A representative picture of RAW 264.7 cells which 
were trypsinized to remove attached BGs is shown in Fig. 2B. At a BG to cell ratio of 1000, 
single BGs as well as clusters of internalized BGs were detectable in every macrophage after 40 
min. 
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Induction of NO production  
Murine iNOS is induced by LPS. As depicted in Fig. 3A, treatment of RAW 264.7 cells with 1-
1000 ng/ml LPS for 20 h led to a dose-dependent generation of NO with a significant output 
starting at 1 ng/ml (P < 0.0001).  
Due to the fact that BGs fully maintain their LPS molecules bound in the envelope [28], 
we were curious to which extent BGs are able to stimulate NO production. It turned out that a 
BG to cell ratio of 10 was sufficient to significantly induce NO generation (P=0.0005) to a level 
similar to 1 ng/ml of free LPS.   
Clear particle-dependent stimulation of NO generation was achieved when cells were 
treated with BGs in a multiplicity of infection (MOI) rate of 100-1000. Higher concentrations of 
BGs (2000 and 5000 particles per cell) did not show any further impact on NO synthesis (Fig 
3B).  
 
Modulating capacity of NO stimulation by RV-loaded BGs 
As already shown in Fig. 3B BGs are able to stimulate NO production in a dose-
dependent manner when applied to macrophages in a BG to cell ratio between 10 and 1000.  
Many studies showed that RV is capable to reduce LPS-induced NO-production [16, 24]. 
We, therefore, examined the potential of RV to modulate BG-induced NO production. For this 
purpose empty E. coli BGs were applied to RAW 264.7 cells in a ratio of 500. Coevally, three 
different concentrations of RV (0.3-30 µM) were added to the cell culture medium. After 20 
min coincubation and two washing steps, released NO was measured as accumulated nitrite 
after 20 hrs. Fig. 4A shows that simultaneous treatment of RAW 264.7 cells with E. coli BGs 
and 0.3 µM, 3 µM RV and 30 µM RV, respectively, influenced BG-induced NO generation. A 
statistically significant decrease of NO production was obtained by 30 µM RV (P= 0.0078). 
Next, we examined whether RV bound in BGs affects BG-induced NO production. We, 
therefore, compared NO release in response to empty BGs versus RV-loaded BGs and BGs plus 
externally added RV. Fig. 4B shows that compared to empty BGs NO production was 
significantly reduced (P = 0.0048) in RV-loaded ghosts in a BG to cell ratio of 100 which refers 
to 0.48+0.25 µM RV. In contrast, a 6-fold higher concentration of externally added RV (3 µM) 
had no effect. Thus, externally applied RV together with empty E. coli BGs did not decrease 
NO release as effective as RV-loaded ghosts (BG to cell ratio 100). 
On the other hand, treatment of RAW 264.7 macrophages in a BG to cell ratio of 1000 
with the same RV concentration reduced NO production significantly (P = 0.0158) (Fig. 4C). 
Similar effects were found when RV-loaded BGs (BG to cell ration of 1000: 8.86+2.21 µM RV) 
were applied to RAW 264.7 cells (P = 0.0002). 
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Determination of cell viability 
In order to investigate the impact of empty and RV-loaded BGs (4.6 fg RV/BG) on cell 
viability of RAW 264.7 macrophages two different treatment conditions were examined with 
three different BG to cell ratios (MOI 10, 100, 1000). The first test was performed analogue to 
the regimen used to stimulate NO production, i.e. 20 min coincubation of cells with BGs, 
followed by two cycles of washing and nitrite measurement after 20 hrs. The second analysis 
determined the effect of BG long-term coincubation (24 hrs) with RAW 264.7 macrophages. As 
depicted in Fig. 5A, E. coli BGs per se had no cytotoxic impact on RAW 264.7 cells 
independent of the time of coincubation. No effect was seen after short-term coincubation of 
RAW 264.7 cells with RV-loaded BGs and with free RV (data not shown). However, enhanced 
metabolic activity was found after treatment of RAW 264.7 cells with RV-loaded BGs in a MOI 
of 10 (P=0.0008) after 24 h (Fig. 5B).  
Furthermore, the impact of 15 µM and 30 µM of externally added RV on cell viability 
was investigated. Fig. 5B shows that the lower RV (15 µM) concentration had no impact on cell 
viability. Viability, however was decreased (81.23 + 10.6 %) after treatment with 30 µM RV. 
An almost similar decrease in cell viability was observed with RV-loaded BGs (P=0.0462) at 
the MOI of 1000 which on average reduced cell viability by 10 % due to the BG delivered RV.  
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Discussion 
 
In the present study we have demonstrated that BGs are inducing NO formation in 
macrophages and that this response can be modulated by RV-loaded BGs. Thus, our findings 
open a new way for therapeutic approaches using BGs to fight macrophage-associated microbial 
diseases. 
It is known in general, that pathogens are phagocytosed by cells of the innate immune 
system like macrophages and dentritic cells of primary antigen presenting cells (APCs). It has 
been demonstrated that BGs are preferentially recognized and taken up by various macrophage 
cell lines and dentritic cells [29-31].  In accordance with earlier findings, uptake was confirmed 
in the RAW 264.7 macrophage cell line after short-term coincubation of BGs. Interestingly, 
microscopic observations with CLSM showed that macrophages are capable to engulf single as 
well as cluster of BGs.  
It is known that toll like receptor (TLR) signalling in macrophages is required for anti-
pathogen responses, including the biosynthesis of NO radicals [32]. This immediate response is 
extremely beneficial to cure pathogen-caused diseases, e.g. Leishmaniasis or Tuberculosis 
which has been demonstrated in several studies [2, 4, 5]. Because LPS is renowned for the 
induction of iNOS through interaction with TLR-4 [1], we conducted comparative experiments 
between long-term incubation (20 hrs) with free LPS and short-term incubation with various 
amounts of BG (20 min followed by determination of nitrite accumulation after 20 hours) in 
RAW 264.7 cells. It turned out that treatment of macrophages with E. coli BGs in a MOI of 10 
showed the same effect than 1 ng/ml LPS.  
Investigations from Panaro et al. with human macrophages demonstrated a direct 
correlation between LPS-induced NO generation and the killing of intracellular Leishmania 
parasites. The efficacy was significantly reduced in both parameters when L -NMMA, a 
competitive inhibitor of iNOS, was present [33]. As they link NO-production and anti-
leishmanial effects we analysed the relation between the observed particle-dependent BG-cell 
association with the extent of NO-release and found a significant positive correlation (Spearman 
r = 1; P value = 0.0167).  
RV, which possesses also antileishmanial activities [22, 23], was shown to influence 
parameters of innate immunity and prior studies demonstrated its suppressing character towards 
iNOS induction [16, 24]. In order to investigate whether such a reduction of NO generation can 
also be achieved by the uptake of RV-loaded BGs into macrophages, the effect of RV, either 
coincubated together with empty BGs or delivered intracellularly via BGs, on BG-induced NO 
production by RAW macrophages was determined. A highly significant decrease in radical 
release was obtained by application of RV bound in BGs when compared with empty BGs, 
demonstrating that RV-loaded BGs were successfully taken up by RAW 264.7 cells and that the 
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compound retained its activity. Moreover, the externally added pure compound at a 
concentration of 3 µM, which is roughly 6 times higher than the concentration delivered by BGs 
in a MOI of 100, had no impact on NO generation in comparison to the BG loaded application 
which reduced radical release by about 15 %.  
As BGs possess all their pathogen-associated molecular patterns (PAMPs) like their 
natural counterpart, they are very effectively recognized by the corresponding host innate 
immune receptors. TLRs recognize bacterial LPS with TLR4 and flagellin with TLR5 [7]. 
Uptake of BGs in the murine RAW 264.7 macrophage cell line is mainly related to TLR4 as 
they hardly express TLR5 [34]. On the other hand, in a recent study it was shown that E. coli 
BGs enter primary keratinocytes by the flagellin-dependent TLR5 pathway as well as other 
uptake mechanisms (Abtin and Lubitz, to be published). Moreover, it was demonstrated that 
BGs lead to induction of the antimicrobial peptides psoriasin (S100A7c) and human β defensin-
2 (hBD-2) in a particle-dependent manner. Furthermore, E. coli BGs strongly induced the 
release of the pro-inflammatory cytokines interleukin (IL)-6 and IL-8.  
To our knowledge, the cellular uptake mechanism of RV is still unclear. Till now, no 
specific receptor has been found for the drug. Due to its structure, RV is able to interact with 
cell surface receptors like estrogen receptors or integrins [16, 35]. Our findings with the 
intracellular delivery of RV by RV-BGs in macrophages which leads to modification of NO 
release, leads to the presumption of the existence of an internal RV receptor. Therefore, we 
propose the term ERVR (endogenous resveratrol receptor) for such a hypothetical receptor. 
It is known that bacterial LPS is responsible for manifold pathophysiological effects on a 
wide variety of mammalian cells. In the worst-case, endotoxic shock and multiple organ failure 
followed by death could be the consequence. This endotoxicity is mediated through the 
activation of the host immune and inflammatory cells, especially mononuclear phagocytes, 
which produce numerous bioactive mediators, including tumor necrosis factor alpha (TNF-
alpha), interleukin 1, IL-6 and nitric oxide [36]. 
As the endotoxin content of Gram-negative bacteria is also present in BGs, safety and 
toxicity studies with BGs have been performed. It has been shown that BGs derived from 
pathogenic E. coli O26:B6 and S. typhimurium C5 investigated for their endotoxic activity by 
the use of standard Limulus amoebocyte lysate (LAL) assay and 2-keto-3-deoxyoctonate (KDO) 
assay, exhibited only 2-5% of the endotoxic activity compared to free LPS [28, 29]. Cell culture 
experiments with RAW 264.7 cells revealed 100-fold more BGs were required for the secretion 
of tumor necrosis factor alpha (TNFα) and prostaglandin E2 (PGE2) synthesis than compared to 
free LPS [28] 
Cytotoxic effects were also investigated after BG application to RAW cells in the present 
study. No cell killing effects of the E. coli BGs per se were observed even when incubation was 
performed up to 24 hrs and cell viability was only reduced when RV was entrapped into BGs 
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(4.6 fg RV/BG). Assumed that all applied BGs (MOI of 1000) will be taken up by the 
macrophage population, the level of 30 µM RV would be reached. However, we know from 
confocal microscopic investigations that roughly 30-50 % of the applied BGs are taken up by 
the cells which would account for an intracellular concentration of 9-15 µM RV. 
Considering that NO-release as well as RV concomitantly contribute to antimicrobial 
effects and the fact that BGs enhance cellular cytokine secretion and antimicrobial peptides, 
highlights the BG system after tailoring for its specific purpose as a novel clue for therapy of 
intracellular pathogens. 
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Fig. 1. A, The correlation between the RV concentration used for BG loading (“loading 
solution”) and the recovered amount from loaded E. coli BGs (after ethanol extraction) is 
depicted by linear regression. Values were obtained by HPLC measurements. B, Linear 
regression between applied and cell-associated (attached and intracellular) FITC-labeled BGs 
after 20 min of BG coincubation with RAW 264.7 cells. Values represent means of four 
independent measurements and were calculated as described in materials and methods. 
 
 
 
Fig. 2. Adherence and uptake of BGs by RAW 264.7 macrophages. Confocal laser scanning 
microscopy was performed after incubation of macrophages with FITC-labeled E. coli BGs in a 
BG to cell ratio of 1000. RAW 264.7 cells were stained with Texas-Red Phalloidin. FITC-
marked BGs located inside the cell appear yellow, and not engulfed appear green. Images 
display a representative single z-stack of various optical sections. Pictures were taken with a 20-
fold objective after 20 min (A) or with a 63x oil objective (B) after 40 min incubation. No 
image processing steps have been performed.  
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Fig. 3. Induction of NO production. A, RAW 264.7 cells were treated with different LPS 
concentrations (1-1000 ng/ml) for 20 hours. B, Impact of increasing amounts of BGs on NO 
generation by RAW 264.7 cells after 20 min of coincubation followed by 20 hrs cell cultivation 
in the absence of BGs. Accumulated nitrite concentrations were determined by the Griess assay 
as described in materials and methods. Bars indicate mean values + SD. Each experimental 
point represents values form four independent experiments measured in triplicate.  
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Fig. 4. Impact of RV and RV-loaded BGs on the NO production by RAW 264.7 cells induced 
by different amounts of BGs. A, BG-induced (BG to cell ratio of 500) NO production by RAW 
macrophages in the absence and presence of different RV concentrations (1-30 µM). B,C NO 
generation in response to BGs (BG to cell ratio of 100 (B) and 1000 (C)) and RV treatment 
using either RV-loaded BGs (RV ghosts) or empty BGs and externally added RV (3 µM). Based 
on the calculation from cell associated BGs, a BG to cell ratio of 100 and 1000 would 
correspond to a RV concentration of 0.48+0.25 µM and 8.86+2.21 µM, respectively. 
Coincubation was performed in all experiments for 20 min. After 20 hrs accumulated nitrite (A-
C) was determined by the Griess assay as described in materials and methods. Bars indicate 
mean values + SD. Each experimental point represents values from four independent 
experiments measured in triplicate. Asterisks indicate values which are significant different 
from their respective control (p < 0.05).  
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Fig. 5. Influence of empty and RV-loaded BGs on cell viability. A, Impact of empty E. coli BGs 
on the viability of RAW 264.7 macrophages. Cells were incubated with three different BG to 
cell ratios (MOI 10, 100, 1000) for either 20 min followed by a 20 hours recovery period (white 
bars) or for 24 hours (black bars). B, The cytotoxic effect of RV in comparison to the 
implication of RV-loaded BGs (46 µg RV/1x1010 BGs) is depicted. Cell viability was assessed 
by use of the neutral red assay. Bars indicate mean values + SD. Each experimental point 
represents values form four independent experiments measured in triplicate. Asterisks indicate 
values which are significant different from their respective control (p < 0,05).  
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A.1. Supplementary data for Chapter 1. 
Impact of freeze drying and lyophilization media on the size of BGs  
In order to optimize the BG-production process, different lyophilization solution were 
analyzed. E. coli BGs were lyophilized either in water, saline or in different 1 or 5% sugar 
solutions (glucose, saccharose, trehalose and lactose). After freeze-drying, the lyophilized BGs 
were weighted and compared to water dried samples. It turned out that BGs dried in 1% sugar 
solutions as well as saline were two time heavier than those lyophilized in H2O and the 5% 
sugar lyophilization-solution resulted in 8 times higher values (data not shown). 
To determine size and clustering behaviour of the samples, BGs were resuspended in 
0.2% Tween-20 solution and were analyzed with a Shimadzu laser diffraction particle size 
analyzer SALD-1100 (Shimadzu Corp., Japan). The samples were measured in triplicate and 
results are shown in Fig. 1.
More or less, the same distribution was found for all investigated BGs and only BGs 
which were freeze dried in 5% glucose showed a shifted size pattern. As we know from 
microscopic studies, lyophilized BGs tend to form clusters which can hardly be separated by 
resuspension. Such a diverse size distribution, single cells and clusters, was also obtained by the 
laser diffraction analyses. In contrast to this, viable E. coli bacteria, which were investigated in 
their late phase, were completely homogenous in their size (1.77 μM; not shown). As it can be 
seen in Fig 1. only 5 % of the lyophilized BGs were found within the range of 1.3-2.6 μM and 
maximum peaks were obtained in the range of 11-22 μM (representing more than 30% of the 
BGs).
APTase activities of lyophilized BGs after long term storage 
The activities of the membrane bound ATPase of three batches of lyophilized E. coli
NM522 (pGLysivb) BGs, with different production dates (2001, 2005, 2006), were investigated  
Enzyme activity was estimated by the release of inorganic phosphate. The used method is based 
on the quantification of the green complex formed with acidic malachite green and ammonium-
molybdate and free orthophosphate and was performed as described elsewhere [1]. ATPase 
activity was defined as the amount of enzyme which releases 1nmol of inorganic phosphate per 
mg protein. The results are depicted in Fig. 2 and no significant differences were observed 
within five years of storage at ambient temperature.  
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Size determination of bacterial membrane vesicles 
In order to prevent the leakage of water-soluble substances out of the BGs, BGs can be 
sealed by fusion of the BG’s membrane with bacterial membrane vesicles at the edges of the 
lysis pore [2].  
It has been reported, that the membrane vesicles fractions, produced by the French press 
method are homogenous in quality and in size (50-200 nm) [2]. As the generated lysis hole of 
BGs is not uniform in size and reaches up to 200 nm, the vesicle sizes have to be determined to 
optimize the sealing process.  
Therefore, bacterial membrane vesicles were prepared by the use the French press method 
by which E. coli NM522 bacteria were disrupted under high pressure with different psi (pounds 
per square inch).Due to this treatment method, right-side out (outer membrane out) and inside 
out (cytoplasmatic membrane out) vesicles are formed which can be separated according to their 
density by sucrose centrifugation ([2]; Fig. 3.)
The obtained samples were investigated for their size with the Zetasizer Nano (Malvern 
Instruments Ltd., UK). The z-average (d-nm)-values were used for evaluation and results are 
depicted in Fig. 4. It can be seen that the vesicle size in the crude fraction (Fig 4A.) was slightly 
higher (mean value of all samples + SD 258.5+37.67) compared to the inner membrane fraction 
(155.8+17.31 nm) as shown in Fig. 4B. However, results from statistical analyses demonstrated 
that all the obtained vesicles were homogenous in size and were 7-11 fold smaller than the 
natural E. coli bacterium (1767.3+42.7 nm). 
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Fig. 1. Size distribution of E. coli NM522 (pGLysivb) BGs after lyophilization in different 
media. The figure shows the particle size distribution measured with the Shimadzu laser 
diffraction particle size analyzer SALD-1100 after resuspension in 0.2% Tween-20 solution.  
2001 2005 2006
0
5
10
15
Production year of BGs
nm
ol
 p
ho
sp
ha
te
 / 
m
g 
pr
ot
ei
n
Fig. 2. Determination of ATPase activity of lyophilized E. coli NM522 (pGLysivb) BGs. 
Enzyme activities were determined by the release of inorganic phosphate. Bars represent mean 
values + SD obtained from four independent measurements.  
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Fig 3. Schematic representation of the experimental design of the preparation of bacterial 
membrane vesicles. 
14
26
0
11
03
4
94
21
78
08
38
91
27
80
11
14 42
0
0
100
200
300
400
500
A
pressure [psi]
z-
av
er
ag
e 
ve
si
cl
e 
si
ze
 [n
m
]
14
26
0
11
03
4
94
21
78
08
38
91
27
80
11
14 42
0
0
100
200
300
400
500
B
pressure [psi]
z-
av
er
ag
e 
ve
si
cl
e 
si
ze
 [n
m
]
Fig. 4. Determination of bacterial membrane vesicle sizes obtained after disruption of E. coli 
cells by the French press under different pressure conditions. The box and whisker diagrams 
depict values obtained from three measurements of crude membrane vesicles (A) and inner 
membrane vesicles (B) with a Zetasizer.  
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A.2. Supplementary data for Chapter 2.1.1. 
Impact of DIG-loaded BGs on the viability of human cell lines 
The cytotoxic effects of empty Escherichia coli NM522 (pGELys) BGs and Escherichia 
coli Nissle 1917 (pGLysivb) BGs in comparison to DIG loaded BGs (loading solution 100 mM) 
was also tested in the following human cell lines: CCL 20.2 (conjunctiva), SK-MEL-28 and 
A375(melanoma) and HT29 (colon). Cytotoxicity assays were performed as described in 
Materials and Methods.Treatment with DIG-BGs led to significant decrease in cell viability in 
all investigated cells after 24 hrs (Fig. 1). The highest sensitivity towards the delivered chemical 
was found for the conjunctival cells CCl 20.2 where only 6-11% stayed alive. Whereas, no 
differences were found on the impact on cell viability between the delivered DIG by the two E. 
coli BGs in the colon cell line HT29, high variations were observed with the melanoma cell 
lines and conjunctival cells. High differences were found in CCL 20.2 cells after treatment with 
DIG-loaded E. coli Nissle BGs and E. coli NM522 BGs (P=0.0005), whereas the latter one 
caused more reduction in cell viability. The opposite was observed with the melanoma cell 
lines. Treatment with DIG-loaded E. coli Nissle BG resulted in a significant decrease of cell 
viability in A375 cells (P=0.0009) and SKMel-28 cells (P=0.0023) than compared to the results 
obtained with E. coli NM522 BG-bound DIG. The biggest variation between the two applied 
BGs were found for SKMel-28, where on average 50 % more cells were killed by E. coli Nissle 
BG delivered DIG. In each experiment, the impact of the DMSO loaded ghosts, which served as 
solvent control from loading experiments and were found to do not differ from empty ghosts, 
was investigated. As depicted in Fig. 1, the viability of all cell lines was not impaired after 
treatment with the BGs per se except for the melanoma cell line SKMel-28. Both strains caused 
cytotoxic effects in these cells to a more or less the same extent (88.22 + 9.32 for Nissle and 
88.21 + 7.39 for NM522).  
However, due to the high discrepancies of the two BG strains in SKMel-28 cells 
concerning their cytotoxic impact when loaded with DIG, it is assumed that this may be cause 
by different adherence/uptake rates of E. coli ghosts. In order to confirm this assumption, 
qualitative fluorescence adherence assays were conducted. For this purpose, the intensity of the 
two FITC-labelled BGs was compared after incubation of HT29 and SKMel-28 cells in a MOI 
of 1000 for 24 hrs. The fluorescence was determined with the Tecan Infinite 200 device 
(excitation 480 nm; emission 520 nm).  
In agree with the obtained results from cytotoxicity studies (Fig. 1), no 
differences were observed between the E. coli BGs with the colon cells (Fig. 2). However, high 
differences were found for the melanoma cell line. Adherence/uptake rates were statistically 
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different (p= 0.0024) between E. coli NM522 and E. coli Nissle, whereby the latter was giving 
the highest fluorescence units. (Fig. 2).
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Fig. 1. Cytotoxic impact of DIG-loaded E. coli BGs on various human cell lines. The cells were 
treated with empty E. coli Nissle 1917 BGs (black bars), empty E. coli NM522 BGs (white 
bars) or with BGs which were loaded in 100 mM DIG (grey bars: Nissle and striped bars
NM522). Serum free-medium treated cells (dotted bars) served as controls.
The viability was determined in neutralred assays after treatment for 24 hrs (MOI 1000). Bars 
represent values of means + SD (N=8-30). Asterisks indicate values which differ significantly 
from controls (p < 0.05). Crosses mark differences between the two E. coli BGs. 
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Fig 2. Comparative qualitative adherence assays with FITC labelled E. coli BGs indicate the 
difference of NM522 (black bars) and Nissle ghosts (striped bars) for their tendency towards 
for the colon cell line HT29 and melanoma cell line SK-Mel 28. The fluorescence background 
levels of the cells are depicted as white bars. Values represent means + SD obtained from three 
independent measurements. 
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A.3. Supplementary data for Chapter 2.2.1. 
Adherence and uptake of BGs by CCL 20.2 cells 
Internalization of the BG was verified by use of confocal laser scanning microscopy 
(CLSM). For this purpose cells were seeded in 8-well chamber slides (Falcon CultureSlide) and 
were allowed to attach. The medium was replaced by 200 μl sf-medium containing FITC-
labeled BG (BG to cell ratio 1000) and the slides were further incubated for 1 hr. Subsequently, 
the cells were washed twice with PBS and 1% paraformaldehyde was added for fixation (20 
min, room temperature). Another two washing steps with PBS were performed before the cells 
were permeabilized with 0,5 % Triton X-100 for 20 min.; followed by other two washing 
procedures. Then, 100 μl of freshly prepared PromoFluor 590-conjugated Phalloidin (5 μl 
methanolic 100 U / ml dye-stock; PBS; 1 % BSA) was added to visualize cell boundaries. After 
45 min incubation the slides were washed again twice with PBS and imaged by CLSM. Images 
displaying representative single z-stacks of various optical sections after coincubation with 
different BGs (S. flexneri, E. coli NK9373 and M. haemolytica) are depicted in Fig. 1. It can be 
seen that FITC-labeled BGs which are already internalized by CCL 20.2 cells stained in red, 
appear yellow. Green colored BGs represent those which are not engulfed but attached to cells. 
Fig. 1. Adherence and uptake of BGs by the CCL 20.2. cells. Confocal laser scanning 
microscopy was performed after incubation of conjunctiva cells with FITC-labeled BGs (S.
flexneri (A), E. coli NK9373 (B) and M. haemolytica (C))in a BG to cell ratio of 1000. CCL 
20.2 cells were stained with Texas-Red Phalloidin. FITC-marked BGs located inside the cell 
appear yellow, and not engulfed appear green. Images display a representative single z-stack of 
various optical sections.  
B) E. coli NK9373 C)     M. haemolyticaA) S. flexneri
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A.4. Supplementary data for Chapter 2.2.2. 
Detoxification of the anti-glaucoma eye drops Pilocarpine hydrochloride and Cosopt 
Since protective effects were observed with various BGs towards BAC induced 
cytotoxicity in CCL 20.2 cells, preliminary experiments were conducted with the BAC 
containing eye drops Pilocarpine hydrochloride (0.2 mg BAC/ml) and Cosopt (0.075 mg 
BAC/ml) in combination with BGs (detailed information about eye drops is provided in the 
Appendix section A.7. “Comparative in vitro studies of the toxicological impact of eye drops 
used for glaucoma treatment”). Cytotoxicity assays were performed as described in Materials 
and Methods (Chapter 2.2.2.). Again, the cytotoxic impact of the investigated drugs was found 
to be significantly reduced in presence of BGs.  
Fig. 1. depicts the cytotoxic effects caused by single and double applications of P-HCl 
(dilution 1:10) alone and in combination with ETEC-BGs for 20 min followed by a 24 hr 
recovery period. Cell viability dropped from 40 % for a single application to 4 % cell viability 
after double treatment with P-HCl. Beneficial effects were found when ETEC-BGs were present 
in the P-HCl solutions. Cell numbers significantly increased after the first (p=0.0024) and 
second (p=0.0015) application. Compared to P-HCl treatment alone, 2-4 fold enhanced cell 
viability was seen with BGs. 
In experiments, conducted with the eye drop Cosopt, also other BGs were investigated for 
their detoxification potential. As shown in Fig. 2., this ophthalmological solution (diluted 1:20) 
dramatically decreased the percentage of viability of CCL 20.2 cells after treatment for 24 hrs 
(36.67+3.06 % were found to be alive). However compared to Cosopt treated cells, protective 
effects were found when BGs were present and viability was enhanced up to 57 %. 
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Fig. 1. Impact of Pilocarpine hydrochloride (P-HCl, 2 %) alone or in combination with ETEC-
BGs on the viability of CCL 20.2. cells. The figure shows the acute toxic effects towards the 
conjunctival cell line after single/double application of the drug P-HCl (dilution 1:10, white 
bars) in combination with BGs (dotted bars) for 20 min followed by a 24 hr recovery period. 
Cells were treated with BGs in a MOI of 1000 and the viability was determined by the use of 
the neutralred assay. Bars represent mean data + SD obtained from three independent 
measurements. Asterisks indicate values which differ significantly medium treated cells (black 
bar) and crosses mark differences of P-HCl induced cytotoxicity in presence of BGs (p < 0.05). 
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Fig. 2. Impact of Cosopt alone or in combination with different BGs on the viability of CCL 
20.2 cells. The figure shows the effects on the viability of the conjunctival cell line after long 
term treatment with Cosopt (dilution 1:20) in combination with different BGs for 24 hrs. Cells 
were treated with BGs in a MOI of 1000 and the viability was determined by the use of the 
neutralred assay. Bars represent mean data + SD obtained from three independent 
measurements. Asterisks indicate values which differ significantly from Cosopt treated cells (p 
< 0.05, 1way ANOVA). 
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A.5. Supplementary data for Chapter 2.3.2. 
Increased fluorescence of FITC-labeled BGs after coincubation with RAW 264.7 cells 
Incubation of the macrophage cell line RAW 264.7 with FITC-labeled E. coli NM522 
BGs resulted in a time dependent increase of FITC fluorescence.  
The experiments were conducted as described in Materials and Methods but were 
extended for several timepoints. Even though the macrophages were coincubated with the same 
ratio of BGs, giving the same fluorescence, the fluorescence intensity of the FITC labeled BGs 
in the media-significantly increased after 12 hrs and 24 hrs (p<0.0001). As depicted in Fig. 1.,
the fluorescence intensity was 2-3 fold higher than at the beginning.  
In order to determine whether these effects are caused by the pH of the cell’s interior or 
by cell’s associated enzymes, FITC-labeled BGs were resuspended in different solutions with 
different pH values or enzyme (Table 1). Fluorescence and pH values were measured at the 
beginning as well as after 24 hrs incubation. 
The results are depicted in Fig. 2. It can be seen that citric acid with the lowest pH 
immediately quenched FITC fluorescence and lasted over 24 hrs. Sodium buffer, which had the 
highest pH value (~ 10), led to PBS-comparable values and had no further impact on the 
fluorescence after 24 hrs. The highest fluorescence units were found with the serine proteases 
proteinase K and TrypleEx. Both digestive enzymes resulted in an increase of fluorescence after 
the incubation time. However, incubation of FITC-labeled BGs in cell-free lysate-fractions of 
RAW cells, which were obtained by repeated thawing and freezing in liquid nitrogen, did not 
result in any fluorescence increase. 
As the pH-values did not change significantly after 24 hrs incubation with FITC-labeled 
BGs (Table 1) the increase of the intensity of the fluorochrome appears to be more related to 
digestive enzymes of the macrophages. 
Tables and Figures 
Table 1. pH values of different solutions after incubation with FITC-labeled BGs 
Treatment pH (0 hrs) pH (24 hrs)
PBS 8 7.5
Na-Buffer 10 10
Citric acid <4.5 4.5
TrypleEx 7 7
Proteinase K 7.5 7.5
RAW-lysate 8.5 8.5
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Fig. 1. Time dependent increase of the fluorescence of FITC-labeled BGs after coincubation 
with macrophages. RAW 264.7 cells were incubated for different timepoints with E. coli
NM522 BGs. A significant increase in FU can be seen after 24 hrs. Fluorescence values were 
determined with a Tecan microplate reader. Values represent means + SD.  
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Fig. 2. Fluorescence behaviour of FITC-labeled BGs in different solvents. White Bars indicate 
fluorescence values measured at the beginning and black bars represent measurements after 24 
hrs. Results are shown as mean values + SD. 
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A.6. Loading capacity of BGs with the coffee compounds
kahweol and cafestol 
Introduction
Coffee is, after water, one of the most widely consumed beverages in the world. Its 
consumption has been associated with numerous health benefits, including the prevention of 
cancer (i.e. in the liver and colon) or other chronic diseases such diabetes, Alzheimer and 
Parkinson [1, 2]. 
The diterpenes kahweol (K) and cafestol (C) are two major lipid components of green 
coffee beans and their chemoprotective effects were demonstrated in several studies. For 
example, in animal experiments they were found to be antitumorigenic against the carcinogene 
7,12-dimethylbenz[a] anthracene (DMBA) in hamster’s buccal pouch [3]. Also antimutagenic 
effects were seen with rat liver preparations against aflatoxin B1 and benzo[a]pyrene [4] and in 
rat an human cell cultures [5]. Another in vivo study demonstrated the chemoprotection of K/C 
against the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine (PhIP), the 
so called cooked food mutagen [6]. It was found, that these coffee components modify the 
activities of the hepatic enzymes N-acetyltransferase (NAT) and glutathione S-transferase 
(GST) and provide therefore protective effects [2]. 
As in the present thesis, BGs have been already demonstrated for their preservation 
properties against oxidative damage and for their controlled drug release (Chapter 2.1.1.), we 
performed additional experiments in which the loading efficiency of BG with the coffee 
compounds C and K were investigated. Our findings show that all compounds were entrapped 
in a dose dependent manner. Furthermore we found, that the solvent highly contributes to the 
loading efficiency.  
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Materials and methods 
Chemicals
Cafestol (purity > 95%) and kahweol /cafestol-palmitate (1:1 blend, i.e. 47% cafestol, 
47% kahweol, 5% isomeric derivatives) were a kind gift from Prof. Wolfgang Huber (Institute 
of Cancer Research, Vienna). 
Loading of BGs 
25-50 mg lyophilized E. coli Nissle 1917 BGs (pGLysivb /BPl; 090421; 1,3x109
particles/mg) were suspended in 1.2 ml of different C (5.1-114.7 mM) and K/C (0.7-14.1 mM) 
solutions. In order to determine the impact of the solvent on the loading efficiency, the 
compounds were dissolved with two ethanol and DMSO. The samples were incubated under 
shaking (650 rpm) for 30 min at 28°C. The loaded BGs were collected by centrifugation at 
11300 g for 15 min and the pellets were washed five times with phosphate buffered saline. 2-3 
mg BG aliquots were stored at -20°C until use.  
Extraction and Quantification of cafestol and kahweol 
C and K/C concentrations were analysed by reversed-phase high-pressure liquid 
chromatography (HPLC) as described by Gross et al. [7]  
K/C-Palmitate loaded BGs were saponified by the addition of 2 ml methanolic 0.3 M 
potassium hydroxide solution. After incubation under agitation for 60 min (RT, IKA-VIBRAX 
agitator, speed 600), 800 μl 2-propanol-ethyl acetate (1:1, v:v) and 800 μl 0.5 M aqueous 
sodium dihydrogen phosphate were added. After extensive mixing, the solutions were 
transferred into C18/PRS solid –phase extraction cartridge tandems which were previously 
conditioned (C18 cartridges were rinsed with 3 ml 2-propanol-ethyl acetate and PRS cartridges 
were rinsed with 3 ml 1 M HCl, 20 ml water and 3 ml 2-propanol-ethyl acetate). The 
preparations were slowly eluted by air pressure (applied with a plastic syringe) and were 
concentrated by use of an exciccator to a final volume of 400 μl. After vortex-mixing the 
samples were filtered through a Nalgene filter tip (0.2 μM , zero dead volume) direct into HPLC 
microvials. C was extracted from BGs by two times addition of 500 μl ethanol (100 %) and 
vortexing for 10 min (1000 rpm). After centrifugation (13000 rpm; 8 min), the supernatants 
were collected and measured by HPLC. 
Chromatographic analysis was performed using a Hewlett-Packard HP 1100 HPLC-FLD 
model.The mobile phase consisted of water (solvent A) and methanol (solvent B). Separations 
were carried out using linear gradient elution conditions (0 min: 30% A, 70% B; 20 min: 5% 
solvent A, 95% solvent B) and the flow rate was 1 ml/min. C was detected at 230 nm and K at 
290 nm.  
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Results and discussion 
In order to determine whether BGs can be used as carriers for the coffee diterpenes C and 
K (Fig. 1), loading experiments were performed with BGs, generated from the probiotic E. coli
Nissle 1917 strain.
The loading of lyophilized BGs was performed by resuspension of BGs in different 
concentrations of C (5.1-114.7 mM) or K/C-palmitate (0.7-14.1 mM) by the use of different 
solvents (ethanol and DMSO). To determine the amount of the compounds in BGs, ethanolic 
extracts were performed and analyzed via HPLC. Clear correlations between the loading 
concentration of the compounds and recovered amount of the substances were observed. The 
results and the correlation coefficients (r2), obtained from linear regression analyses, are 
depicted in Fig. 2. The highest loading efficiency was obtained after suspension of lyophilized 
BGs in a K/C (DMSO) solutions (Fig. 3).
Furthermore, the impact of the solvent on the loading efficiency is exemplified in Fig.4.
Indeed, in comparison to ethanol, 2-4 fold more of C was bound in BGs when DMSO was used 
as the solvent. 
Our findings show that high molecular weight compounds like the K/C-palmitates (MW 
1106.86) can be successfully entrapped into BGs and that the polarity of the used solvent 
influences the loading capacity.  
C and K were shown to cause modifications of the xenobiotic metabolism, such as the 
induction of GST and inhibition of NAT, thereby leading to chemopreventive effects. 
Therefore, studies should be conducted in which the impact of loaded BGs on these metabolic 
enzymes should be investigated. Furthermore, since coffee consumption has been associated 
with reduced incidence of colon cancer [1] and K/C was found to decrease the formation of 
colonic DNA-adducts [6], the effects of C and K loaded BGs should be further examined in 
genotoxicity assays.  
The data from the preliminary study open a new application pathway for BGs as 
functional food ingredients. For example, C or K/C loaded BGs could be added to instant 
coffee, which contain only very low concentrations of C and K [7]. 
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Figures
Fig 1. Chemical structures of the diterpenes kahweol (K) and cafestol (C). 
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Fig. 2. Standard curves and linear regressions of the of the loading experiments. The plots 
depict mean values obtained from extraction experiments (μg chemical per 1x1010 ghosts) 
versus the loading solution (mg/ml). Squares represent mean values of at least two 
measurements.  
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Fig. 3. Dose-dependent loading of E. coli Nissle 1917 BGs with the coffee compounds K/C-
palmitate (mixture ratio 1:1) in DMSO.  Bars represent means + SD obtained from two loading 
samples. Black bars show the cafestol and white bars the kahweol content of the measured 
samples.  
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Fig. 4. Solvent dependent loading efficiency of lyophilized E. coli Nissle 1917 BGs with 
cafestol. White bars indicate the extracted values from loading procedures where DMSO was 
used as solvent; black bars show the results obtained from loading with ethanol as solvent.  
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A.7. Comparative in vitro studies of the toxicological impact
of eye drops used for glaucoma treatment 
Introduction
According to the WHO, glaucoma is characterized as a group of diseases which damage 
the eye’s optic nerve and is the third leading cause of blindness in the world at the moment. 
Latest statistics from the organization show that more than 12 %, equitable to approximately 4.5 
million people, of all the global blindness is caused by primary glaucoma. Higher numbers are 
predicted by Quigley & Broman for the prospective future [1]. They estimate that by 2020 about 
80 million people will suffer from these diseases. While the primary prevention strategy of 
glaucoma remains unclear, early stage diagnosis gives rise to effective methods in surgical and 
medical treatment. The latter one is predominantly used as first-line therapy and it has been 
shown that intraocular pressure (IOP)-lowering agents, like prostaglandin analogues, play a 
major role [2]. 
As glaucoma is a neuropathy of the optic nerve, topically applied anti-glaucoma drugs 
have to cross the cornea and the conjunctiva to reach their sites of action. It has been 
demonstrated that the permeability of the pharmaceutical could be vastly enhanced by addition 
of an preservative [3].  
However, since glaucomatous patients receive topical therapy for many decades, a lot of 
adverse events and side effects have been reported [4]. Besides pain and discomfort of the 
patient during instillation, development of cataracts, the leading cause of visual impairment, 
have been associated with antiglaucoma medication [5, 6]. Furthermore, the epithelium can 
respond to medication related stress by inflammation reactions which lead to severe damage of 
the cornea and conjunctiva itself [4]. The loss of vascularization and the exhibition of a 
spectrum of metaplasia ranging from loss of goblet cells, which is closely related with the dry-
eye syndrome, and stratification as well as keratinisation have been demonstrated [4, 7, 8]. 
It is still a debate if the obtained side effects may be attributable to the active compound 
per se or if they are relatable to the preservatives in the drug solution. The quaternary 
ammonium compound benzalkonium chloride (BAC) is the most commonly used preservative 
in ophthalmic medications. Its cytotoxicity is well studied and it is known that the substance is 
responsible for proapototic and necrotic effects in vitro and in vivo [4, 9, 10]. Moreover, topical 
long term application of BAC has been shown to decrease aqueous tear basal secretion as well 
as MUC5AC-related mucin production and leads to deprivation of mucin producing goblet cells 
[4, 8, 11].  
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Since overexpression of oxidative stress markers was observed in the aqueous humor and 
plasma of glautomatous patients and increased levels of 8-oxo-deoxyguanosine were found in 
the trabecular meshwork [12-14], it has been suggested that oxidative stress could be a key 
player in glaucoma pathophysiology. It was demonstrated that ocular surface irritations were 
predominantly higher with preserved than with preservative-free IOP-lowering agents and 
indicated that reactive oxygen species (ROS) were partly involved [11, 15-18]. Several clinical 
and experimental studies showed that long-term use of BAC-preserved ophthalmic medications 
induced overexpression of inflammation-related receptors/molecules such as HLA-DR and 
intracellular adhesion molecule - ICAM-1 (CD54) expression [11, 19]. A positive correlation 
was found between class HLA-DR expression and the apoptotic Fas antigen (CD95) [20]. 
Furthermore, it was shown that BAC caused overexpression of the apoptotic marker Apo2.7 [9] 
and induced the activation of cell death receptor P2X7 due to ROS overproduction [16]. BAC-
related oxidative stress correlated with ocular cytotoxicity [21] and was linked to apoptosis in 
conjunctival cells [22]. Furthermore, the transcriptional activation of the stress-related genes c-
fos and c-jun after BAC-containing medications was shown [23]..  
The conjunctiva represents a mechanical barrier against pathogens and protects the eye 
against allergens and toxic substances. Because these epithelial cells of the eye’s font are the 
first tissues to be exposed by medical treatment,. a lot of studies were conducted with the 
commercial available human derived conjunctival epithelial cell line CCL 20.2 [9, 15, 16, 24].   
The purpose of the present in vitro study was to determine the potential cytotoxic effect 
of BAC on CCL 20.2 cells and to investigate the cytotoxic from common topical glaucoma 
medications containing BAC. Moreover, toxicological studies were performed in parallel with 
human conjunctiva-derived epithelial cells obtained from biopsy material for comparative 
analysis with the conventional conjunctival cell line.  
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Materials and methods 
Cell culture 
The Wong-Kilbourne derivate of Chang conjunctival cells (clone 1-5c-4, ATCC CCL 
20.2) were kindly provided by Prof. Bernd Binder (Medical University Vienna, Centre of 
Biomolecular Medicine and Pharmacology, Vienna, Austria). The cells were cultured under 
standard conditions (37 °C moist atmosphere of 5% CO2) in RPMI 1640 medium (Sigma 
Chemical Co., St. Louis, MO) supplemented with 10% heat inactivated fetal calf serum (FCS, 
Sigma), 100 U/ml penicillin (Invitrogen, Carlsbad, CA), 100 μg/ml streptomycin (Invitrogen),  
2 mM L-glutamine (Invitrogen), 10 mM HEPES buffer (Lonza, Verviers, Belgium), 0.1 mM 
MEM Non-Essential Amino Acids (NEAA, Lonza) and 5 μg/ml plasmocin (Lonza). 
When cultures reached confluency, the cells were washed with phosphate buffered saline 
(DPBS, Lonza), detached with TrypLETM Express (Invitrogen), centrifuged and subcultured in 
the microtiter plates. 
Human conjuctival biopsy specimens were obtained from patients who suffered either on 
chalazion or ectropion and were undergoing eye surgery. Informed and signed consent was 
obtained in each case in accordance with the Declaration of Helsinki from all subjects prior to 
surgery. Upon excision, the specimens (approximately 2x2 mm) were placed into sterile ACL-4 
(provider) culture medium [25]. The explants were cut into small pieces and were placed into 
collagen-precoated (|Collagen solution type I from calf skin; dilution 1/20; Sigma-Aldrich) cell 
culture flasks. The tissue parts were allowed to attach and were covered with ACL-4 medium. 
The samples were incubated at 37 °C in a humidified atmosphere of 5% CO2. Culture medium 
was changed every 2-3 days. The development of the cultures was assessed daily by phase 
contrast microscopy. Confluent cultures were subcultured by trypsinization specify (Invitrogen). 
The cultured primary cells were named ME-1 (derived from chalazion surgery) and ME-2 
(derived from extropion surgery). 
Immunocytochemistry 
Conjunctival epithelial marker expression was studies by use of antibodies against 
cytokeratin-7 (CK-7; mouse-anti-cytokeratin-7 FITC-conjugate; clone LP5K; isotype IgG2b) 
and vimentin (mouse-anti-vimentin PE conjugate; clone VI-RE/1; isotype IgG1); both obtained 
from Abcam (UK). Samples were stained according to the manufacturer’s instructions. Briefly, 
cells grown on 96-well imaging culture plates (PAA Laboratories GmbH, Pasching, Austria) 
were fixed in cold methanol and washed twice with PBS. After 10 min of permeabilization with 
PBS containing 0,25% Triton X-100  the cells were washed three times with PBS and incubated 
with 1% BSA(provider) in PBS for 30 min. Next, the cells were incubated with antibodies in a 
final dilution of 1:50 at room temperature in the dark for 1 hr. After extensive washing with 
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PBS, the fluorescence was analyzed using a Zeiss LSM310 microscope. Obtained digital images 
were converted to black-and-white images (Adobe Photoshop CS3, Adobe Systems, Mountain 
View, CA). 
Chemical treatment of conjunctival cells 
Commercial available eye drop solutions, commonly used in glaucoma therapy, 
were investigated in the CCL 20.2 cell line as well as in cultured primary cells for their 
possible cytotoxic and genotoxic actions. The medications contained four different active 
components (Dorzolamide - carbonic anhydrase inhibitor, Timolol - beta-adrenergic receptor 
blocker, Brimonidintartrat - alpha2-adrenergic receptor agonist, and Pilocarpine hydrochloride -
representative cholinergic agent) alone or in combination with or without different 
concentrations of the preservative-BAC (Table 1). All dilutions and further treatment steps 
were performed in serum-free media. 
Cytotoxicity Assay
The neutral red uptake assay for the estimation of cell viability/metabolic activity was 
performed as described previously [26]. 1x105 cells per well plated 24 hrs before adding of drug 
in 96-well plates were incubated for different timepoints in 200 μl solution of the antiglauoma 
drugs (diluted 1:10) (Table 1). To mimic a repetitive character of drug treatment, cells were 
also re-exposed to the drugs, 60 min after the initial treatment. The cell viability was determined 
after a 24 hrs recovery period in complete medium. The recovery phase was included to 
simulate the clinical conditions in which the conjunctival tissue may recover after topical eye 
drop administration.  
After each treatment, two washing steps with PBS were performed. Subsequently, the 
cells were incubated with 100 μl of NR (80 μg/ml final concentration; Roth) for two hrs (37°C; 
5 % CO2). After the dye had been discarded, the wells were washed two times with PBS and 
dye was released by the addition of 100 μl of the destaining solution (1 ml acetic acid, 73 ml 96 
% ethanol and 26 ml deionized water). After shaking, the absorbance was measured at 570 nm 
(reference wavelength 690 nm) with a microplate reader (Opsys MR, DYNEX Technologies). 
The tests were performed in triplicate and mean values from 3 independent plates were 
determined. Data are represented as means + SD. Values obtained with medium treated cells 
were considered as control and were set as 100 % viability.  
Statistics
All results were analysed by GraphPad Prism (version 5, GraphPad Software, Inc; San 
Diego; CA, USA). Data are expressed as means + SD. Statistical analysis was performed by one 
way ANOVA with Dunnett's multiple comparison test as post-test or by Student’s t-test when 
only two groups were compared. P-values < 0,05 were considered statistically significant.
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Results
Cultivation of conjunctiva derived cells 
Conjunctiva cells obtained from biopsy specimens (ME-1 and ME-2) demonstrated a 
mixed-shape population of polygonal and more elongated cells with very slow growth. 
Confluence was reached after 20 days of cultivation and cells were successfully subcultured at 
an split ratio of 1 to 2. 
Cells in passages 10 and 14 (ME-1) and in passage 7 and 9 (ME-2) were used for 
characterization. The epithelial-cell like character was observed and maintained in every 
passage of ME-2 whereas ME-1 showed more spindle growth compare to CCL 20.2 cells (Fig.
1). At the same time, the expression of the epithelial specific marker Cytokeratin-7 (CK7) was 
evaluated. Positive reaction against CK-7 antibodies was obtained with the CCl 20.2 cell line 
(Fig.1B) and with ME-2 cells (Fig. 1F). ME-1 cells gave negative results (Fig. 1D)
Vimentin filaments were described to be detectable in conjunctival cells in culture [27]. 
Positive reactions were found with ME-1 (Fig. 1G) and ME-2 cells (Fig. 1H). However, a great 
difference in the arrangement of the filaments could be observed, showing that ME-1 cells had 
more fibroblastic appearance. 
Cytotoxic impact of eye drops on human conjunctiva derived cells 
Due to the lack of an standardized protocol for testing of eye drops in cell cultures, 
concentrations ranging from the undiluted form to 1:1000 with incubation times varying 
between 15 min to 24 hours were reported [10, 18, 24]. Based on preliminary studies (data not 
shown), only short-term exposure times (5 to 30 min) were examined in all cytotoxicity assays 
and eye drop solutions were tested in 1/10 dilutions.  
Comparative investigations of BAC induced cytotoxicity were performed using CCL 20.2 
and ME-1 cells. Incubation of conjunctiva cells for 20 min with increased BAC concentrations 
(> 0.01 mg/ml) followed by a 24 hr recovery period resulted in a dose-dependent decrease of 
cellular viability (Fig. 2). Significant toxic effects (P<0.05), were already found after addition of 
0.01 mg/ml BAC to the culture system were observed for both CCL 20.2 and ME-1 cells. 
Obtained results revealed that cells obtained from tissue biopsy (ME-1) were more 
sensitive to the treatment with BAC in comparison with CCL 20.2 cells, when 0.025 mg/ml 
BAC had on ME-1 cells the same toxic effect as 0.05 mg/ml BAC on CCL 20.2 cells.   
No acute toxic effects were detected when eye drops were applied for short time period 
(5-30 min) to the conjunctiva cells at dilutions 1:10 (data not shown). However, the same 
exposure times (5 or 30 min) resulted in a dose dependent decrease of viability when cells were 
treated with various eye drop solutions and were cultured further for another 24 hrs. An 
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example is given in Fig. 3A where CCL 20.2 cells were exposed to Pilocarpine hydrochloride 
(P-HCl, 2%).
Furthermore it was demonstrated that the cytotoxic impact of Pilocarpin was not only 
time dependent but also dose-dependent. When P-HCl was applied twice (one hour break 
between the exposure times), followed by a 24 hours recovery period, a dramatically decrease in 
cell viability was observed. Again, ME-1 cells were more sensitive to the drug than CCL 20.2 
cells (as already demonstrated in (Fig. 2)). Whereas 62 % of the CCl 20.2 cells stayed alive 
after a double dose treatment, only 32 % of the primary ME-1 cells were viable (Fig. 3B).
Cytotoxic studies of the model conjunctival cell line (CCL 20.2) and the two human 
conjunctiva derived primary cell cultures (ME-1 and ME-2) incubated with diluted (1:10) 
ophthalmic medications (Cosopt sine, Cosopt, Pilocarpin Puroptal 1%, Pilocarpin Puroptal 2 %, 
Timoftal and Alphagan) for 20 min followed by a 24 hour recovery period showed almost in all 
cases decreased cellular viability of all tested conjunctiva cell types (Fig. 4). However,
remarkable distinctions were observed between the analyzed cells. While the BAC containing 
medications (Cosopt and Pilocarpin) dramatically induced decrease of viability in all tested 
cells, incubation of cells with Timoftal had toxic impact only on cells obtained from 
conjunctival biopsies (ME-1 and ME-2).  
Even though Alphagan contained also the preservative, no harmful impact was 
observable. As well the preservative-free Cosopt solution did not cause any significant effect in 
the viability of the cells. However, the impact of BAC could be seen in the in all cell lines, 
when BAC-containing Cosopt was applied to the cells. In order to the BAC-content of the 
investigated medications (P-HCl > Timoftal > Cosopt > Alphagan) a significant negative 
correlation was found for ME-2 under these conditions (P=0.003; Pearson r=-0.9970).The 
preservative concentrations of the respective drugs are given in Table 1.
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Discussion
The conjunctival cell line CCL 20.2 has been shown to have many features in common 
with primary conjunctival tissues [28] and therefore was used together with primary cells (ME-1 
and ME-2) obtained from conjunctival biopsy as model conjunctiva cells for comparative 
investigations concerning the cytoxic impact of commercial available medications against 
glaucoma on the conjuctival cells
Many in vitro and in vivo studies have extensively described a wide spectrum of cytotoxic 
and inflammatory reactions after administration of antiglaucoma drugs [4, 29]. However these 
effects were mainly related to the agents used as drug preservative, mostly to the BAC [11, 15, 
17-19]. The immortalized human conjunctiva derived cells IOBA-NHC were shown to possess 
many phenotypic characteristics of the normal conjunctival epithelium and, in contrast to CCL 
20.2 cells which are contamined with HeLa cells [30], do not have any other cell type 
contamination [31]. Recently, also differences concerning the BAC induced cytotoxicity were 
found between the IOBA and CCL 20.2 cell line [24]. Such discrepancies were also seen in our 
study where BAC  (0.025 mg/ml) caused more cytotoxic effects in ME-1 cells, derived from 
human conjunctival biopsy, than in CCL 20.2 cells (Fig 2).
Pilocarpine, the-antiglaucoma drug with the highest content of BAC of all investigated 
drugs, was chosen for time-dependent cytotoxicity studies. Although acute toxic effects were 
negligible after short incubation periods (5 and 20 min) with the drug diluted 1:10, it turned out 
that after 24 hours of cell recovery the cellular viability dramatically decreased (Fig.3 and 4).
Surprisingly, even though single dosage of the pilocarpine solution did not induce any lethal 
effects after 5 min exposure, results from double treatment; having one hour break between the 
applications, led to extreme cytotoxic consequences after 24 hours cell recovery Viability of 
CCL 20.2 cells after incubation with Pilocarpin (dilution 1:10) was up to 60% whereas only 30 
% of the conjunctiva derived ME-1 population was detected. Obtained results indicate that high 
toxicity of Pilocarpine is directly connected to the high content of preservative in the drug (0.02 
mg/ml BAC in undiluted solution) and may explain the different behaviour of the investigated 
conjunctival cells. 
Our results from comparative cytotoxicity studies using the CCL 20.2 cell line and the 
two conjunctiva derived primary cells ME-1 and ME-2 (Fig.4) are pointing on the negative 
correlation between BAC containing eye drop preparations and cell viability showed previously 
[15, 17, 18]. Furthermore, it has been demonstrated that the cytotoxic impact of BAC-
containing Pilocarpin was dramatically enhanced when double doses were applied, representing 
simulations for daily applications of the drug. However, further studies are required to 
investigate the cytotoxic impact of the pure compounds as well as interactions of combinations 
with other active drugs or preservatives. 
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Tables and figures 
Table 1. Characteristics of eye drops for glaucoma therapy used in the present study. 
     
Trade name Active component(s) Concentration[mg / ml] 
BAC
[mg/ml] Company 
     
Cosopt sine Dorzolamid / Timolol 20 /5 not included MSD 
Cosopt Dorzolamid / Timolol 20 /5 0.075 MSD 
Pilocarpin Puroptal (1%) Pilocarpine hydrochloride 10 0.200 Agepha 
Pilocarpin Puroptal (2%) Pilocarpine hydrochloride 20 0.200 Agepha 
Timoftal 0.25 % Timolol 2,5 0.100 Agepha 
Alphagan 0.2% Brimonidintartrat 2 0.050 Allergan 
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Fig 1. Phase contrast micrographs of confluent cultures from the CCl 20.2 cell line (A), from 
the primary cells ME-1 (C) and ME-2 (E). CCl 20.2 cells (B) as well as ME-2 cells (F) showed 
positive reaction against FITC-labeled anti-CK-7 immunofluorescence staining, whereas ME-1 
cells reacted negative (D). Magnification x 20. Reactions with the vimentin PE-conjugated 
antibody are shown for ME-1 cells (G) and ME-2 cells (H). Note the diffuse arrangement of the 
filaments in ME-1 cells compared to ME-2 cultures.  
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Fig. 2. Results obtained from cytotoxicity assays by the use of the neutralred assay are depicted. 
CCl 20.2 cells (white bars) and from human conjunctival biopsy derived ME-1 cells (black bars) 
were exposed to various BAC concentration for 20 min and viability was determined after 24 
hours. Bars represent mean values + SD obtained from four measurements. P-values <0,05 were 
considered. As indicated with asterisks, all BAC concentrations led to statistically significant 
difference compared to their respective control. Statistically significant difference marked by a 
cross, was also found between CCl 20.2 and ME-1 after treatment with 0.025 mg/ml BAC. 
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Fig. 3. Evaluation of cytotoxicity obtained after various treatment conditions with the eye drop 
solution Pilocarpine hydrochloride (P-HCl), 2 %) by use of the neutralred assay. In each 
experiment a 1/10 dilution of the substance was used. The time dependent effects obtained after 
different exposure times to CCl 20.2 followed by a 24 hours recovery period are depicted (A).
The toxicity of a double dose exposure towards CCl 20.2 (white bars) and ME-1 cells (black 
bars) is shown (B). Cells were treated with P-HCl twice for 5 min (one hour break between 
applications). After 24 hours the viability of the cells was examined. Bars represent mean values 
+ SD obtained after three determinations. Asterisks indicate statistically significant differences 
compared with control (p < 0.05) 
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Fig. 4. Determination of various eye drop solutions for their possible cytotoxic effects. The 
human derived cell line CCl 20.2 (white bars) and primary cells obtained and cultured from 
conjunctival biopsy tissues ME-1 (black bars) and ME-2 (dotted bars) were examined. 
Cytotoxicity was evaluated by use of the neutralred assay after 20 min treatment with various 
eye drops followed by a 24 hour recovery period. Each tested solution was diluted to 1/10. Bars 
represent means + SD obtained from three different measurements. Asterisks indicate values 
which are statistically significant different (P-values <0.05) from their respective control.  
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